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Summary. 
This study had two aspects. The first was the production and purification of 
TIMP-l. The second was a series of biophysical studies of TIMP-l and a TIMP-l 
derived peptide. 
A monoclonal antibody affinity column was developed and used to purifY large 
quantities of human TIMP-l for further experiments. Two E.coli expression systems 
were studied to determine whether they would be suitable for large scale production of 
recombinant protein. In the first system TIMP-I was to be secreted as a fusion protein 
which could be cleaved, leaving a free N-terminus. It was discovered that it was not 
possible to cleave off the fusion protein. In the second system, the protein was secreted, 
without additions to the periplasm. Although a~tive protein, with the correct N-tenninus, 
was obtained, the yields were too low to be of use for large scale expression. 
Secondary structure analysis by CD and FTIR showed TIMP-l to be a mostly f3-
sheet protein (approaching 50%) with around 20% a-helix. A temperature study using 
these techniques found that little change occurs until temperatures of over 60°C where 
the protein aggregates. The small changes appear to be a general loosening of the 
structure. 
In analyses of the surface of TIMP-l, additional carbohydrate was identified 
(other than the two N-linked chains) using Con-A probing of Western blots. TIMP-l 
purified from WI-38 foetal lung fibroblast cells can be separated into two pools by 
Concanavalin A-Sepharose chromatography. These two pools were found to have a 
different set of pIs and a different monosaccharide composition. 
The use of NMR paramagnetic probes identified a hydrophobic region exposed 
on the surface of TIMP-I. This region probably includes a tyrosine residue and either a 
tryptophan or phenylalanine. The presence of an exposed hydrophobic region was also 
shown in binding studies using the fluorescent probe ANS. These studies identified a 
single, low affinity binding site. An additional study with the N-terminal fragment of 
Vlll 
type-I collagenase found no binding sites on the enzyme, but a change in fluorescence 
occurred when TIMP-I was present. 
A pt~ptide was designed based on the N-terrninal sequence of TIMP-I. High 
homology, susceptibility to mutation and an interesting resemblance to the Bowman-Birk 
family of inhibitors suggested that this peptide might be inhibitory. It was found to have 
only a weak inhibitory activity against gelatinase. NMR studies of this peptide in water 
showed a large number of conformers as a result of stabilisation of the cis isomer of its 
proline residues. This preference for the cis form was retained for one proline in the 
solvent, TFE. 
Preliminary NMR studies were also carried out which concluded that TIMP-I 
should be suitable for further structural studies using isotopic labelling. 
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Preface. 
The tissue inhibitors of metaJloproteinases are a small family of proteins which 
specifically inhibit the matrix metaJloproteinases They are found in many tissues and 
have an essential role in the regulating the turnover of the extracellular matrix. 
To maintain healthy extracellular matrix, an even balance between synthesis and 
degradation must be retained. When this balance is disturbed the result is seen as a 
number of disease states. Overproduction of matrix is associated with fibrotic type 
diseases, whilst excessive matrix breakdown is seen in arthritic conditions. The matrix 
metalloproteinases, together, have the capability to break down all the components of the 
extracellular matrix. Since the TIMPs are specific inhibitors, they represent an important 
potential source of therapeutics. Compounds designed to mirror the inhibition by the 
TIMPs could be used to target the MMPs and control their activity in destructive 
pathologies. 
If such compounds are to be developed, it is essential to understand the 
mechanism of MMP inhibition by the TIMPs. Part of this is to determine the structure of 
all of the proteins involved. Since the important regions for inhibition are found on the 
surface of the protein it is important that this is carefully characterised, both alone and in 
an enzyme-inhibitor complex. 
This study has been devoted to TIMP-J, the first of the family to be discovered. 
At the outset of this work, very little was known about its structure. It was known to be 
highly stable (to temperature and pH), with six characterised disulphide bonds and two 
glycosylation sites where a total of 8 kDa of carbohydrate was attached. 
xv 
The aims of the study were twofold. The first was to develop an expression 
system that would guarantee a supply of TIMP-l for all further studies. The second was 
to obtain as much structural information about the TIMP-l molecule as possible using a 
number of spectroscopic techniques, including NMR. 
XVI 
Chapter l. 
An Introduction to Matrix Metalloproteinases and the Tissue 
Inhibitors of Metalloproteinases. 
The matrix metalloproteinases (MMPs) are a large family of enzymes involved in 
the breakdown of connective tissue components [1, 2]. Their normal function is in the 
turnover of extracellular matrix materials such as collagens and proteoglycans. Together, 
they car. break down all of the components of the extracellular matrix. To maintain a 
balance between synthesis and breakdown it is essential that the MMPs are closely 
regulated. The regulation is complex, with several regulatory mechanisms involved at 
different stages. The production, activation and extracellular activity is contro/led 
through stimulation by cytokines, transcriptional and translational controls, the 
maintenance of enzyme latency, the activation process and the direct inhibition of the 
active form. 
Malfunctions in connective tissue turnover can lead to a variety of disease states. 
Reduced enzyme activity is seen in fibrotic conditions such as alcohol induced liver 
fibrosis [3J. Excessive, or undesirable activity is seen in the degenerative processes of the 
rheumatic diseases and the metastatic activity of tumour cells. A greater understanding of 
the mechanisms of connective tissue turnover and the enzymes and inhibitors involved 
may lead to the development of new therapeutics. 
The tissue inhibitors of metalloproteinases (TIMPs) are very important, specific 
inhibitors of the MMPs. The TIMPs inhibit the active form of the enzymes, and in certain 
cases are involved with maintenance of the latent state. To understand the function of 
these inhibitors it is also necessary to understand the nature and function of the MMPs. 
1.1. l\latrix Metalloproteinases. 
Vertebrate collagenolytic activity was first identified in tadpole tails [4], where a 
metallo-enzyme was found that broke de wn the collagen of the tail during the resorption 
process. Over the next thirty years a range of different metalloproteinases was identified 
in many species, that degraded either collagen or other connective tissue matrix proteins. 
To date there are at least ten named enzymes, although there are almost certainly others 
that remain to be identified. 
l.l.l. What Makes an MMP? 
Table ],1 (below) lists the known matrix metalloproteinases. Some of the 
enzymes have acquired t' number of alternative names. This was a result of differing 
naming strategies and the circumstances of the original identification, these names are 
included in the table. Also included are the substrate specificities of each enzyme. 
Enzyme Alternative names MW Substrates 
Colla2enases 
Interstitial Collagenase MMP-l 55 kDa Collagen I, II, III, X. 
Vertebrate Collagenase gelatin. 
Fibroblast Collagenase proteoglycan core 
protein 
Neutrophil MMP-8 75 kDa As MMP-I 
Collagenase 
Collagenase-3 MMP-13 54kDa Collagen I 
Gelatinases 
Gelatinase A MMP-2 72 kDa Gelatins type I, II, III 
72 kDa gelatinase Collagens type IV, V, 
Type IV collagenase VII,X,XII 
Aggrecan, Elastin. 
Gelatinase B MMP-9 92 kDa As gelatinase A 
92 kDa gelatinase 
Type IV Collagenase 
Stromelysins 
Stromelysin- t MMP-3 60/55 kDa Aggrecan, link 
Transin protein, fibronectin, 
Proteoglycanase laminin. Gelatins I, 
Procollagenase III, IV, V. Cross-link 
activator collagens II, IV, IX 
pro-collagens 
Activates pro-
collagenase and 
gelatinase B 
Stromelysin-2 MMP-I0 60/55 kDa As for stromelysin-l . 
Transin-2 
Stromelysin-3 MMP-ll 58 kDa N-terminal fragment 
is a weak caseinase. 
Also laminin, 
fibronectin and 
aggrecan. 
Matrilysin MMP-7 28 kDa As for stromelysin-l. 
PUMP-l Elastin. 
Uterine 
metalloproteinase 
Other ElIZ)'mes 
M etalloelastase MMP-12 53 kDa Elastin, Fibronectin 
Membrane Type MMP-14 63 kDa Activates Gelatinase 
Metalloproteinase A 
Table 1·1. The Matrix metalloproteinases and their substrates. Most of the 
information in this table is derived from Murphy et al [5]. 
There are several features that distinguish the MMPs as a unique class of enzyme. 
The first of these is that their sequences should be strongly homologous to that of 
collagenase [6]. Sequences for the human forms of each of the MMPs have been 
determined, except for MMP-12 (murine form only) and are shown aligned in Appendix 
1. 
3 
All the MMPs are based around a very similar modular structure. The basic 
pattern is of a hydrophobic signal sequence, which is necessary since the MMPs are 
secreted [7]. A conserved propeptide, which is involved in maintaining the latent state of 
the secreted enzyme, must be removed for the enzyme to attain activity [8]. The catalytic 
domain contains a highly conserved consensus sequence which forms a zinc binding site 
[9]. Next, is a proline rich hinge region that is also essential for activity. The C -terminal 
domain consists of four repeats that resemble hemopexin and vitronectin [10]. In both of 
the gelatinases (72 kDa and 92 kDa) three repeats of a type II fibronectin like domain are 
inserted before the zinc binding site [11]. Matrilysin is unusual in that it is a truncated 
MMP [12]. It does not have the pexin domain and the hinge region is much shorter than 
in the other MMPs. The membrane metalloproteinase, (MMP 14) also has an additional 
transmembrane anchoring domain. Through variations on this theme they have a range of 
molecular weights between 28 kDa (matrilysin) and 92 kDa (92 kDa gelatinase or MMP-
9). Figure 1·1 shows the different domai 1S and relative sizes of H'e MMPs. 
The final unique feature that distinguishes the MMPs, is that they can all be 
inhibited by one or more of the TIMP family. 
Another feature of the MMPs is not unique to them, but includes them in a larger 
group of proteinases. This is the highly conserved sequence in the catalytic domain that 
forms the catalytic domain zinc binding site r 13]. The consensus sequence, HEXXH 
draws in other proteins such as thermolysin, peptidase N and the tetanus toxin. An 
extension of this consensus sequence and the inclusion of a methionine tum later in the 
sequence refines the group to a superfamily named the metzincins [14]. This includes 
very similar proteins such as astacin and some of the snake venom metalloproteinases. 
The Collagenases. 
There are now three known human collagenases, fibroblast collagenase (MMP-
1), neutrophil collagenase (MMP-8) and collagenase-3 (MMP-13). Of all the enzymes, 
only the collagenases are capable of cleaving triple helical collagen to give the 
characteristic 1/4-% fragments [15, 16]. Of the three, fibroblast collagenase is the most 
4 
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Figure 1·1 Representative diagram showing the multi-domain structure of the 
Matrix Metalloproteinases. 
5 
widespread, being produced by a number of cells [1 J including skin [17J, and 
macrophages [18]. The expected molecular weight is 52 kDa with an apparent molecular 
weight of 52 or 56 kDa in the secreted, latent form [19]. The variation is due to 
heterologous glycosylation. MMP-8 is only produced by PMN-Ieucocyte cells [20] and 
has a slightly different specificity from fibroblast collagenase. It is larger than fibroblast 
collagenase (75 kDa - precursor form) but is also glycosylated. Recently a third protein 
was added to this group on the basis of its collagenolytic activity, and close sequence 
homology to the other coJ1agenases. This is collagenase-3 or MMP-13 [21]. It has a 
sequence of 471 amino-acids and an apparent molecular weight of 65 kDa by SDS-
P AGE. This MMP is unusual in that so far it has only been identified in breast 
carcinomas and no other human tissue. Its role may therefore be unique to the processes 
of invasive breast cancer. The only other MMPs that resemble this was originally 
identified as MMP-l in rats [22] and mice [23]. However, it5 activity and sequence were 
unusual for an MMP··1 (it has the ability to cleave other sites in the collagen molecule). 
The rat and mice collagenases have a greater homology with the human MMP-13, and 
no equivalent to MMP-I has been identified in these species. 
The site where the u chains are cleaved in triple helical collagen, is unique even 
though the cleaved residues (Gly-775 - I1elLeu-776) occur in other regions of the 
molecule. The sequences on either side of the scissile bond appear to be important in 
determining the cleavage site [24]. This region may be structurally different to the rest of 
the collagen molecule, unfolding to allow enzyme access [25]. 
The unique action of the collagenases is not associated with a particular domain 
but requires both the N- and C - terminal domains of the enzyme. It is essential that the 
entire molecule is present. Experiments with chimeric proteins have shown that triple 
helical collagenolytic activity cannot be re-created by mixing the N- and C - terminal 
domains of different MMPs [26, 27]. 
6 
Once active, (human fibroblast) collagenase can break down into two fragments 
by way of an autolytic cleavage between Pro-250 and Ile-251 (numbered from the first 
residue of the pro-peptide) [28]. The larger 26 kDa fragment is inactive, but the smaller 
22 kDa fragment retains all activity bar that of a triple helical collagenase. Truncation 
mutants of neutrophil collagenase suggest that the specificity is associated with a 62 
residue sequence in the C-terminal domain [29] Chemical modification of neutrophil 
collagenase indicates that a tyrosine residue and a lysine residue are essential for the 
enzyme activity [30). 
The Gelatinases. 
There are only two members of the gelatinase family, gelatinase A (MMP-2) and 
gelatinase B (MMP-9). Unlike the collagenases they are able to degrade type IV collagen 
as well as denatured triple helical collagens. Gelatinase A is the smaller of the two 
~nzymes (72 kDa in its secreted form) ,1nd is generally not glycosylated. It is produced 
by many connective tissue cells, including bone [31], epithelia [32J endothelia [33] and 
skin [34]. The larger protein, gelatinase B is a 92 kDa glycoprotein. It is less widespread 
than the 72 kDa gelatinase, being produced by keratinocytes [35], leucocytes [36], 
monocytes and macrophages [37]. It is also found in a number of transformed cells. 
The additional fibronectin like domain consists of three contiguous repeats of the 
fibronectin type II unit. Fusion of a single repeat of this unit to I~-galactosidase allowed it 
to bind gelatin [38]. Deletion mutants of gelatinase A, where the fibronectin domain was 
absent had many of the normal properties such as TIMP binding, activation by APMA 
and kea! for a synthetic substrate. [39] These mutants could not bind to collagen type IV 
and had a lower activity against casein and gelatin. The fibronectin domain appeared to 
be responsible for the high affinity of the gelatinases for gelatin and the gelatinolytic 
activity. Further study [38] has found that the first and last of these three repeats are 
responsible for the most of the binding activity. The three units are not entirely conserved 
and the difference in binding affinity is due to variation in a non-conserved region. 
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The type IV collagen cleavage by the gelatinases has been partially characterised. 
Gelatinases cleave the molecule at approximately 1/4 of the distance from its N-terminus 
[40] at the Gly-446 - lIe-447 scissile bond [41] which is probably part of a triple helical 
portion of the molecule. 
The Stromelysins. 
There are three enzymes that have been named as stromelysins, stromelysin-l 
(MMP-3), stromelysin-2 (MMP-lO) and stromelysin-3 (MMP-l1). 
The first two stromelysins are closely related in both sequence, [42] and 
specificity [43, 44, 45]. The differences are that stromelysin-l also degrades the 
proteoglycan link protein, laminin, procollagen peptides and type X collagen. Both 
enzymes are capable of activating pro-collagenase. 
Stromelysin-3 was identified by screening a eDNA library and was classified as a 
stromelysin on the basis of its location in the stromal cells of breast carcinomas [46]. 
However, its sequence is unusual, having a relatively low similarity to the other 
stromelysins and the MMPs (40% homology to other stromelysins and collagenase, 
compared with 79% between the two stromelysins and 56% for the similarity between 
stromelysin-l and collagenase-I). In a phylogenetic analysis of the MMP family, 
stromelysin-3 appears as a very early branch off the main line [42] It is also found on a 
different chromosome to the majority 'Jf the MMPs, locating to the q 11'2 region of 
chromosome 22 [47] rather than chromosome 11 q22-q23 [48]. The difference between 
the sequence of stromelysin-3 and the remainder of the metalloproteinases implied that 
there could be differences in the activity or mechanism. This was borne out on expressing 
the murine stromelysin-3 gene in Ecoli [49]. The gene product was a 57 kDa protein 
that did not show any enzymatic activity, and could not be activated by the conventional 
methods. However treatment with organomercurials generated 55158 and 27/28 kDa 
forms. The short form had lost the propeptide and much of the C -terminal domain. This 
N-terminal piece was found to have very weak caseinase activity as well as degrading 
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fibronectin, laminin and proteoglycan. It has no type I collagenolytic activity, 
gelatinolytic activity is very weak and type IV collagen was only degraded at 37°C. Like 
the other stromelysins it is able to potentiate the activation of collagenase by trypsin and 
can be inhibited by TIMP-l. 
Other MMPs. 
The remammg MMPs have not been characterised sufficiently to be 
described as either a collagenase, a gelatinase or a stromelysin. Some do not fit the 
descriptions of any category. Matrilysin (MMP-7) is the best described of the remaining 
MMPs. This short form metalloproteinase was originally identified in uterine tissue on 
the basis of its substrate specificity and response to certain inhibitors [50]. Its activity is 
similar to that of the stromelysins, degrading gelatins, proteoglycan and fibronectin. It 
also has the ability to activate procollagenase [12]. Unlike the other stromelysins it can 
not degrade type X collagen. Although the C -terminal domain is absent, it behave;, much 
as any other .MMP, being secreted as a latent pro-enzyme that can be activated by 
organo-mercurials and inhibited by 1, 10-phenanthroline and TIMP-I. 
Metalloelastase (MMP-12) has the same domain structure as the rest of the 
family and is approximately the same size (53 kDa in pro- form and 45 kDa when active). 
However it does not show a wide spectrum of activity. Its only substrate identified to 
date is elastin [51]. The most recent addition to the MMP family is the only one that is 
not secreted from the cell to the matrix. Instead it is found on the cell membrane. This is 
MMP-14 or membrane type matrix metalloproteinase [52]. The predicted amino acid 
sequence shows that it also follows the basic multi-domain structure of the other MMPs 
but contains two differences. The first of these is an insertion of 10 residues similar to 
one seen in stromelysin-3. The second is a sequence in the haemopexin domain that is 
very rich in hydrophobic residues and could thus act as the transmembrane anchor. The 
function of this enzyme appears to be the activation of the 92 kDa pro-gelatinase A at 
the cell surface. 
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1.1.2 Metal Requirement. 
Both zinc and calcium are required for activity. Early experiments showed that 
zinc was pn:sent in the collagenase molecule and that it was essential for the enzyme's 
activity [53]. Initially there were no quantitative determinations of the amount of zinc 
present in each molecule. A conserved sequence in the catalytic domain looked like a 
promising candidate fori zinc binding site. The catalytic zinc atom is found at the active 
site, in all of the known MMP structures forming ligands to the three conserved histidine 
residues, His-2I8, His-222 and His-228 (numbered according to the human fibroblast 
collagenase sequence). Further studies of stromelysin showed that two moles of zinc 
were present per mole of enzyme [54]. This is probably the case for all the MMPs. The 
function of the additional zinc was revealed on the publication of the first crystal 
structure of a truncated MMP [55]. It has a structural, rather than catalytic function in 
the enzyme. Calcium is also found to interact with the enzyme and is again essential for 
its activity, increa~ing its overall stability [56}. Stromelysin-l has bel~n shown to requir'~ a 
minimum of 2 mM calcium to maintain the thermo stability of the enzyme and prevent 
autolysis [57}. This concentration of calcium is also important for the activation of the 
enzyme. Evidence from the structure of full length human fibroblast collagenase (T.E. 
Cawston personal communication) has found 3 calcium atoms in the N-terminal domain 
and I in the C-terminal domain. The hinge region and part of the fibronectin inserts in the 
gelatinases have regions that are rich in Glul Asp and subsequently are good candidates 
for calcium binding sites in this group of MMPs. 
10 
1.1.3. Activation and Latency. 
All of the MMPs are secreted In a latent pro-enzyme form that reqUires 
activation. On activation the molecular mass of the enzyme decreases by around 10 kDa. 
Early evidence could not determine whether this was a result of the removal of a 
propeptide [58], or tht: loss of an inhibitor [59]. 
A number of chemical agents have been found that can activate the MMPs. These 
include organo-mercurials such as p-aminophenylmercuric acetate (APMA) [60], 
chaotropic ions including sodium thiocyanate and sodium iodide [61], and detergents 
[62]. Many proteinases can also activate the MMPs. Trypsin [63], several serine 
proteinases [64], bacterial proteinases [65], plasmin [66], mast cell chymase [67] 
collagen (gelatinase only) [68] and other MMPs that have already been activated [69, 
70]. 
All of the zymogen forms of the MMPs have a pro-peptide that is lost during the 
processing to the active species. This peptide has an essential role in maintaining the 
latent state. Part of the pro-peptide sequence is highly conserved throughout the M~1Ps. 
The consensus sequence of this conserved region is MRKPRCGVPD. Peptides 
containing this sequence were found to inhibit active 72 kDa gelatinase [71]. The same 
effect was also seen for free cysteine alone. This pointed to the importance of the pro-
peptide cysteine residue in the latency, and activation of the MMPs. The initial work 
suggested that the cysteine in the pro-peptide could co-ordinate with the zinc atom at the 
active site. This was supported by studies of mutants lacking Cys-73 [72]. Fibroblast 
collagenase that was secreted without Cys-73 either exhibited more autoactivation or 
could be more easily activated than the wild type protein. The final confirmation was the 
identification of the Cys-Zn ligand in stromelysin [54]. The presence of the peptide 
would serve to partially block access to the active site. In addition, the cysteine ligand 
occupies a site normally occupied by a water molecule that is essential for catalysis. For 
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the MMPs to be activated this interaction must be perturbed and a resulting 
conformational change lead to the completion of the activation process. 
The involvement of the Cys-Zn ligand in the latency of the MMPs has given rise 
to the cysteine switch model of activation [73] The dissociation of the cysteine from the 
zinc as a result of external influences ac:s as a switch, turning the zinc atom from an 
inactive state, into a catalytic one, allowing autolytic activation to occur. Another 
experiment identified the formation of a covalent complex between the cysteine residue 
and the Hg atom of APMA during the activation process, supporting the switch model 
[74]. This model describes the activation process for most of the MMPs under most 
circumstances. Interestingly the activation of stromelysin-l required more than the 
disruption of the Cys-Zn coordination. Dissociation by modification of the Cys residue 
did not activate the protein and further APMA or proteinase treatment was required 
[75]. The reaction appears to be due to other structural changes. 
Although the final product of the activation is essentially the same, the fine details 
of the mechanism differ for the chemical and proteolytic methods. 
For stromelysin-l, proteolytic activation can be by a number of proteinases that 
generally cleave the pro-peptide at an exposed sequence [63]. The exact site varies 
between different proteinases and is followed by a second autolytic cleavage at the His-
82 - Phe-83 bond. This stepwise activation appears to be universal throughout the 
MMPs, including matrilysin which lacks the C -terminal domain [76]. 
Stromelysin-l has been found to activate 92 kDa gelatinase (MMP-9) in a two 
stage reaction, the first cleavage exposing the second cleavage site [69]. Stromelysin-l 
(MMP-3) has also been shown to activate pro-collagenase [77]. When APMA was 
included in the reaction the final activity was greater than that of either MMP-3 or 
APMA alone. In this case the initial activation (by APMA or other proteinases) leads to a 
reduction in molecular weight and some activity. Stromelysin-l cleaves the Gln-80 - Phe-
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81 bond resulting in increased activity [78]. This superactivation appears to be related to 
the formation of a salt bridge between the N-terminal NH group and Asp-232 [79]. 
Of the chemical activators, the mechanism of activation by APMA has been best 
studied. The activation by organo-mercurials is dependent on their concentration. In the 
activation of the 72 kDa pro-gelatinase, residues 1-80 are cleaved at a specific locus 
leaving a single N-terminus for the active 63 kDa protein [80]. This cleavage is 
autoproteolytic, and for enzyme activity to be present there must be some re-
arrangement of the proteins structure to allow it. A similar picture is seen for the 
activation of polymorphonuclear leucocyte collagenase (PMN1~). Rather than a single 
cleavage, the reaction occurred via three steps, giving a final N-terminus of either Met-
SO or Leu-Sl [SI]. 
When HgCl2 is used as the activating compound for 92 kDa gelatinase the 
cleavage of the N-terminal pro-peptide occurred in several steps [82]. F,)ur individual 
cleavage reactions occurred giving an N-terrninus at residue 76 and the conserved 
sequence containing the active cysteine of the pro-peptide remained intact. An additional 
set of three cleavages took place at the C -terminus removing other cysteine residues. It is 
possible that the 92 kDa gelatinase has a different mechanism of activation, using a 
disulphide rearrangement rather than the destabilisation of the cysteine-zinc ligand. The 
function of the Hg atom in either an organo-mercurial or in HgC12 alone is to destabilise 
the Cys-Zn ligand by altering the equilibrium so that the Cys forms a ligand or covalent 
complex with the mercury atom. This allows the water molecule to return to the zinc 
atom, restoring activity. The other compounds that activate the MMPs are all thought to 
act in a similar manner. Mercurials, thiol reagents, metal ions and oxidants directly 
disrupt the Cys-Zn ligand [l]. Other agents such as chaotropes and detergents (e.g SOS) 
have a general effect on the proteins structure, inducing large scale conformational 
changes that would shift the equilibrium of the Cys-Zn towards the active state. 
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1.1.4 Structures. 
It has proved to be very difficult to determine the structure of the MMPs. The full 
length active enzyme (collagenase in particular) tends to fragml~nt To date the only 
completed structures are those of N-terminal fragments, produced using recombinant 
techniques. The recent developments in NMR technology have m{~ant that the truncated 
proteinase was suitable for solution studies. The first structural details to appear were the 
secondary structure assignments of truncated stromelysin-l [83]. The 19 kDa catalytic 
domain is composed of a five stranded ~1-sheet with four parallel and one anti-parallel 
strand and three helices. The secondary structure is very similar to that of astacin, a 
related proteinase [84]. The crystal structures of truncated human fibroblast and 
neutrophil collagenases give the overall structure [55, 85]. When complexed with a low 
molecular weight inhibitor, the structure of neutrophil collagenase is essentially spherical 
with a small cleft separating the main portion from a smaller C-terminal subdomain. The 
first zinc is found at the bottom of the active site cleft, whilst the second is packed onto 
the top of the sheet along with two calcium ions. The fibroblast collagenase structure is 
extremely similar to this [86]. All of the N-terminal structures solved so far share the 
same topology and it is likely that other MMP structures will share the same overall fold. 
However, the C-terminal domains may show greater variability. 
1.2. An Inhibitor of Metalloproteinases. 
During the latter part of the 1970's collagenase inhibitory activity was identified 
in various mammalian body fluids and tissues. Woolley et al [87] discovered a small (40 
kDa) protein in serum that showed high specificity to collagenase, but did not inhibit any 
other class of enzyme. Sellers et al [88] described another inhibitor in the medium of 
rabbit foetal bone cultures. This showed inhibitory activity against stromelysin and 
gelatinase as well as collagenase. The protein appeared to have a molecular weight of 30 
kDa by gel filtration. It was also shown to be inactivated by trypsin, chymotrypsin and by 
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boiling for 15 minutes. A closely similar inhibitor was identified in tissues from gravid 
uterus [89]. These inhibitors were produced in the early stages of the culture (days 1-3) 
[90] during the log phase, and before collagenase could be detected in the medium. They 
also showed a cross species specificity, inhibiting murine and porcine collagenases [88]. 
Tissues from several different species were also shown to contain collagenase inhibitors 
(reviewed in detail by Reynolds et al) [91], including, chick bone [92] porcine smooth 
muscle [93], porcine gingiva [94] bovine nasal cartilage [95], bovine aorta [96], human 
skin fibroblasts [97], human rheumatoid synovium [98], human tendon [99], and human 
gingiva [100]. All of these inhibitors showed several distinctive features in common, 
which can be used as an aid in identifying new proteins as TIMPs. They were stable at 
high temperatures for short periods. e.g. 60°C for 10 minutes. but were destroyed at high 
temperatures. They were: also resistant to low pH (as low as pH 2'0) [96] and 
Iyophilisation [l0 I]. Inhibitory activity could also be abolished by 30 mg/ml trypsin 
[102], reduction and alkylation [93] and 3M KSCN [l00]. The molecular weight of the 
proteins as determined by various gel filtrations and gel electrophoresis ranged from 22 
kDa [95] to 45 kDa [961, although most estimates were in the high twenties. Woolley et 
al named their inhibitor I~ I-anti collagenase from its original identification as a p-serum 
protein [87]. In the paper by Cawston et al [103]. describing the purification scheme for 
rabbit bone inhibitor, the name, tissue inhibitor of metalloproteinases (TIMP) was 
proposed for this protein. This inhibitor is now known as TIMP-l. Other related 
inhibitors are numbered in order of discovery. 
1.2.1. A Family of Inhibitors. 
There are three identified tissue inhibitors of metalloproteinases TIMP-I, TIMP-2 
and TIMP-3. They have been identified in many species and tissues. and it is likely that 
the TIMPs are ubiquitous throughout the mammals. 
During the preparation of the 28· 5 kDa inhibitor (TIMP-l), occasionally other 
inhibitory activities were seen. One was seen at a lower molecular weight of around 22 
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kDa [104]. This did not bind to Concanavalin A Another [105], had an apparent 
molecular weight of 75 kDa, and was eventually shown to be an inhibitory enzyme-
inhibitor complex. The second member of the TIMP family was confirmed by two 
separate groups, in 1989 when the sequences of human [106], and bovine [107] 22 kDa 
TIMP-2 were publi5.hed concurrently. Previously, a bovine inhibitor with an apparent 
molecular weight of 28 kDa by gel filtration, had been partially sequenced [108). This 
sequence was identical to that of the published TIMP-2, although it was not identified as 
a distinct protein at the time. 
The most recent addition to the TIMP family was initially identified in chicken 
embryo fibroblasts [I 09J, as a protein produced during the early stages of cell 
transformation. It is one of a series of metalloproteinase inhibitors that were identified in 
the media and extracellular matrix of the cell cultures. Again it is a protein of 
approximately 21 kDa, and like TIMP-2, is not glycosylated. However, its sequence 
(110). differs sufficiently from those of TIMP-l and TIMP-2 for it to be classed as a 
third, distinct TIMP, TIMP-3. 
1.3. Sequences and Relationships. 
In 1983 the first 23 N-terminal residues were determined by Stricklin et al [Ill] 
for a 28· 5 kDa inhibitor from human ::.kin fibroblasts. They also suggested that the 
protein contained no free thiols, but did contain a large number of disulphides (although 
this number was initially overestimated). 
The first complete TIMP sequence to be published was the nucleotide sequence 
of TIMP-l from human cells [112]. This indicated a protein of 184 residues with an N-
terminal sequence of 23 residues cleaved during processing. Two potential glycosylation 
sites were identified at Asn-30 and Asn-78. Also of.note was the large number of 
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cysteine residues (12) The amino acid sequence of human TIMP-I, as derived from its 
nucleotide sequence, is shown below (table 1-2). 
CNSDLVIR MTKMYKGF 
50 TPAMESVC GLLHITTCS 
100 RRGFTKTY CLSIPCKL SGTHCLWTD 
150 IA 
Table 1-2. Amino acid sequence of human TIMP-l. 
This sequence is identical to the partial sequence described by Stricklin et al [111]. 
There are now complete TIMP-I sequences for mouse [I 13], human [112], 
bovine [114J sheep [115], rat [116], rabbit [117], pig [118] and baboon [119]. TIMP-2 
sequences have been determined for mouse [120], human [106], bovine [107] and rat 
[121] inhibitors. Three sequences for TIMP-3 in different species have also been 
generated in quick succession, the original, chick [122], human [123], and mousl~ [124]. 
1.3.1. Homologies. 
Computer analysis of the TIMP sequences gives the relative homologies between 
the different molecules within, and between species. In humans, TIMP-l and TIMP-2 
share a 41 % direct homology, with a further 29% of residues as conservative 
substitutions [106]. TIMP-3 has a 37% and a 42% direct homology to TIMP-l and 
TIMP-2 respectively. [ 123]. In all three proteins, across all species, the cysteine residues 
are entirely conserved, implying that these residues are essential to the structure, and 
subsequently the inhibitory process. In addition all three tryptophan residues are entirely 
conserved. Particular regions show a higher than average degree of conservation. Most 
notably, the N-terminal stretch of 24 residues which has a 66% identity between the three 
TIMPs. The three sequences aligned using the Clustal program are shown in Appendix 2. 
The equivalent analysis for the murine forms of liMP gives an identity of 35 -7% 
and 36-8% with TIMP-l for TIMP-2 and TIMP-3 respectively and 43-0% between 
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TIMPs 2 and 3 (calculated using the method of Lipman and Pearson [125]). Again the 
cysteines and tryptophans and strong N-terrninal homology are retained. A Clustal 
alignment showing all the known TrMP sequences is included as Appendix 3. 
It is interesting, that the pre-sequences of TIMPs 1 and 2 also show a high degree 
of homolob'Y [126 J which may point to an important role for the pre-sequence in the in 
vivu processing of the protein. The presequence of TIMP-3 [122, 123] is also very 
similar having a run of lysine residues and ending with an alanine before the N-terrrunal 
cysteine. 
1.4. Physical Properties. 
Since TIMP-I was identified several years before the other members of the TIMP 
family, much more is known about its structure and physico-chemical properties. 
Subsequently this description of the physical properties concentrates primarily on TIMP-
1. 
1.4.1. Amino Acid Composition. 
The amino acid composition of TIMP-] is set out in table 1'3. 
Ala Cys Asp Glu Phe 
I I 12 5 9 10 
Gly His De Lys Leu 
12 6 7 8 18 
Met Asn Pro Gin Arg 
3 4 10 12 10 
18 
Ser Thr Val Trp Tyr 
13 16 9 3 6 
Table 1·3. Amino acid composition of human TIMP-l. When compared with the 
mean composition of 1465 proteins [127], TIMP-1 is rich in cysteine, glutamine and 
threonine, but has relatively little asparagine and aspartic acid. 
1.4.2. Glycosylation 
TIMP-1 is a glycoprotein, and will bind to Concanavalin A [128]. The other 
TIMPs are apparently non-glycosylated, having no clear glycosylation consensus 
sequences, or anomalously high molecular weights on SDS-P AGE. However towards the 
C-terminus of TIMP-3 is the sequence Asn Ala Thr, which is a potential glycosylation 
site. Although the chicken TIMP-3 was not found to be glycosylated, there may be 
situations where carbohydrate is attached. 
The amino acid sequence of TIMP-l has two sites at Asn-30 and Asn-78, which 
are part of consensus sequences for N-linked glycosylation (Asn-Xaa-Thr/Ser). TIMP-l, 
with 184 amino-acids would be expected to have a molecular weight of 20· 5 kDa. The 
actual molecular weight of 28·5 kDa is made up of extensive glycosylation at both N-
linked sites. This is indicated by the appearance of an intermediate band of approximately 
25 kDa, when the protein is treated with N-glycosidase [129]. A further indication that 
both sites are glycosylated is that both asparagine residues are not seen during 
sequencing unless the protein is deglycosylated [130]. The N-terminal fragment of 
TIMP-l expressed in mouse myeloma cells shows more than one molecular weight 
which is reduced to a single SDS PAGE band by deglycosylation. From the appearance 
19 
of tryptic fragments on rpHPLC it would appear that the primary glycosylation site is 
Asn-30, and that this glycosylation is heterologous [131]. 
Human skin fibroblast TIMP- I was found to contain 13 hexose residues per 
molecule [Ill], although this does not account for the total extra mass. The most 
detailed study of the sugar composition of TIMP-l was carried out using TIMP-I 
(apparent Mw 29 kDa) from bovine dental pulp [132]. This showed TIMP-l to contain 
complex-type oligosaccharides composed of a substantial quantity of glucosarnine, with 
large proportions of mannose and galactose, with fucose, glucose and sialic acid as minor 
components. The binding to Concanavalin A indicates that a-D-mannopyranosyl or a-D-
glucopyranosyl is available. TIMP-l does not bind to wheat germ lectin Sepharose, 
indicating that there are no free N-acetyl giucosarninyl residues [128]. 
The isoelectric focusing pattern of TIMP-I shows considerable heterogeneity. 
has 
Bovine TIMP-l gives two pIs of 5'6 and 6·5 [132], rabbit bone TIMP-IA,values of 5'9, 
6·4 and 6·6 [133]. Human TIMP-l also shows a number of different pIs [134]. 
Neuraminidase treatment reduces the number of these isoforms and results in pIs of 
between 8 and 9. However the value predicted by computer analysis of the sequence is 
close to 7 (my calculation) which has implications for the tertiary arrangement of acidic 
and basic residues. Concanavalin A purification of foetal lung fibroblast TIMP-I has 
identified a form of TIMP-l that does not bind to the lectin, but is otherwise identical to 
the binding form [135]. These facts would suggest that the glycosylation pattern IS 
heterogeneous, with most of the heterogeneity due to variable sialation. 
1.4.3. Disulphide Pattern 
The absence of free thiols [111] indicates that all of the cysteines in TIMP-l are 
found as disulphide bonds. Determination of the amino acid composition [111] showed 
the presence of twelve cysteines, and thus, six disulphide bonds. The arrangement of the 
disulphides was determined by rpHPLC analysis of trypsin degradation fragments, 
identifying disulphide bonded fragments by differences occurring on reduction [136]. 
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This gives disulphide pairs of Cys-I - Cys-70, Cys-3 - Cys-99, Cys-13 - Cys-124, Cys-
127 - Cys-174, Cys-132 - Cys-137 and Cys-145 - Cys-166. The arrangement of the 
disulphides is such that TIMP-l has two apparent domains. The first domain is between 
Cys-l and Cys-124, the second from Cys-127 to the C-terminus, with a linker of Glu-
125 - Glu-126 between. Since the cysteines are entirely conserved, this pattem is 
assumed to be consistent throughout the TIMP family [137]. The nature of the linker 
between the two domains is variable, with one or two small, often acidic residues 
present. 
The order of the disulphides is such that it is possible to draw a representative 
diagram of TTMP-I (Figure 1'2), where none of the loops have to cross in three 
dimensions. 
Although the disulphide pattern has only been determined for human TIMP-l, the 
cysteine residues are conserved throughout the TIMP family. Thus, it is assumed that the 
pattern holds true for all of the other TIMPs [137], and similar structures can be created 
using the equivalent, assumed disulphide pairs. 
1.4.4. Stability. 
One of the notable features of the TIMP family is the exceptional stability of the 
proteins under extreme conditions. Although the biophysical properties of TIl\1P-3 have 
yet to be fully determined it is likely that it will be similar. 
TIMP-l from many different species and tissues shows a high degree of thermal 
stability. TIMP-I can survive for an hour at temperatures of up to 60°C [133]. However, 
boiling for extended periods does destroy the activity [93]. It is also very resistant to low 
pH, being almost unaffected by incubations at pH values as low as 2 [93]. Much of this 
stability IS attributed to the high number of disulphide 
")1 
Glycosylation site 
* Residue implicated in MMP inhibition 
_ Disulphide bond 
o Tryptic cleavage site 
Figure 1·2. Representative Diagram of TIMP-l Showing Features of Interest. 
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bonds present, although it is possible that TIMP-l can sustain substantial damage 
without any immediate effect on its inhibitory capabilities. 
1.4.5 Proteolysis and Peptide Mapping. 
TIMP-l has differing susceptibilities to degradation by prot eases [13 8]. It is 
sensitive to trypsin and a-chymotrypsin, which break TIMP-l down into a series of small 
fragments. This degradation was originally used in conjunction with thermo stability tests 
to identifY TIMP like inhibitors. Human neutrophil elastase also destroys the activity at a 
relatively low concentration (10 )..I.g/ml). Other proteinases had little or no effect on 
TIMP- I, even at high concentrations. Plasmin, thrombin, and plasma kallikrein do not 
affect the activity in any way, whilst cathepsin G and pancreatic elastase require high 
enzyme concentrations to give only a partial inactivation. These enzymes do not affect 
the molecular weight of TIMP-1 on a non-reducing PAGE, but only when the 
disulphides are reduced, do smaller polypeptides appear. This suggests that the 
conformation is held very firmly by the disulphides, and the prOteolysis only affects 
activity when sections of the protein are removed by multiple cleavages. 
The trypsin cleavage used to identifY the disulphide bonded fragments also 
identified an insoluble tryptic core [136]. This core included five out of the six disulphide 
pairs (all but Cys-145 - Cys-166). A further study of the tryptic fragments generated a 
detailed peptide map [139] shown in table 1-4. 
Tryptic cleavage of the non-reduced form ofTiMP-l produced insoluble peptides 
of residues 1-20, 60-75, 89-113, 119-138 and 170-180, with the remaining peptides in a 
soluble fraction. Analysis of the rate of cleavage in the whole protein and N-terminal 
fragment of TIMP-1 (Cys- I - Glu-126) identified particular peptides that are released 
faster and hence are more accessible than others. The last four residues (180- I 84) were 
released first, but only require one cut, rather than two. Evidence from the quick release 
of peptides suggests that the C -terminus, and the region Arg-l 13 - Lys-118 are exposed. 
The region Lys-23 - Arg-59 is also exposed, but to a lesser extent, with the three 
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Residue Numbers Sequence 
1-20 CTCVPPHPQT AFCNSDL VIR 
21-22 AK 
23-37 FVGTPEVNQTTL YQR 
38-41 YEIK 
42-44 MTK 
45-47 MYK 
48-59 GFQALGDAADIR 
60-75 FVYTPAMESVCGYFHR 
76-79 SHNR 
~..!O-88 SEEFLIAGK 
89-113 LQDGLLHlTTCSFV APWNSLSLAQR 
114 R 
f--
115-118 GFTK 
119-138 TYTVGCEECTVFPCLSIPCK 
139-157 LQTGTHCLWTDQLLQGSEK 
158-162 GFQSR 
163-169 HLACLPR 
170-180 EPGLCTWQSLR 
181-184 SQIA 
Table 1·4. Tryptic Cleavage Fragments of TIMP-l. This table has been modified from 
the original paper and includes Ser-76 - Arg-79, AJa-21 - Lys-22 and Arg-114 which 
were not detected but their existence is derived from the data. 
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peptides it contains being released in a distinct sequence. It has been noted that TIMP-I 
preparations that became bacterially contaminated are also cleaved in this region 
(between Gly-53 and Asp54) [Clark, I.M. unpublished results]. 
Interestingly, TIMP-3 has a different sensitivity to TIMP-I. Whilst susceptible to 
chymotrypsin and the non-specific action of Pronase, it is resistant to trypsin regradation 
[140]. It is also resistant to the proteinases produced by transforming cells, but since 
these would include matrix metalloproteinases, each enzyme would need to be assayed 
individually. 
1.4.6. Solution Structure of the N-Terminaj Domain of TIM P-2. 
A recent publication has described the partial solution structure of the N-terminal 
domain of TIMP-2 [141]. Expression in a mammalian cell system meant that isotopic 
labelling was not possible and all the data were obtained using homonuclear, three-
dimensional NMR methods. The overall fold is that of a five stranded, antiparalle~ I~-
barrel, where ~-sheet comprises 40 % of the total secondary structure content. Two 
short stretches of helix are also found. The remainder of structure consists of ill 
determined loops. This structure is similar to the fold seen in the OB 
(oligosaccharide/oligonucleotide) binding family of proteins. 
The highly conserved VlRAK sequence forms part of a structurally important 
helix. Folding studies of N-terminally truncated TIMP-I and TIMP-2 (wild type and 
.. 
mut~nts) indicate that Ala-21 in particular is important for the structural stability [142]. 
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1.5. Regulation of Expression. 
1.5.1. Regulation at the gene level. 
Chromosomal Location. 
Each of the genes for the human TIMPs is found on a different chromosome. 
TIMP-l is found on the X-chromosome [143], as part of a conserved linkage group that 
includes the genes for ornithine transcarbamylase, synapsin-l and one of the rqf 
oncogene family. The gene for human TIMP-l has been mapped to position Xp 11 ,1-
pII·4[144,145]. 
The gene for human TIMP-2 has been localised to the end of chromosome 17, at 
position 17q25 [146]. Other genes in this region include galactokinase, avian 
erythroblastic leukaemia viral oncogene homologue 2-like (ERBA 2L) and the thyroid 
honnone binding protein. The murine equivalent has been found on chromosome II 
close to a protein kinase gene, and again to theERBAgene. 
The human TIMP-3 gene has been identified on chromosome 22, at position 
q 12 'l-q 13· 2 [123]. In this case the position was detennined by ill situ hybridisation so 
there is no information as to other closely linked genes. 
There is a fonn of regulation that is unique to the X chromosome, X-linked 
inactivation. Early in female development one of the X-chromosomes is shut down, with 
a large number of its genes being inactivated. Although the TIMP-l gene lies close to 
one of the genes that are expressed, analysis of mRN A production from active and 
inactive X chromosomes indicates that the active chromosome mRNA production is one 
hundred times that of the inactive chromosome [147]. 
(iene Structure ami Regulatory Sequences. 
Much of the early work on the TIMP-I promoter region was carried out using 
the murine genome. The murine TIMP-I gene was originally identified as 16C8, which 
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was co-induced with IFNB I on infection with Newcastle Disease virus [148, 1491. The 
gene could also be induced by serum and phorbol estel s [150]. Analysis of the upstream 
sequence and comparison with the human TIMP-I eDNA identified an arrangement of 
six introns, five exons and a number of regulatory sites [ lSI ]. 
The exact size of the upstream regulatory region is unknown. A length of 230 bp 
is sufficient to anow expression [113, 151], and deletion of the region -230 to -52 
abolishes transcription. The p-galactosidase gene under the control of a region of the 
TIMP-l promoter (from -2158 to- 58) shows nonnal expression and control suggesting 
that distal sequences have a role in the full regulation of the gene [152]. 
There is no clear TAT A box and to date, eight possible transcription start sites 
have been identified [151]. The induction by Newcastle Disease virus is associated with 
four CCAA T boxes present in intfOn 1 which increase the level of transcription when 
present [153]. IntfOP I itself is not translated. Phorbol ester (e.g. 12-0-
tetradecanoylphorbol-13-acetate) and serum responses are associated with a non-
consensus AP 1 (activating protein 1) site at position -59/-53 [154]. Interestingly this 
partial site only functions correctly in the context of the TIMP-I gene. Close to this 
downstream site, and also involved in the serumlphorbol response is a 24 bp dyad of 
symmetry which contains a PEAJ (polyoma enhancer AJ) site [ISS]. These two sites 
make up the TRE (TPA-responsive element). It is thought that the TRE is responsible 
for the basal level of TIMP-1 gene transcription. The TRE site is flanked by a pair of sp 1 
sites (GC boxes) which are commonly found in housekeeping genes [155]. Further 
upstream is a true API enhancer site flanked by a further two possible PEA3 sites [ISS]. 
Also present, between the TRE and are two potential AP2 sites surrounding another 
potential sp I site [153]. 
The set of regulatory regions (including potential sites) in the murine TIMP-I 
promoter is summarised in Figure 1· 3. 
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multiple transcription start site 
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-900 -690 
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D AP2site 
Figure 1'3. Regulatory Elements of the murine TIMP-I Promotor. 
Evidence from constructs with reporter genes suggests that all of these regions are 
important for transcription. However only the API site at -59 has been shown to bind 
nuclear AP 1 factors. 
The presence of housekeeping regulatory elements as well as inducible elements 
in the TIMP-l gene agrees well with the observation that in many cell lines TIMP-l is 
produced at a basal level, but can also be induced by a number of different substances. In 
contrast TIMP-2 appears to be a constitutive gene which does not respond significantly 
to inducing agents [120]. 
Although there have been detailed studies of the murine promoter less is known 
about the nature of the human TIMP promoters. However a study of the human TIMP-2 
gene suggested that by comparison with the murine TIMP-l gene, TIMP-l and TIMP-2 
are differentially regulated [156]. The human TIMP-2 gene shows characteristics that are 
very typical of a housekeeping or constitutive gene. In this case a TAT A like element is 
found, along with a number of possible transcription start sites. There are several sp I 
motifs, a C'pG island, an AP2 site and an AP 1 site that forms part of a negative control 
element. 
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A study of the TIMP-] gene in T -cells infected with the human T-cell leukaemia 
virus (HTL V) has shown that TlMP-I can be induced by the viral tax 1 protein [157]. 
This induction is associated with the presence of an AP] site that is conserved between 
the human and mouse sequences. 
1.5.2. RNA stability 
It is has been reported that the mRNA transcripts of TlMP-l from TPA 
transformed/induced cells have an increased stability in the cytoplasm [158]. Differently 
sized mRN A transcripts of the TIMP-l gene have been seen. Northern blotting using a 
poly-dT oligo, showed them to be due to variations in the length of the poly-A tail over 
time, reaching a minimum after 12 hours [148]. 
1.5.3. Regulation by Cytokines. 
When TlMP-l was first identified it was produced in the early stag(~s of a serum 
free cell culture, normally for the first few days [88]. This expression was either at a 
basal level or was a result of stimulation by agents produced by the cultured cells. There 
are now many compounds produced ill vivo that are known to affect the expression of 
TIMP-l. Usually the effect is the upregulation ofTIMP-1 production, although in certain 
circumstances down-regulation may occur. The ill vivo regulation of TIMP-I would 
appear to be very complex, different cells mayor may not produce TlMP-l at a 
detectable level and their response to different regulatory substances also varies with cell 
type. 
Interleukin-I is a 17 kDa peptide produced by a range of cells, including 
monocytes and leukocytes. It acts on many cell types and is involved in upregulating the 
inflammatory response. The presence of IL-l in cartilage cultures induces cartilage 
breakdown [159]. IL-l has very little effect on TIMP-l production in articular 
chondrocytes (160], although there is a greater response than that to TNF-a. No 
significant stimulation is seen in porcine synovial fibroblasts [161], human rheumatoid 
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synovial fibroblasts [162] or normal chondrocytes [163]. Although most cells do not 
show a significant increase in TIMP-I production with IL-l there are reports that TIMP-
1 is elevated in IL-I treated cervical fibroblasts and that protein kinase C is involved in 
the response [I64]. Tumour necrosis factor-ft is another inflammatory cytokine secreted 
by macrophage andnonocyte cell lines which has cytotoxic and protein regulatory 
properties. TNF induces TIMP-I expression in human skin fibroblasts [165] but has no 
effect on the expression of TIMP-I in articular chondrocytes [166]. The effect of TNF is 
seen at low concentrations in fibroblasts (0-005 nglml) but a suppressive effect is seen at 
higher concentrations. Thus the effect is bifunctional, both stimulating and suppressing 
[167]. TNF alone could not increase the expression of TIMP-J in endothelial cells, but 
when EGF was added a synergistic effect was seen [168] and TIMP-l production was 
increased. 
Transforming growth factor -~~ has been implicated in the regulation of connective 
tissue matrix regulation. When TGF-~ is present it results in the deposition of more 
matrix [169]. When included in cultures of human fibroblasts an increase in TIMP-I 
production was seen [170]. This increase could be small and was increased when other 
growth factors were also present [171]. TGF -~3' induction of TIMP-l is accompanied by a 
concomitant decrease in the production of collagenase [172]. The induction of TIMP-l 
was also seen in rat calvarial osteoblasts; where one line could be significantly induced 
and the other, with a much higher basal level of expression did not respond [170]. 
Synovial cells will also produce TIMP-l on exposure to TGF-13 [173]. Other cells such 
as articular chondrocytes [174], calvarial osteoblasts (in the presence of 1,25(OHhDj) 
[175], and hepatomas [176] respond similarly. It has also been shown to partially prevent 
the II-I induced degradation of bovine cartilage [159]. 
There have been differing reports on the effect of interleukin 6 (IL-6) on the 
production of TIMP-l. Most show an increase in synthesis, although the opposite has 
been seen in the same cell type. Upregulation is seen in human skin and cervical 
fibroblasts [177] and shows a linear dose dependency. It has also been seen in human 
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articular chondrocytes, synoviocytes [178] and hepatoma cells [176]. However another 
study showed no IL-6 response in skin fibroblasts. High levels of IL-6 have been seen in 
the synovial fluid of patients with rheumatoid arthritis [179]. Since IL-6 does not 
stimulate the rroduction of MMPs [177] this finding could suggest that there is an 
attempt by the affected tissues to prevent cartilage breakdown. 
The actions of oncostatin M, leukemia inhibitory factor (LIF) and interIeukin II 
are closely linked to that of IL-6. They all act on cells via the same signal transducer, 
GP 130 [180, 181]. Each of these agents has been shown to increase the production of 
TIMP-I. Interleukin 11 is a very recently discovered cytokine that has been shown to 
increase TIMP-l synthesis. Oncostatin M selectively upregulates TIMP-l in human 
fibroblasts without an associated increase in MMP prcduction [182]. This increase is also 
notable in that it is much greater than that produced by IL-6 or any other stimulatory 
cytokine. LIF also increases the expression of TIMP-l without an accompanying 
increase in the production of MMPs. 
Progesterone and 17f1-estradiol are steroid hormones which have been shown to 
increase the production of TIMP-l in rabbit uterine cervical fibroblasts [183]. 
Progesterone also stimulates TIMP-2 production in rabbit cervical fibroblasts [184]. 
Prostaglandins acting on granulosa cells can stimulate inhibitor activity. This activity can 
be inhibited by the antiprogesterone RU486 [185]. Other hormones such as leuteinising 
hormone stimulate th~ production of TIMP-l in rat ovarian tissue. This is thought to 
have an important role in the connective tissue changes accompanying ovulation [186]. 
Prostaglandins might also be involved in the increased level of TIMP-l and 
TIMP-2 mRNA found in menstrual tissue (187]. Interestingly prostaglandin E2 does not 
affect the production of TIMP-l in other cell lines such as dermal fibroblasts [188], and 
osteogenic sarcoma cells [189]. This implies a specific receptor mediated response. 
Retinoic acid has been shown to stimulate the production of TIMP-l in human 
synovial fibroblasts [ 190]. 
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1.6. Localisation. 
TIMP-] was originally identified in serum where it makes up less than 5% of the 
anti-metalloproteinase activity present [87]. Its concentration was determined at ],03 ± 
0·27 l-1g/ml (191)' Su\.)s(:quently in the circulatory system other MMP inhibitors are 
dominant. The most important of these is a2-ma.croglobulin, which is responsible for 
more than 95% of the total metalloproteinase inhibitor activity in human plasma [S7). 
The a2-macroglobulin is a general proteinase inhibitor that forms irreversible complexes 
with all four classes of proteinases, including the MMPs, on cleavage of a bait region. 
This eventually leads to removal of the inactive enzyme-inhibitor complexes via the liver 
[192]. However this inhibitor is very large, forming a tetrameric complex of 
approximately 750 kDa. This makes access to tissue spaces difficult, restricting activity 
to the circulatory system and inflammatory body fluids such as rheumatoid synovial fluid. 
This leaves the TIMPs as the primary regulators of MMP activity away from the 
.:;irculatory system. 
One of the most notable features of the TIMPs is their ubiquity. TIMP-I in 
particular is found in a large range of cells, tissues and body fluids. In most cases the 
presence of one or more of the TIMPs is usually associated with the expression of the 
MMPs which are in tum found wherever the connective tissue matrix is being 
remodelled. TIMPs have been associated with fibroblast cells [193], mesangial cells 
[194], endothelial cells [195], smooth muscle cells [196], macrophages [197], osteoblasts 
[198] and tissues undergoing osteogenesis [199], corneal tissue [200], in the roots of 
growing hairs [201], teeth [202], periodontal tissue and crevicular fluid [203]. It is 
particularly prevalent in ovarian tissue including the follicular fluid [204], amniotic fluid 
[205J, granulosa and luteal tissues [206] where MMP (and subsequently TIMP) activity 
is strongly associated with the processes of ovulation [207] and the endometrial 
remodelling processes associated with menstruation and embryonic implantation [20S]. 
TIMP is also found in areas of active growth such as the growth plate of bone [209] and 
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in various foetal tissues where control of the extracellular matrix is essential during 
development [210). 
In pathological states it has been found in synovial fluids [211, 212] and the cells 
of the rheumatoid synovium [213], scaning [214] and fibrotic tissues [3). There is a 
strong association with cancerous tissues and cells. TIMPs have been identified in many 
tumour cells including pulmonary carcinomas [215], colorectal tumours [216], non-
Hodgkins lymphomas [217] and transformed fibroblasts [218]. 
1. 7. Inhibition of the Matrix Metalloproteinases. 
1.7.1. TIMP and Enzyme Latency. 
The TIMPs have been found to regulate enzyme activity at two levels. Mostly 
regulation is by directly inhibiting the fully active enzyme. However, regulation by the 
TIMPs has been identified prior to the activation of the enzyme. Here they have been 
found to be involved in the control of activation for some of the MMPs. 
Both TIMP-l and TIMP-2 have been shown to form exclusive inhibitor-zymogen 
complexes with the 92 kDa and 72 kDa pro-gelatinases respectively, but for no other 
MMP. TIMP-I forms a complex with the pro-enzyme form of the 92 kDa and TIMP-2 
forms a complex with the 72 kDa form [219, 220]. These complexes are produced by a 
range of cells and have also been identified in synovial fluids [221]. Of the two it is the 
TIMP-2/72 kDa gelatinase that has been studied in most detail. 
The TIMP-2172 kDa pro-gelatinase complex has two interesting features. The 
first is that it is possible for activation to occur whilst the inhibitor is still present in the 
complex [220]. No dissociation is necessary, although it is possible that the inhibitor 
could be dissociating for long enough for activation to take place. Activation is still 
possible using conventional materials such as APMA [222]. It has been shown that 
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stromelysin can activate the TIMP-2172 kDa pro-gelatinase complex [223 J and that 
APMA will further increase the activity. A protein based activator of 72 kDa gelatinase 
has also been associated with cell membranes [224, 225]. This may be the membrane 
metalloproteinase identified recently [52]. 
The additi;:m of extra free TIMP-I or TIMP-2 will inhibit both the activation and 
the activity of the activated enzyme. The ability of additional TIMP to fonn a further 
complex with the TIMP-2172 kDa pro-gelatinase complex suggests that an additional 
binding site is present on one or both of the molecules. Non-denaturing SDS-P AGE and 
cross linking experiments suggest that higher order (tetramaeric) complexes can also 
fonn [226]. 
The second feature is that this complex is itself an inhibitor of the MMPs. This 
activity was originally identified as an additional inhibitory peak in gel filtration profiles 
of foetal lung fibroblast media [220J and it has also been found in synovial fluids [227]. 
This also suggests that TIMP-2 may have more than one binding site for the 72 kDa pro-
geiatinase. One site that is involved in the direct inhibition of the active enzyme and 
another that binds the latent enzyme, leaving the inhibitory domain free to inhibit 
additional molecules of active gelatinase. Further confinnation comes from the fact that 
TIMP-2 will still bind to 72 kDa pro-gelatinase in the presence of 1, 10-phenanthroline 
[228]. This hypothesis has been supported by the identification of inactive ternary 
complexes consisting of two molecules of gelatinase bound with a single molecule of 
TIMP-2 [229J. This showed that if the TIMP-2 molecule was binding to both enzymes 
simultaneously then by deduction there must be two functional sites on the TIMP-2 
molecule. Deletion studies of the TIMP-I molecule have shown that the C-tenninus of 
the protein is involved in the second interaction with the 92 kDa pro-gelatinase [230]. 
The same has been found for the TIMP-2172 kDa gelatinase complex (unpublished 
results cited in [231 D. 
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Data from studies using peptides have located an additional binding site in the c-
terminal portion of the gelatinase molecule. It was found some distance away from the 
active site (in the region starting at residue 414). The presence ofa second site in the C-
terminus of pro-gelatinase has also been shown in experiments with deletion mutants. 
Here, inhibition was reduced in C-terminal deletion mutants and a separately expressed 
c- terminal piece was found to bind to TIMP-2 [232]. This second site has been 
described as a stabilisation site [228]. The dissociation constants have been determined 
for both sites. For the active site the Kd is 0·72 nM and the stabilisation site has a Kd of 
0·42 nM, both of which indicate tight binding complexes. 
The function of the TIMP-2 molecule here appears to be to prevent the 
autodegradation of the enzyme [233]. The capacity to bind the additional site appears to 
be lost once the enzyme has been fully activated. This would allow a pool of stable, 
inactive enzyme to remain in the tissues alongside a store ofTIMP-2. Once activated this 
TIMP-2 would then be immediately available as an inhibitor at the active site. In addition 
there is evidence that TIMP-2 will not bind pro-gelatinase that lacks the C-terminal 
domain and that this mutant pro-enzyme can not be activated by membrane preparations 
[23 I]. In this instance the role of TIMP-2 may be to regulate the activation of the 72 
kDa gelatinase by cell membranes. 
Cross linking studies of TIMP-2172 kDa pro-gelatinase complexes suggest that 
79% of the material is in the form of a binary complex and that the remainder is in the 
form of a ternary complex consisting of two molecules each of TIMP-2 and gelatinase 
[233]. When the cross-linked binary complex is activated it has normal activity but is less 
susceptible to inhibition by free TIMP-2. This suggests that occupation of one site partly 
prevents occupation of the second. 
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1.7.2. Inhibition of Enzyme Activity. 
The three different TIMPs that have been described so far have different 
specificities for the different MMPs. Although they are likely to share the same overall 
topology it iii not guaranteed that they will share the same mechanism. Subsequently it is 
important to consider the structure ana function of the enzymes involved and the details 
if the interactions of each with the MMPs. 
With the exception of the complexes formed between TIMPs I and 2 and the 
latent gelatinases all of the TIMP-MMP interactions have a 1: 1 stoichiometry. A number 
of studies have looked for the sites on both the TIMPs and the MMPs that are involved 
in the interaction. 
Whilst it is possible for both TIlVrP-l and TIMP-2 to inhibit all of the MMPs (the 
details of TIMP-3 are not fully determined) there is a variation in the relative specificity 
of each inhibitor for (:ertain enzymes. TIMP-I binds preferentially to the 92 kDa active 
form of gelatinase whilst TIMP-2 binds the active 72 kDa form [219, 220]. Also the 
smallest of the MMPs, matrilysin has, a Ki of4'5 x JO -9 M (binding TlMP-I) compared 
with that of the binding constant for the interaction of TIMP-l with stromelysin (Ki = 
8'3 x JO -10 M) [234]. Matrilysin differs from the other MMPs in not having a C-terminal 
domain, consisting only of a pro-peptide and a catalytic domain [12]. This differential 
binding is an indication that the C-terminus of the enzymes is involved in the interaction 
with the TIMPs in addition to the assumed binding site in the active site. 
One study of the differential binding used C -terminal deletion mutants of 
stromelysin and collagenase [26]. The Kj was determined using a synthetic substrate in 
the enzyme assay which gave approximate values. This indicated that there was no 
difference in the interaction of TIMP-I with stromelysin with and without the C -terminal 
fragment. However, a difference of an order of magnitude was found when the Ki of 
TIMP-l binding to intact collagenase was compared with that of TIMP-I binding to the 
C -terminally truncated form «0-2 nM, compared with 1-2 nM). The autoproteolytically 
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generated N-terminus of fibroblast collagenase was shown to have a significantly reduced 
ability to be inhibited by TIMP-I [28]. 
Another study of stromelysin mutants did find a difference in the relative abilities 
of intact and C-terminal deleted mutants to bind TIMP-I. This ~ave a Kj 14% that of the [234] 
intact enzyme (8·3 l( to -10M int:lct, 5·95 x to -9 truncated t Analysis of the association 
rates of TIMPs 1 and 2, and stromelysin in contrast showed that the C-terminal domain 
has no effect on the rate of association [235]. 
Similar experiments using C-terminal deletion mutants have been carried out for 
the 72 kDa gelatinase. Again it was found that the truncated enzyme had altered binding 
affinities for the inhibitors. In this case TIMP-2 showed greatly reduced binding and 
TIMP-I did not bind at all [231]. This suggests that the C -terminus of some of the 
MMPs is important in the interaction with TIMP-l in addition to the N-terminus.. 
The role of the different domains of the TIMPs in relation to the formation of 
higher order TIMP/gelatinase complexes has already been discussed (see section on 
latency). The N-terminus of TIMP-I alone has been shown to inhibit the MMPs [230]. 
The C-terminus appears to be involved in the interaction with some of the MMPs and not 
with others. There is little effect on the rate of binding of TIMP-I and TIMP-2 to 
stromelysin-I, whereas the interaction with the 72 kDa gelatinase is much more 
dependent on the presence of the C-terminal domain [235]. 
Mechanism of Action. 
In all studies of the TIMPs, the binding to the MMPs has been shown to be 
reversible. TIMP molecules are not consumed in the reaction, nor is an irreversible co-
valent complex formed with the MMP. In all cases studied so far it is possible to retrieve 
active TIMPs from the various complexes. The most probable mode of action is a steric 
hindrance preventing access to the active site by the substrate. 
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The association constants are very high, such that the complex once formed is 
unlikely to dissociate. Estimates made over a period of time have increased the value as 
the methodology has improved. Initial calculation of the binding constant for the TIMP-l 
- collagenase interaction gave a Kd of 1-4 x 10 -10 M PJ6], another calculation gave a 
figure of I x 10 -9M. A more recent analysis using surface plasmon resonance technology 
estimated the Kd to be 4- I x 10 -9 M [237]. However when a.2-macroglobulin is present 
the majority of collagenase molecules will bind to this in preference to TIMP-l [238]. 
This is due to a faster binding rate than for TIMP-l. 
Although the interaction is very tight it is possible for other small molecules to 
enter the TIMP-l-collagenase complex. A small collagen based peptide coupled to a 
chelating hydroxamate group can both block complex formation and encourage the 
dissociation of TIMP- I from collagenase [239]. A biological factor, endothelial cell 
stimulating angiogenesis factor (ESAF) is also able to release TIMP-l from enzyme-
inhibitor complexes [240]. 
There has only been one detailed kinetic study of the interaction of TIMPs and 
MMPs. This was a study using a variety of deletion mutants of TIMP-l and TIMP-2 and 
the 72 kDa gelatinase [241]. In this case the reaction is a simple bimolecular association 
with a kon that is not unexpected for such an interaction. Again the kon seen for both of 
the C-terminal deletion mutants (TIMP- I and TIMP-2) was similar to that seen for other 
interactions of this type, although the rates for both were up to three orders of magnitude 
lower than for the native protein. TIMP-2 has a series of charged residues at its C-
terminal tail (interestingly, a feature it has in common with TIMP-3). The kinetic study 
showed that this portion was important in maintaining the kon· If these charged residues 
were removed, the kon was four times slower than before. This ties in with the inverse 
relationship between the inhibitory activity of TIMP-2 and ionic strength. Ionic 
interactions are also involved in the inhibition of 72 kDa gelatinase by the N-terminal of 
TIMP-2, since the sensitivity to salt remains even in the absence of the C-terminal 
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peptide This effect is not seen for TlMP-I, suggesting that for gelatinase inhibition, 
alternative binding mechanisms (such as hydrophobic interactions) are involved. 
In another study, the glutamic acid residue at the active site of the 72 kDa 
gelatinase (Glu-375) was mutated to either Asp (same charge), Ala (replacing an acidic 
side chain with a hydrophobic one) or GIn (uncharged equivalent) [242]. None of these 
changes affected the ability of TIMP-l to bind to the activated 72 kDa gelatinase 
indicating that Glu-375 is not involved in the interaction between TIMP-l and the active 
site. 
1.7.3. Identifying Important Residues. 
Sequence Homologies. 
Various regions of the TIMPs have been proposed as being potentially important 
for activity on the basis of the strong conservation of their sequences. The larger,t of 
these is the N-terminal sequence where most residues are identical throughout all of the 
TIMPs. Even where there are variations in the absolute homology the difference is 
normally a conservative substitution. These highly conserved sequences may be 
important to the ability of TIMPs to inhibit MMPs. It is also possible that they are 
essential to the general structure of the TIMP family. As mentioned previously, all of the 
cysteines are conserved and there is a high degree of conservation amongst the residues 
surrounding the cysteines. To look for conservations that are retained within one of the 
TIMP family across different species, but differ in the other TlMPs might indicate 
regions of the molecules that are important to the individual specificity and function of 
each of the TIMPs. 
Appendix 3 shows the alignment of all the fifteen known TIMP sequences along 
with an indication of the extent of conservation, within each TIMP type and across the 
whole family. Over all the TIMPs only a few key residues are conserved entirely. All 
twelve of the cysteine residues are entirely conserved, reflecting the importance of the 
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disulphide bonding to the overall structure of the proteins. Residues adjacent or close to 
the cysteines also tend to be conserved. The VlRAK sequence identified by Woessner is 
also entirely conserved. In the solution structure of TIMP-2 this sequence forms part of a 
helix which is presumably essential to the overall TIMP structure. The other conserved 
residues are scattered throughout the sequence and probably represent key points in a 
common fold. 
TIMP-I does not hav(; many residues that are unique and conserved. This in part 
reflects the larger number of sequences studied. The sequences V-29NQTTL YQ-36 and 
L-1SILQGSEK-IS7 (human) are unlike the other TIMPs, and are mostly conserved 
across the different species. Many other sequences are shared with TIMP-2 or TIMP-3. 
Among the four known TIMP-2 sequences, there is a very high degree of conservation, 
with only ten of the 194 residues showing any variation. Interesting features include the 
sequences G-37NPIKRIQ-44, K-89AEG-93, T-152EKSING-158 and Q-18SEFLDIE-
193, which are unique to TD\4P-2. TIMP-3 also appears to be highly conserved, although 
only three sequences were available for alignment. The sequence SNFGHS stands out as 
being different from other TIMPs. Some of these features, particularly in the C-terminal 
domains, may be associated with the growth factor properties of the TIMPs. In the case 
ofTIMP-2 the unique sequences may be involved in its additional binding site for 72 kDa 
gelatinase. The overall lack of clearly unique sequences could suggest (and agrees with 
peptide and antibody competition studies described later) that the inhibitory action of the 
TIMPs is associated with large parts of the molecule rather than a single region. 
Modifications and Mutagenesis. 
In addition to the proteolytic analyses, chemical methods have been used to 
identifY surface residues that may be involved in the inhibitory process. This method is 
more specific, identifYing functional residues, rather than those that are simply exposed. 
Mutagenesis has also been used to identifY important regions and residues. On large 
scale the N-terminal domain of TIMP-I has been cloned and expressed separately (Cys-, 
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1 - Glu-126), and shown to be fully active [230). On a smaller scale, individual residues 
and short stretches of sequence have been altered or deleted. 
It was found that diethylpyrocarbonate (DEPC) inactivated TIMP-l [243]. 
DEPC carboxylates nucleophiles, primarily histidine (although other residues can be 
carboxylated) under certain conditions. At 50% inactivation of TIMP-I, only 1·5 
molecules of carboxyl groups were bound per TIMP-I molecule suggesting a specific 
inactivation mechanism. Peptide mapping identified His-95, His-144 and His-154 as 
carboxylated after DEPC treatment [131], one other could not be identified. If the 
inhibitory activity is purely due to the N-terminal domain [230], then, if a histidine was 
important for the activity it is unlikely to be His-144 or His-154. Another study where 
site directed mutations were found that affected the activity of TIMP-I suggested that 
His-95, was not essential for inhibition. Instead His-7 was singled out as important [244]. 
It is interesting to nDIe that both His-7 and His-95 are conserved. DEPC modification of 
mutant TIMPs has not clarified the situation. A His-95 mutant (His95Gln), which 
remains active [244] is affected by DEPC treatment. However, His-7 which shows 
reduced activity when mutated to Ala-7 [244], also remains sensitive to DEPC [131]. 
Unfolding experiments have suggested that the DEPC modified protein is not 
significantly less stable than the wild type, so any structural perturbations caused by the 
carboxylation are local, and do not affect the overall structure or stability. 
One sequence is highly conserved tnroughout all of the TIMPs, this is the 
VIRAl< sequence from close to the N-terminus (18-22). The high degree of conservation 
could indicate that this region has a functional importance. Deletion of this sequence 
results in no significant yield of protein indicating that its function may be structural 
rather than inhibitory [230]. 
It is possible that the mechanism of interaction cannot be explained by a simplistic 
model of a few spatially close residues. This idea is supported by a recent study using 
peptide competition and identifying the epitopes of antibodies that block inhibition [237]. 
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These results suggest that a large part of the TfMP-l sequence may be involved in the 
MMP interaction. Residues 2-45, 70-145 and 165-184 were implicated in competition 
experiments using long peptides. Shorter peptides refined this to residues 2-25 and 121-
136. This would suggest that the C -terminal, previously thought to be unimportant, may 
have a function in the inhibitory process Of particular interest was the 'hinge' region 
between the two domains. This does not agree with other work that shows the inhibitory 
activity to be based solely in the N-terminal domain [230]. Previous studies of tryptic 
susceptibility show no protection of the N-terminus by the C-terminus [139]. 
Subsequently it may be possible that the C -terminus has a function in direct inhibition 
that has not been defined. 
Structure and Inhibition. 
Not all of the stru<;ture is necessary for inhibition but it appears that all of it is 
required for normal kinetics and the fonnatiof} of higher order complexes. 
It is also not necessary for the structure to be intact for inhibition to occur. 
TIMP-I that had been cleaved by bacterial proteinases [Clark I.M. unpublished results] 
was found to retain its activity. TIMP-2 has been purified in a two chain form that has 
also been shown to be active in spite of a proteolytic cleavage [245]. Interestingly, this 
two chain fonn does not bind to the 72 kDa progelatinase. 
1.8. TIMP as a Growth Factor. 
Although TIMP-l was first identified on the basis of its inhibitory activity an 
entirely different line of investigation identified TIMP-l not as an inhibitor, but as a 
growth factor. A factor was identified that had the ability to stimulate the differentiation 
of erythroid precursors [246, 247]. This proteinaceous factor was called 'erythroid 
potentiating activity' or EPA Many of the early studies on the regulation of the TIMP 
gene were carried out before the co-identity was known. Only when the complete 
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sequence of TIMP-l was determined and compared with the N-terminal sequence of 
EPA [248], were they found to be the same protein. 
TIMP-l is produced by the stromal cells of human bone marrow [249] where 
local release allows direct stimulation of the erythropoietic pfl~cursor cells. A wide 
ranging study found that the stimulatory activity extends beyond the erythropoietic cell 
lines causing cell proliferation in all of those tested [250]. Cell lines shown to respond to 
TfMP-l stimulation were huma.n gingival fibroblasts, Burkitts lymphoma cells, human 
Iymphoblasts, epithelial cell, smooth muscle cells, chondrocytes, leukaemia cells and 
transformed human lung cells. TfMP-l has also been found to stimulate keratinocytes 
[251]. A monoclonal antibody was found that blocked both the proliferative and 
potentiating activities of TIMP-l in an erythroleukaemia cell line [252] showing that the 
two activities are closely linked. 
Initial assays of the ability of TIMP-2 to stimulate cell proliferation did not show 
any activity [250]. It was originally thought that the stimulatory activity of TIMP-l was 
connected to a region of the N-terminal sequence that had a high homology to 
granulocyte-macrophage colony stimulating factor [253]. TIMP-2 does not share this 
homology. However a later study found that TIMP-2 could stimulate the differentiation 
of the same erythroid cells as TIMP-l (BFU-E) [254] as well as the proliferation of a 
human fibroblast line [255]. This would suggest that the region of the TIMPs involved in 
these growth factor properties is one shared by both TIMP-I and TIMP-2. TIMP-2 also 
appears to be more potent than TIMP-l at stimulating a range of cells, requiring a tenth 
the concentration of protein to achieve the same degree of promotion [256]. When 
TIMP-l or TIMP-2 are complexed with the progelatinase B or progelatinase A 
respectively, no stimulation of proliferation is seen. However this growth promoting 
activity is found in the reduced, alkylated forms of the proteins. Evidence has also been 
found for the presence of TIMP-2 receptors on the surface of cells from a lymphoma 
line. 
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1.9. MMPs and TIl\JPs in Disease States. 
MMP and TIMP activity is seen in an enormous number of cells and tissues. 
Their role in controlling the turnover of connective tissue components is an extremely 
important one. Wherever there are changes occurring in the tissue matrix the MMPs and 
the TIMPs are likely to be involved. An error at any point in the control structure can 
lead to a number of diseases. 
The degradation of cartilage that occurs in arthritis is associated with an 
imbalance in the enzyme-inhibitor ratio that results in excessive MMP activity [257]. 
MMPs have been identified in the synovial fluid of patients with arthritis [258] and 
localised in rheumatoid synovium [259]. TIMP is not always absent from sites of matrix 
breakdown (it has also been found as a complex with collagenase in synovial fluids 
[212]). 
MMPs have been identified in metastatic tumour cells, and are often found with 
TIMPs. The breakdown of the basement membrane collagens (type IV) in particular 
allows cells to escape the confines of their original location and move to new sites. The 
problem here is also one of an imbalance between matrix breakdown and enzyme 
inhibition. In experimental models treatment with additional TIMP (both TIMP-I and 
TIMP-2) can prevent the metastatic process [260, 261]. 
MMPs are also associated with periodontal disease [262]. The quantity of 
collagenase found in periodontal tissues is generally related to the severity of the 
condition. TIMP-I has also been found in dental material (see section on localisation) 
again indicating that the problem is an imbalance rather than an absence of inhibitor. 
There is evidence that malfunctions in the TIMP gene are associated with familial 
otosclerosis [263]. Stromelysin has also been linked to this condition [264]. MMPs are 
involved in the processes of fibrosis and inflammation development. The ubiquity of the 
MMPs and TIMPs, their crucial role in connective tissue turnover and the potential for 
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serious illness resulting from a malfunction in their activity means that it is essential that 
we fully understand the nature and control of the enzymes and their inhibitors. With this 
information we can make new advances in the treatment of disease. 
1.10. The Development of New Therapeutic Agents. 
This study has been carried out against a background of research into the 
mechanisms involved in arthritis. Its long term aim is to contribute information that will 
be useful in the development of new anti-rheumatic drugs. Since MMP activity is also 
associated with the processes underlying tumour metastasis compounds that can 
modulate their activity may also prove useful in the treatment of cancer. 
1.10.1. Compounds Used In Vivo. 
Patients with arthritis are commonly treated whh drugs from one or more of the 
non-steroidal anti-inflammatory (NSAID), steroidal or disease modifying anti-rheumatic 
drugs (DMARDS). The NSAIDs are benzoic acid derivatives the commonest of which is 
salicylic acid (aspirin). Their primary action is the inhibition of prostaglandin synthesis, 
although dependant on the dosage used, other processes are inhibited. These include 
histamine release, transmembrane anion transport, mitochondrial metabolism and various 
membrane proteinase activities [265]. Although very effective, these compounds are 
associated with gastrointestinal problems where they can cause ulceration in the stomach 
and duodenum [266]. The DMARDS are a hTfOUP of unrelated drugs with the ability to 
affect the progress of the disease. The best known are methotrexate, gold, penicillamine, 
sulfasalazine and the anti-malarials [267]. Other treatments use immunosuppression 
(cyclosporine) [268] dietary modifications, immunotherapy, interferon treatment [269] 
and humanised monoclonal antibodies that target T -cells [270). 
Many of these treatments rely on modifying the inflammatory response. An 
alternative approach would be direct modulation of MMP/TIMP activity. One method 
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would be cytokine therapy, using them to tip the balance of enzyme-inhibitor away from 
a net breakdown of matrix. However the functions of the cytokines are very complex, 
being involved in many physiological processes where modifications might not be 
desirable. Another approach that has attracted a great deal of interest is to specifically 
inhibit one, or more of the MMPs. 
1.10.2. Compounds Used In Vitro. 
Many compounds have now been identified that will inhibit the MMPs ill vitro. 
Compounds that chelate the zinc atoms such as EDT A and 1,10 - phenanthroline and 
compounds that reduce the disulphide bridges (DTT and p-mercaptoethanol) will destroy 
enzyme activity. More specific inhibitors have been designed, based on the cleavage site 
in the collagen molecule. These include the peptide hydroxamic acids which are based on 
the tripeptide (Pro)-Leu-Gly [271, 272]. Phosphonamidate and phosphoramidate 
inhibitors [273, 274] have aho been based around a peptide. In these cases the peptide 
was LeulIle-AJa-Gly. The inhibition is thought to be a result of the interaction of the 
phosphoryl atom with the active site zinc. Sulphur-based substrate analogues, again with 
a similar peptide sequence have also been found to be effective [275]. 
Other inhibitors have been found amongst the antibiotics. Tetracycline is known 
to have an anti-inflammatory action connected to the inhibition of collagenase activity. 
This may be an indirect effect rather than a direct inhibition. Actinonin is a pseudopeptide 
antibiotic produced by actinomycetes which has a Ki of 1·4 x 10-6 M against collagenase. 
The incorporation of a zinc ligand into a synthetic substrate has proven to be relatively 
effective in a series of inhibitors designed by Roche (150 = 17 nM) [276]. The ACE 
inhibitor, captopril has been shown to inhibit both the 72 kDa and the 92 kDa gelatinases 
[277]. Again it is thought to act by the chelation of the zinc atom at the active site. 
Another strategy is to mimic the action of the TIMPs. A good mimic could be 
based on either the structure/sequence of one of the TIMPs. AJtematively it might be an 
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entirely novel molecule based on the specific interaction of a TlMP molecule with an 
MMP. 
1.11. Summary. 
In pathological conditions the delicate balance of connective tissue breakdown 
and synthesis is perturbed, often with serious and debilitating consequences. A detailed 
understanding of the mechanism of connective tissue turnover may identify key points at 
which the process can be modified by suitable therapeutic agents. The matrix 
metalloproteinases and their inhibitors playa vital role in connective tissue turnover. To 
understand their function it is essential to include detailed structural and functional 
studies. 
TIMP_l has only been ~roduced in sufficient quantities for this type of s.tudy in 
recent years. Subsequently only a few details are known of its structure and mechanism. 
Attempts to crystallise wild type TIMP-l have been unsuccessful, possibly due to its 
extensive glycosylation. However a mutant TIMP-I where the glycosylation sites are 
removed has crystallised [278]. Recent developments in NMR technology have increased 
the upper size limit of suitable proteins to over 20 kDa. Since TIMP-I has a protein 
molecular weight of 20·5 kDa it should be possible to determine its structure using 
multidimensional NMR spectroscopy. This requires that an expression system is availabk 
to produce large quantities of isotopically labelled, non-glycosylated TIMP-l. 
This study uses a variety of spectroscopic techniques to elucidate structural 
features of TIMP-l including its secondary structure content, surface properties and 
interactions with collagenase. Also included are the developments of expression and 
purification protocols designed to maintain a reliable supply of recombinant TIMP-I for 
continuing studies. 
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Chapter 2. 
General ~Iethods and Materials. 
2.1. Assays. 
2.1.1. Collagenase and TIMP Bioassays. 
The biological activity of collagenase and TIMP is measured using a modification 
of the diffuse collagen fibril assay [279]. 
At 37°C type I collagen dissociates into individual fibrils. Collagenase breaks 
triple helical collagen and fibrils into well characterised Y.t and % fragments of the whole 
molecule. On centrifugation these cleaved fragments remain in the supernatant and the 
undigested fibrils form a pellet at the bottom of the tube. If the collagen fibrils are 
radio labelled, collagenase activity can be assayed by assessing the radioactivity of the 
supernatant containing the cleaved fragments. 
Controls for this assay are a blank to assess the residual radioactivity in the 
supernatant after the intact, radio-labelled fibrils have been removed from solution. 
Trypsin breaks down anj collagen fibrils that are unwound (damaged) and subsequently 
accessible to other proteinases, and is included as a control for the quality of the collagen 
fibrils. A bacterial collagenase control is included to cleave all of the collagen fibrils. This 
shows the radioactivity to be expected from supernatants where all of the collagen is 
cleaved (100% lysis), and is used in calculating the collagenase activity of a test sample. 
Collagenase activity is calculated from the raw counts as overpage: 
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100 1000 1 
x x = assay factor 
Bac. Cvll (cpm) Sample volume (J.1I) tim'~ (minutes) 
enzyme activity = assay factor x (Sample cpm - blank cpm) 
One unit of collagenase activity is defined as the amount that digests 1 J.1g of collagen per 
minute at 37°C. 
To assay inhibitory activity a known amount of collagenase, sufficient to gIve 
approximately :'0°/.:1 lysis is added to each sample and used as an additional control. 
Inhibitory activity is calculated using the equation below: 
inhibitory activity = assay factor (as above) x (enzyme cpm - sample cpm) 
One unit of inhibitory activity is defined as the amount of inhibitor that reduces the 
activity of two units of enzyme by 50%. 
Materials. 
Microcentrifuge tubes are from Hughes and Hughes, Romford, UK. 3H type I calf skin 
collagen is produced by the Rheumatology Research Unit Cambridge UK [279]. Trypsin 
and clostridium histolyticum collagenase are from Sigma Chemicals, Poole, UK. 
Scintillation fluid is Optiphase 'Hisafe' II, from LKB Instruments Ltd, Surrey, UK. Other 
chemicals are analytical grade reagents from standard sources. 
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Experimental Detail .... 
Radiolabelled type I calf skin collagen is prepared by dissolving the collagen in a 
Borate buffer, 200 mM NaCI, 0·02% (w/v) NaN3, pH 9 and labelling with 3H-acetic 
anhydride. The final activity is approximately 2·5 x 105 dpm mg -1 
Porcine collagenase purified in the Rheumatology Research Unit is activated by 
the addition of APMA to 0·7 mM [280]. 
Control tubes are, (1) buffers and collagen only, (2) 10 III of Imglml trypsin in 1 
rnM HCl, (3) 20 Ilg of bacterial collagenase, and for the inhibitor assay, sufficient active 
enzyme to produce approximately 70% lysis of the collagen. 
100 J.!l of SO mM Tris, 1 mM CaCI2 pH 7·9 is added to all tubes. Sample volumes 
range from 10-50 Ill. All samples and controls are made up to 200 III with 25 mM 
sodium cacodylate, 0·05% (v/v) Brij-35, pH 7·6. 100 III of 3H collagen is added to each 
tube, which is then mixed and incubated for 16 hours in a waterbath at 37°C. 
After the incubation sample tubes are centrifuged for 10 minutes at 13700 rpm, 
4°C. 200 III of each supernatant is transferred to scintillation vials and mixed with 3 ml of 
scintillation fluid. Activity is counted for 15 seconds per vial on either an LKB Rackbeta 
scintillation counter or a Wallac 141 0 liquid scintillation counter. 
2.2. Enzyme-Linked Immunosorbent Assays (ELISAs). 
The exact quantity of TIMP-I in samples is determined using a sandwich enzyme 
linked immunosorbent assay (ELISA) [135] developed in the Rheumatology Research 
Unit. Plastic 96 well plates are coated with a monoclonal anti- TIMP-l antibody, then 
blocked with BSA to prevent non-specific adsorption of the samples to the plastic. The 
sequence of incubations is first the samples, then a second, biotinylated monoclonal 
antibody to TlMP-l and finally streptavidin linked horse-radish peroxidase. The 
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detection method uses horse-radish peroxidase, which breaks down OPD to give a 
yellow product. The colour development is stopped by the addition of sulphuric acid. 
The quantity of TIMP present is determined from the absorbance of the final product at 
492 nm in comparison with a standard curve. 
Materials. 
Ninety-six well maXlsorp microtitre plates are from Nunc. Monoclonal, and 
biotinylated monoclonal antibodies are prepared in the Rheumatology Research Unit 
[135]. Horse-radish peroxidase conjugated streptavidin is from Dako Ltd, High 
Wycombe, Bucks, UK Citrate phosphate buffer and phosphate buffers are made up from 
capsules and tablets purchased from Sigma. OPD is from Sigma. Wash buffer consist~; of 
phosphate buffered saline plus 0-1 % (w/v) thimerosal. Protein diluent is wash buffer plus 
0·5 mg/ml bovine serum albumen (BSA, from Sigma). Blocking buffer is 10 mglml BSA 
in P.3S, plus 0·02% (w/v) ]-.;aN3. 
Experimental Details 
Assay plates are coated with 100 III per well of G 1 OC6 anti-TIMP-I antibody at 
4 ~lg/ml in PBS. Plates are incubated overnight at 4°C, the antibody solution removed, 
then they are blocked for a minimum of 1 hour with 150 IlVwell of blocking buffer. 
Before use the coated plates are washed automatically with wash buffer using a Titertek 
plus M96 washer (leN Flow). Samples are diluted in protein diluent and applied in 
duplicate to the plate at 100 IlVwell. A standard curve of TIMP-I at 5-50 nglml is 
prepared in the same diluent. 
Samples are incubated for two hours at room temperature then the plate is 
washed three times. 100 III of biotinylated P2H 1 0 monoclonal antibody is added to each 
well at 200 nglml and the plate incubated for a further two hours. It is then washed again 
three times and 100 III of HRP linked streptavidin added to each well at a 1/5000 dilution 
(in protein diluent). The plate is incubated for a further 30 minutes followed by three 
51 
washes. Colour is developed in the dark by the addition of 100 J.lVwell of OPO (one 15 
mg tablet in 12 ml phosphate-citrate buffer). The reaction is stopped when sufficient 
colour has developed (normally 2-15 minutes) by the addition of 50 IlVwell 2M H2S04. 
The absorbance of the samples is read on a Titertek muit:scan plus MK II plate reader 
(leN Flow) at 492 nm and results calculated from the standard curve using the TiterSoft 
analysis package. 
2.3. Protein Assays. 
2.3.1. Absorbance. 
The absorbance of protein solution at 280 nrn are determined on a Cecil 6600 
UV/vis spectrophotometer, using either quartz or disposable polymethyl methacrylate· 
UV grade cuvettes from Jencons Scientific. Protein concentrations arc approximated on 
the assumption that an A280 of 1'0 corresponds to a concentration of 1 mg/ml. 
2.3.2. BCA Protein Assay. 
Thebicinchoninicacid binding assay is used to determine the protein concentration 
for some samples of mixed proteins and when an immunoassay is not suitable [281]. This 
is performed using the Be A assay kit from Pierce-Wallac following the manufacturers' 
instructions. 
2.4. SDS-PAGE. 
Materials. 
SDS gel electrophoresis is routinely carried out using the mini-protean II system 
from Bio-Rad Laboratories Ltd, Hemel-Hempsted, Herts, UK. Large gels are produced 
using the Bio-Rad protean system. Polyacrylamide-bis- acrylamide is purchased as a 40% 
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(w/v) (39: 1 - acrylamide:bis) solution from Amresco. Ammonium persulphate (APS) is 
purchased in 0·2 g sachets from BOH Ltd, Upminster, Essex, UK and used at 0·2 gm 
/mJ. TEMED is from BDH. 4x lower gel buffer consists of l' 5 M Tris, 0'4% (w/v) SDS, 
pH 8·8. 4x upper gel buffer consists of 0·5 M Tris, 0·4% (w/v) SDS, pH 6·8. 5x final 
sample buffer consists of 250 mM Tris pH 6.8, 40% (v/v) glycerol, 10% (w/v) sodium 
dodecyl sulphate (SDS), 0,5% (w/v) bromophenol blue. 5x running buffer consists of 
125 mM Tris, 1M glycine, 5% (w/v) SDS. Coomassie stain contains 2·5% (w/v) 
Coomassie blue G-250 in 40% (v/v) methanol, 60% (v/v) H20. Destain contains 5% 
(v/v) acetic acid and 40% (v/v) methanoL Proteins for molecular weight markers and all 
other materials. are of good quality, from standard sources. 
Experimental Detail .... 
All SDS PAGE is based on the method of Laemmli [282]. Lower gels of 0·75 and 
1'0 mm are prepared at an acrylamide concentration of 12%. Upper gels are prepared at 
a concentration of 4·5%. Gels are set using 60 III 0,2 glml APS and 20 III TEMEO per 
12 ml of gel. 
Samples requiring concentration are treated in one of two ways. For one method 
two volumes of acetone are added to the sample which is then incubated at -20De for a 
minimum of 30 minutes. The sample is centrifuged for 10 minutes at 13700 rpm to form 
a pellet of precipitated protein, the solvent is decanted and the protein dried under 
vacuum. In the second method 600 111 methanol, 200 III chloroform and 200 III water are 
added to 300 III of the sample. The sample is centrifuged at 13700 rpm for 2 minutes, the 
upper layer removed, taking care not to disturb the protein at the interface, and 750 III of 
methanol added. After a final 5 minute centrifugation (at 13700 rpm) the supernatant is 
decanted and the pellet vacuum dried. All precipitated samples are taken up in FSB 
diluted to the working concentration. Samples not requiring concentration are prepared 
by the addition of FSB (to the working concentration). All samples are boiled for 4 
minutes prior to loading on the gel. 
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Samples are electrophoresed at 200 V for approximately 45 minutes (until the 
dye front passes the end of the gel). Gels are Coomassie stained for a minimum of 10 
minutes, destained, photographed and dried under vacuum. 
2.5. Western Blotting. 
Immunoblotting and transfer to PVDF membrane for Protein Sequencing. 
Materials. 
Western blotting is carried out using an LKB 2117 multiphor II semi-dry blotter 
(LKB Instruments Ltd, Surrey, UK). Transfer buffer contains 39 mM glycine, 48 mM 
Tris, 0'037% (w/v) SDS, 20% (v/v) methanol. Filter paper is IF grade, from LKB. 
Nitrocellulose (2 Ilm) is from Schleicher and Schuell, Oassell, Gennany. PVDF 
membrane (ImmobiIon-p) is from Millipore Corporation Bedford M.A. USA. Pre-stained 
molecular weight markers (low range) are from Bio-Rad Laboratories Ltd, Hemel-
Hempsted, Herts, UK. Wash buffer is Tris-buffered saline (TBS) with 0'1% (v/v) 
TWEEN, pH 7'6. Blocking and antibody buffers contain TBS-TWEEN with 5% (w/v) 
non-fat milk (Marvel). Polyclonal anti-TIMP-I and anti-collagenase antibodies are 
produced from rabbit, at the Rheumatology Research Unit [135, 283J. Horse-radish 
peroxidase linked, swine antibodies to rabbit immunoglobulins are obtained from Dako 
Ltd, High Wycombe, Bucks, UK. 4-chloronaphthol is from Sigma. Alkaline phosphatase 
linked goat antibodies to rabbit immunoglobulins are obtained from Bio-Rad 
Laboratories Ltd, Hemel-Hempsted, Herts, UK. Alkaline phosphatase colour 
development kit is also from Bio-Rad. 
Experimental Details 
SOS PAGE gels are run as described using 5-10 III of pre-stained markers in one 
lane. All materials are soaked in transfer buffer prior to use. A sandwich is fonned on the 
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anode of the blotter of; 9 sheets of filter paper, 1 sheet of nitrocelluloselPVDF, the SDS 
gel and finally a further 9 sheets of filter paper. A current of 200 rnA is applied through 
the sandwich for 45-60 minutes and the blot transferred immediately to blocking buffer 
for I hour. 
For immunoblotting the membrane is then incubated overnight with the' 
polyclonal antibody at a concentration of 1·5 ~l/m1. It is then washed (3 x 10 minutes) in 
wash buffer and incubated for a further 4 hours in the HRP-linked antibody. The blot is 
then washed a further three times and the colour developed in 60 ml of developing buffer 
(l x 15 mg tablet of 4-chloronaphtho~dissolved in 10 ml methanol, 50 ml wash buffer, 33 
~l H20 2). 
Alternatively, for the alkaline phosphatase development the second antibody is 
used at a dilution of 1 :3000, with an hour long incubation. The final wash before colour 
development does not contain TWEEN. The colour is developed using an alkaline 
phosphatase conjugate substrate kit from Bio-Rad Laboratories Ltd, Hemel-Hempsted, 
Herts, UK. This uses 50 III of reagent A (nitroblue tetrazolium in aqueous 
dimethylforrnamide containing magnesium chloride) and 50 III of reagent B (5-bromo-4-
chloro-3-inolyl phosphate in dimethylformamide) in 20 rn1 of bicarbonate buffer pH 9·5. 
Colour development is stopped by washing with water. 
For PVDF blots the membrane is pre-soaked in methanol, then washed with 
water. The transferred blot is passed quickly through Coomassie stain and immediately 
de stained extensively. 
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2.6. Other l\laterials. 
All other general laboratory chemicals where the source is not explicitly described 
are of analytical grade and obtained from eitler FSA Laboratory Supplies, 
Loughborough, Leics, UK, BOH Ltd, Upminster, Essex, UK or Sigma. Laboratory 
plastic-ware is obtained from leN Flow Ltd, Rickmansworth, Herts, UK. 
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Chapter 3 
Purification Of TIMP-l. 
3.1. Introduction. 
F or detailed biochemical and structural studies it is necessary to have large 
quantities of highly purified protein that can be produced quickly with minimal losses. 
TIMP-I was originally partially purified by gel filtration techniques [88]. Identifying it as 
a glycoprotein also aided the purification [128]. The protocol that was used for the initial 
TIMP-I preparations was that devised by Cawston et al [103]. This used a series of 
filtration and affinity columns that result in a sample of very pure protein. Since the 
TIMP-I was to be purified from human cell media, an initial chelating-Sepharose column 
was included as a first step to remove collagenase from the media prior to the TIMP-l 
purification. 
Another strategy for purifYing a protein is to use either monoclonal or polyclonal 
antibodies to that protein, covalently attached to a support matrix. Solutions containing 
the protein of interest can then be passed down the affinity column and if the antibodies 
used were of high specificity, highly pure protein can be eluted in a single step. This 
strategy had previously been applied successfully for TIMP-I by other workers [136]. 
To determine the most suitable matrix for an antibody affinity column, three 
different types of Sepharose with different linker groups for the ligand were tested. On 
the basis of these tests a much larger quantity of antibody coupled Sepharose was 
produced and used to purify a large quantity of TIMP-1 from human culture media. This 
approach is also shown to be applicable to the purification of recombinant TIMP-l. 
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3.2. Methods. 
3.2.1. Materials 
All cell culture media used for the purification of TIMP-I came from WI-38 foetal lung 
fibroblast cells [284]. This was kindly produced in bulk by SB. Chelating-Sepharose, 
heparin-~epharose, AcA44 gel filtration matrix, Concanavalin A·Sepharose, epoxy-
activated Sephaarose and activated CH-Sepharose are all from Pharmacia Fine 
Chemicals, Uppsala, Sweden. CNBr-activated Sepharose was also from Pharmacia and 
kindly provided in bulk by SB. Column chromatography equipment was purchased from 
Amicon, Upper-Mill, Gloucestershire, UK. Pumps and fraction collectors were from 
LKB Instruments Ltd, Surrey, UK. Monoclonal antibodies (P3G6) were developed in the 
Rheumatology Research Unit [135] and produced in bulk by SB. Dialysis tubing is from 
Medicell J ntemational, London UK. Concentrators and filtration membranes (Diaflow) 
are from Amicon. All other materials are of good quality from standard suppliers. 
3.2.2. Experimental Methods. 
At all stages of the purification the samples and column fractions are assayed for 
protein (by absorbance), inhibitory activity (by bioassay) and a specific ELISA for TIMP-
1 (see General Methods). The purity of the sample is also determined during the 
preparation by analysis on SDS PAGE. For all purifications CaCl2 (to 10 mM) is added 
to the bulk media and sodium azide added to 0·02%. It is then concentrated 10-20 fold, 
the medium adjusted to 50 mM Tris, 10 mM CaCI2, 0'02% NaN3, (pH 7'2) and passed 
down a chelating-Sepaharose co~umn. The chelating-Sepharose flow through pool 
contains TIMP-l which does not bind to the column. 
Multi-step Purification. 
F or this method the sample was dialysed into AcA column buffer (25 mM sodium 
cacodylate, 1 M NaCl, 0'02% NaN3• 0'05% Brij-35 pH 7·2). Samples were concentrated 
to a minimum volume (2-40 ml) and loaded onto a 1·2 L gel filtration column of 4·5 cm 
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in diameter at a flow rate of 40 mllhour. Fractions of 10 ml were colJected. Those 
fractions identified as containing TI~1P-l were pooled, concentrated and dialysed into 
heparin-Sepharose buffer (25 mM sodium cacodylate 0·02% NaN1, 0·05% Brij-35 pH 
7·2). Samples were loaded onto a column of 50 ml at 40 mllhour and 6 ml fractions 
taken. The column was washed with th.;! loading buffer and bound proteins eluted with 
either a salt gradient of 0-1·0 M NaCI or a salt jump of 1 M NaCi. Again TIMP-l 
containing fractions were pooled and concentrated if necessary. The sample was then 
dialysed into the loading buffer for the Concanavalin A-Sepharose column (25 ml\1 
sodium cacodylate, 100 mM NaCI, 0·02% NaN1, 0·05% Brij-35, 10 mM ZnCh, (used 
instead of MnCI2 which could affect NMR studies) 10 mM MgCh, pH 7·2. It was loaded 
onto a 100 ml column at 60 ml/hour. The column was washed with the loading buffer 
taking fractions of 6 ml. Bound proteins were eluted using the loading buffer with the 
addition of 0·5 M glucopyrannoside. For some samples an additional 'polishing' gel 
filtration step was used. 
For some preparations Brij-35 was omitted from the latter stages of the 
purification. To remove residual detergent, the sample was dialysed into a 10 mM 
ammonium hydrogen-carbonate buffer and passed three times down a 10 ml column of 
Extractigel-D 0·05% Brij-35, washing with ammonium hydrogen-carbonate buffer. After 
each elution the sample was re-concentrated. 
NMR Spectra. 
One-dimensional NMR spectra were recorded on a Bruker AMX 360 
spectrometer for a sample at approximately 8 mg/mt. For the I D spectrum, 1024 FIDs 
were acquired into 16 K data blocks with a 60 degree excitation pulse of 6 ms, a spectral 
width of 7042 Hz, an acquisition time of 1·16 s and a relaxation delay of 1· 5 s. 
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Preparation anti A.~,~essment of Antibody-Coupled Sepharose. 
Coupling was performed according to the general instructions supplied by the 
manufacturer. For the coupling of P3G6-antibody to CNBr-activated Sepharose the 
matrix was swollen for 15 minutes in 3x the final expected volume of 1 mM HCl, then 
washed with 30 volumes of 1 mM HCI followed by 3 volumes of coupling buffer (0'1 M 
NaHCO j 0'5 M NaC!, pH 8'3). Antibody was coupled at 1 mg/ml of gel in sufficient 
coupling buffer to give a soft slurry. The coupling mixture was incubated on an end over 
end mixer for either 16 hours at 4°C, or 2-4 hours at room temperature. To block 
remaining groups on the matrix the coupled gel was blocked with 1 M ethanolamine for a 
further 2 hours at room temperature. The blocking agent and excess protein were 
washed off with alternate washes of O'IM sodium acetate, 0·5 M NaCl pH 4·5 (acetate 
buffer), and coupling buffer. The matrix was finally washed with antibody column buffer 
(25 mM sodium cacodylate, 100 mM NaC!, 0'02% NaN) pH 7'2). 
Activated CH-Sepharose was prepared and coupled to the antibody much as for 
CNBr -activated Sepharose. After the incubation with the antibody solution the matrix 
was washed with 10 volumes of coupling buffer, then incubated for 1 hour at room 
temperature in 50 mM Tris, 0'5M NaC!. pH 8·0 (Tris buffer). The matrix was given 
extensive alternate washes of Tris buffer and acetate buffer, and finally transferred to 
antibody column buffer. 
Epoxy-activated Sepharose was prepared by swelling in an excess of distilled 
water for 15 minutes followed by extensive water washing. The ligand and matrix were 
incubated at 37°C (water bath) in coupling buffer for 16 hours with occasional gentle 
shaking. The coupled matrix was washed in 20 volumes of coupling buffer then given 
alternate washes of water, coupling buffer and acetate buffer. Remaining groups were 
blocked by a 1 hour incubation in 1 M ethanolamine, the matrix washed extensively with 
water and transferred to column buffer. 
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Initially small columns (approximately 2 ml in volume) were prepared for each 
matrix type. Media known to contain TIMP-l was passed down the columns under 
gravity and 1 ml fraction:. collected manually. The columns were washed extensively with 
antibody column buffer. Proteins were eluted using a sodium citrate buffer at pH 3·0. 
Fractions were assayed for TI~-1 by ELISA. 
Purification of TIMP- J on an Antibody Affinity Column. 
A large quantity of antibody affinity matrix was prepared using CNBr-activated 
Sepharose. This was washed with antibody column buffer, and packed into an Amicon 
chromatography column (P70x250) with a total bed volume of 760 ml. 
C.liture medium from WI-38 foetal lung fibrobiasts was processed as described to 
remove any collagenase present. Batches of the flow through pool were passed directly 
through \ the monoclonal antibody affinity column at 500 mllhour. The column was 
washed extensively with antibody column buffer. TIMP-l was eluted from this column 
using 3M NaI in either 50 mM Tris, 0·1 M NaCl, pH 7·2 (Tris buffer) or antibody 
column buffer. Fractions of 500 ml were collected and immediately transferred to dialysis 
against either 50 mM Tris 100 mM NaCl, pH 7·6, or antibody column buffer. Dialysed 
fractions were assayed for protein, TIMP-l and inhibitory activity. Purity was 
determined by analysis of SDS PAGE gels using an LKB Ultrascan XL laser 
densitometer and accompanying software (LKB Instruments Ltd, Surrey, UK). For wild 
type TIMP-l an additional Concanavalin A-Sepharose affinity column was used to 
separate different glycoforms. 
/"yophilisation. 
TIMP-l for structural studies was dialysed into 10 mM ammonium bicarbonate 
and Iyophilised . 
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3.3. Results. 
3.3.1. Purification ofTIMP-l Using Multi-Step Procedure. 
TIMP-l was purified from WI-38 media in several batches. Figures 3'1,3'2 and 
3· 3 show examples of column profiles for each step. Figure 3·4 shows an SDS-PAGE gel 
of the final purified products. Table 3· I shows the respective yields for each stage. A 
total of 23'6 mg of TIMP-l was purified in this manner. 
volume / inhibitor / protein / yield / Specific 
ml units mg % activity 
/units/m~ 
Concentrated Chelating- 156 515004 477'6 100 1078·3 
Sepharose Filow through 
Pool 
Gel Filtration Pool 814 378376 75·3 73·5 5025'0 
Heparin-Sepharose Pool 542 355488 32·4 69 10971·9 
Con A-Sepharose Pool 337 227475 16 44 14217·2 
Con A flow throu~h Pool 150 106875 18·5 21 5777'0 
Polishin~ AcA Pool 316 49088 7'6 9·5 6459'0 
Table 3'1. Purification data for TIMP-l derived from WI-38 media. The original 
volume of the chelating-Sepharose flow through was 7·5 L. Total quantity of purified 
TTh1P-l was 26·1 mg with a total activity of 334350 units (after Concanavalin A-
Sepharose purification). The overall yield for the procedures was 44% for the CAB pool 
and 9·5% for the NC AB pool. 
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Figure 3·1. Example Gel Filtration (AcA44) Column Profile 
for TIMP·l Purification. 
WI-38 cell culture media is concentrated. dialysed into AcA column buffer and 
the column run at 60 ml/hr. The figure shows the profile for a 2L column. where 
10 ml fractions are collected and assayed. Fractions are pooled to include the 
protein and inhibitory peaks. Fractions containing less than 20 uglml of TIMP-I 
(by ELISA) are discarded. 
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Figure 3'2. Heparin Sepharose Column Profile for 
TIMP-I purification. 
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Material pooled from gel filtration is concentrated, dialysed into low salt 
buffer and the column run at 40 mllhr. The figure shows the profile for a 
100 ml column where 6 ml fractions are collected and assayed. Elution 
with a salt gradient gives the elution profile above. Fractions containing 
TIMP-I are pooled. 
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Figure 3·3. Example Concanavalin A Column Profile 
for TIMP- j Purification. 
-. 
The pool from heparin-Sepharose is concentrated. dialysed into Con A-
Sepharose buffer and loaded onto a 100 ml column at 60 mllhr. Bound 
glycoproteins are eluted with O·5M glucop)'Tanosidc . Fractions of 6ml 
IUO 
)lO 
60 
40 
2() 
() 
are collected and assayed. The fractions are pooled as either NCAB (flow 
through prior to elution) or CAB (eluted). 
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Figure 3·4. SOS PAGE of TIMP-l Purified Using Gel Filtration and Affinity 
Chromatography. 
Lane 1: molecular weight markers. Lane 2: NCAB TIMP-l pool. Lane 3: CAB TIMP-I 
pool. TIMP- I runs as a single band close to the 29 kDa marker. 
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After passing through Concanavalin A-Sepharose matrix, the TIMP-I is divided 
into two pools. The first does not bind to the matrix but is retarded. This can be seen on 
figure 3'3. This material is designated as non-Concanavalin A-Sepharose binding 
(NCAB) TIMP-l. The remainder of the material binds to the matrix and is eluted with 
the glucopyranoside buffer and is designated as Concanavalin A binding (CAB) TIMP-l. 
Although the CAB TIMP is pure after Concanavalin A-Sepharose chromatography, the 
material that does not bind to the column (NCAB TIMP) is less pure (see figure 3'4). 
This material is subjected to an additional polishing step on another gel filtration column. 
3.3.2. t D NMR Spectrum of Purified TIMP- t. 
A one-dimensional NMR spectrum of TIMP-l purified usmg the original 
procedure is shown in figure 3·5. There are two strong peaks at 2·9 ppm and 0·8 ppm. 
These are not signals from the protein which has much weaker signals. The chemical 
shifts are indicative of a simple hydrocarbon. One-dimensional spectra were recorded for 
the different buffer components used during the purification, and this contaminant 
identified as Brij-35. 
3.3.3. Development of a Monoclonal Antibody Affinity Matrix. 
Three different Sepharose based support matrices were produced and tested to 
determine the most effective matrix for antibody coupling. Small columns (2m1) were 
prepared of P3G6 monoclonal anti-TIMP antibody coupled to CNBr-activated 
Sepharose, epoxy-activated Sepharose and activated CI1-Sepharose. Equal volumes of 
the same TIMP-l containing media were passed down the columns and the eluted 
material (neutralised by the addition of sufficient 1M Tris) assayed by ELISA or 
bioassay. 
Column profiles for each of these matrices are shown in figures 3'6, 3·7 and 3'8. 
CNBr-activated Sepharose-P3G6 bound 650 units of inhibitory activity/ml of matrix. 
Epoxy-P3G6 Sepharose was found to have a binding capacity of 41 unit simi of 
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Figure 3-5. 1 D NMR Spectrum of TIMP-l. The spectrum was recorded for a sample of TIMP-l at 8 mg/ml. The signals from the 
protein are just visible as irregularities in the baseline around 7 ppm and 1·8 ppm. The main signals in this spectrum are the water close to 
5 ppm and signals from the detergent Brij35 around 3·5 ppm and 1 ppm. 
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Figurt 3'6. Column Profilt for CN-Br-Activated Stpharose P3G6 
Eluted with Citrate Buffer Over a pH Range of 3·0 - 6·0. 
Pooled material from chelating-Sepharose is loaded directly onto the column. 
The elution is carried out with buffers of different pH to identify the highest pH 
that elutes all of the protein. The majority of the protein is eluted at pH 4'0, 
however at pH3'0 additional protein is eluted. 
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Figure 3·7. Column Profile for Epox},-Activated Sepharose-P3G6. 
Pooled material frrrn chelating-Sepharose is loaded direcly onto the column 
and eluled with citrate buffer at pH J·O. From the figure it can be seen that 
most of the TIMP- J passes straight through the column. 
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Figure 3·8. Column Profile for Activated CH-Sepharose-P3G6. 
Pooled material from chelating-SeJitarose is loaded direct~ onto the 
column and eluted with citrate buffer at pH 3·0. In this case none of the 
TI\lP-1 is seen to bind the column. The small protein peak eluted is 
probably bound non-specifically. 
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matrix. No TIMP-l, or inhibitory activity was found to bind to the activated CH-
Sepharose-P3G6 
For the CNBr-activated Sepharose-P3G6, TIMP-l could be eluted from the 
matrix over the entire pH range used although most material came off at pH 4 and a.ny 
remainder came off at pH 3. For an initial sample loaded, of 500 ng of TIMP-l, 405 ng 
were recovered giving a yield of 81 %. 
A larger column of 25 ml of affinity matrix was prepared using the CNBr-
activated Sepharose (taken from the large batch preparation) For this preparation the 
coupling efficiency was found to be 97% by comparing the E280 before and after the 
,:oupling reaction. Elution wa5 with citrate buffer at pH 3·0. It was found that in this 
larger volume the protein was eluting very slowly giving many dilute fractions and an 
unacceptably large pool volume. Elution with 3M sodium iodide in the loading buffer 
gives the column profile shown in figure 3·9. This elutes all of the protein from the 
column using less than a column volume of elution buffer. The binding capacity of this 
matrix was calculated to be 0·14 mg/ml As with the smaller columns, most of the yields 
were in the order of 80% (by both bioassay and ELISA). 
3.3.4. Large Scale Purification of TIMP-l. 
A total of 400 litres of WI-38 culture medium were concentrated and passed 
through a chelating-Sepharose column to remove the collagenase from the media. The 
resulting flow through pool had a total volume of 13 litres. A total of 8 litres of this 
product was passed in batches through the CNBr-activated Sepharose-P3G6 affinity 
column using 3M NaI as the elutant. This material was further purified by the separation 
of different glycoforms on a Concanavalin A-Sepharose column. This separation divided 
the material into two pools as with the previous purification, one that bound to the 
column 
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Figure 3·9. Column Profile for CNBr-Activated Sepharose-P3G6 
Column Used for Large Scale Purification of TIMP- J. 
Pooled material from chelating-Sepharose is loaded di rectly onto the column. 
The 760 IllI column is run at 500 mlihr taking 500 ml fractions. Elution is 
with 3M Nal. All of the TIMP-I elutes in two fractions. 
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and a second that was retarded rather than entirely non-binding. The column profile for 
an example antibody affinity column run is shown in figure 3·9. 
SDS PAGE gels of the purified TIMP-I showed a single band and were 
detennined to be 97% pure by gel-densitometry (figure 3'10). 
A total of 90 mgs of TIMP-I were prepared in this way and subdivided into 
Concanavalin A-Sepharose binding (CAB) material and non-Concanavalin A-Sepharose 
binding (NCAB) material. The yields for each batch on the monoclonal affinity column 
were greater than 80%. The subdivision of the purified material reduces the overall yield 
to 70% giving a pool of CAB TIMP-l of 49·7 mg with a specific activity of 23875 
units/mg and 28·5 mg ofNCAB TIMP-l with a specific activity of27617 units/mg. 
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Figure 3·10. SDS-PAGE ofTIMP-1 Purified Using an CNBr-Activated Sepharose-
P3G6 Column. 
Lane M : molecular weight markers. Lane J : Chelating-Sepharose pool . Lane 2 : Flow 
through from CNBr-Activated Sepharose-P3G6 Column. Lane 3 : Eluted TIMP- I from 
CNBr-Activated Sepharose-P3G6 Column. 
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3.4. Discussion. 
The purification of TIMP-l using the method of Cawston et al [103] produced 
material that gives a single band on an SDS PAGE gel. The overall yield for this 
procedure is 54%. Protein loss is occurring at each column, dialysis and concentration 
steu. After extensive dialysis against ammonium hydrogen-carbonate buffer the mass of 
the initial preparation of Iyophilised material was greater then expected. Analysis by 
NMR found this material to be chemically contaminated by the detergent Brij-35. The 
sample could be cleaned to chemical purity using Extractigel-D. a matrix with a high 
affinity for detergents. Dialysis under the condition used does not appear to be sufficient 
to remove all traces of detergent. This might be due either to some binding capacity of 
the dialysis tubing or to the structure of the detergent molecule being elongated inhibiting 
its passage through the tubing pores. Alternatively TIMP-I may have an affinity for 
Brij35. which could suggest some degree of hydrophobic exposure at the surface. 
To avoid this problem recurring. Brij-35 was omitted where possible and samples 
routinely treated to remove residual detergents. 
A monoclonal antibody affinity column has been developed to purify TIMP-I in a 
single step. Three different antibody-coupled Sepharose matrices were tested to 
determine which coupled matrix had the highest TIMP-I binding capacity. Of the three, 
activated CH-Sepharose-P3G6 did not appear to bind TIMP-l under the conditions 
used. Epoxy activated-Sepharose-P3G6 bound a small fraction of the TIMP-l that had 
been loaded onto the column. CNBr-activated Sepharose-P3G6 matrix binds TIMP-l 
with a capacity of 0·14 mg/ml of matrix. 
P3G6 bound to CNBr-activated Sepharose proved to be the most effective for 
binding TIMP-I. On scaling up from a 2 ml column volume to a 25 mi. and 760 ml 
column, it was found that the original elutant (citrate pH 3·0) was not suitable. Elution 
with the low pH buffer did not give a sharp elution peak, instead the protein came off the 
column in an unacceptably large volume. The chaotropic salt NaI proved more effective, 
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giving a very sharp and predictable elution profile even for the largest column volume 
(760 ml). 
This method gave an overall yield (before separation by Concanavalin A-
Sepharose) of 80%. This is 20-30% greater than for the conventional method and is 
achieved in a single step. Purification from large volumes of cell culture medium 
provided 90 mg of highly pure TIMP-l, again with an overall yield of 80% before 
separation of glycoforms. The separation of the different forms on Concanavalin A-
Sepharose does not alter the apparent molecular weight of TIMP-l on SDS-PAGE. 
AJthough there is a difference in the specific activities of the two pools, this can be 
attributed to slight differences in purity and the accuracy of the inhibition assay. 
The differences in the binding of TIMP-l to Concanavalin A-Sepharose can be 
attributed to heterogeneity in the attached carbohydrates. Whether a carbohydrate will 
bind to the Concanavalin A-Sepharose lectin depends on its composition. Slight 
differences in the content, or arrangement of the sugars can alter the ability of the 
carbohydrate to bind to the matrix. A particular source for heterogeneity is the sialic acid 
residues at the ends of the carbohydrate chains. These are gradually hydrolysed in the 
extracellular environment, altering both the charge and structure of the carbohydrate 
moiety. Subsequently the ability of the protein to bind to Concanavalin A-Sepharose can 
be affected, dividing the wild type protein into pools containing one or more different 
glycoforms. 
It should also be possible to purity large quantities of recombinant TIMP-I in this 
manner. 
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Chapter 4. 
Evaluation of Expression Systems for TIMP-I in Escherichia 
Coli. 
4.1. Introduction. 
Detailed structural studies of proteins demand a ready supply of large quantities 
of material. For a protein such as TIMP which is produced in vivo in relatively small 
quantiries the best solution is an over-expression system. The carbohydrates attached to 
TIMP-I do not appear to have any function and would make analysis of NMR data 
extremely difficult. Signals from sugars are much sharper than those from the protein due 
to their high mobility, and overlap the region of an N.\1R spectrum where signals are 
found from residue side-chains. This makes expression in E. coli preferable since proteins 
are not glycosylated by the cells. Expression in E. coli can give a very high yield of 
protein per litre of growth medium., important when considering the production of 
TIMP-I isotopically labelled for heteronuclear NMR studies. 
Possibly the most difficult aspect of expressing TlMP-l in E. coli is the need to 
form all six disulphide bonds correctly. The cytoplasm of Ecoli is a reducing 
environment and others who have attempted to express TIMP-l (murine) have found that 
it forms insoluble aggregates [285]. Attempts at refolding the insoluble human protein 
have met with varied success. One the most effective strategies so far has been to use a 
very careful renaturation procedure using oxidised glutathione and 4M urea in the 
refolding buffer [286]. Another group has reported the successful expression of human 
TIMP-l in E.coli, again using a careful renaturing process [287]. However they do not 
give figures for the yield in terms of expression per litre of medium, an important figure 
when determining the feasibility of isotopically labelling a recombinant protein. 
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Baculovirus [288] and CHO cell [289] expression systems have also been used 
successfully to produce wild type TIMP-I (murine and human). However these are not 
suitable for the expression of TIMP-I for NMR structural studies. This is because in 
these systems, expressed proteins are normally glycosylated. Mutants of TIMP-l where 
the glycosylation sites have been mutated out have been expressed in mouse myeloma 
cells [278]. However, isotopic labelling in these systems is currently prohibitively costly. 
Two different strategies have been used in an attempt to produce soluble TIMP-l 
in E.coli. The first used the pEZZ18 expression vector, which is based on pEMBL8+ 
[290]. This includes a synthetic version of part of the Staphylococcal protein A (SpA) as 
a fusion product with the protein of interest. SpA has the ability to bind to the Fc portion 
of most IgGs. This function is contained within five homologous IgG binding domains of 
around 58 residues each. In the pEZZ 18 vector two IgG binding domains are present, 
based on the B domain of the original. This should allow the protein to be purified on 
IgG Sepharose. The inclusion of the N-terminal signal domain from SpA allows the 
fusion product to be secreted to the periplasm. Since the expression of the SpA gene in 
gram -ve strains of E.coli creates a leaky phenotype, proteins from the periplasm are 
secreted into the media. In the extracellular media the environment is not reducing and 
subsequently TIMP-l should be able to fold correctly. To allow removal of the fusion 
protein a factor Xa cleavage site (lEGR) was inserted into the TIMP-l cDNA before the 
N-terminal cysteine using PCR techniques. Factor Xa cleaves after the R of this sequence 
to give a free N-terminus. To generate a truncated TIMP-l the cDNA was modified to 
create a stop codon after residue Glu-126, which lies in the linker region between the 
two domains. 
The second strategy took advantage of the fact that the peri plasmic space of 
F:.co/i contains a protein disulphide isomerase [291, 292]. The presence of a disulphide 
isomerase allows disulphide bonds to be re-arranged, increasing the amount of correctly 
folded protein. To do this the expression vector pASK60-strep was used. This utilises 
the N-terminal leader peptide (21 residues) of the OmpA protein which targets the 
79 
There are four different gene products expected in these experiments. From the 
pEZZ 18 vector, full length, and truncated TIMP-) are secreted to the media as fusion 
proteins with a pair of IgG binding domains at the N-terminus (abbreviated to ZZ-). 
From the pASK60 vector, full length and truncated TIMP-I are produced with an N-
terminal ompA signal sequence which directs the protein to the periplasm where the 
signal sequence is cleaved, leaving the N-terminal cysteine of TIMP. The expected 
molecular weights of these products (including those expected after successful cleavage 
of the fusion protein with factor Xa) are shown in the table below. 
Product Molecular Weight (kOa) Weight after Xa Cleavage (kOa) 
ZZ-TIMP-I 36 21 
ZZ-~TIMP-l 28 I3 
(ompA) TIMP-I 21 nla 
(ompA) ~TIMP-l 13 nla 
It should be noted that the ZZ-(~)TIMP-I proteins do not run as expected on 
SOS PAGE. ZZ-TlMP-I appears close to 45 kDa, whilst ZZ-~ TlMP-I appears close to 
21 kOa. 
protein to the peri plasmic space. This peptide is cleaved as the protein is transported into 
the periplasm, leaving a free N-terminal residue. This vector also included a r -terminal 
strep-tag for easy purification of the final product. However, since an efficient 
purification system was already available and additional residues were undesirable, this 
C-terminal extension was removed. This method was also attempted with both full 
length, and truncated TIMP-1. Truncated TIMP-I (~TIMP-I) was assessed alongside 
the full length systems to provide material for potential enzyme-inhibitor interaction 
studies and as a possible alternative, were the full length recombinant protein to prove 
unsuitable for NMR studies. 
This chapter describes the development and assessment of these two strategies. 
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4.2. Methods. 
4.2.1. Materials. 
The TIMP-l cDNA was a generous gift from Dr. Alan Galloway at British 
BIOtechnology, Oxford UK The pEZZ 18 vector was from Pharmacia Biotech UK, S1. 
Albans, Herts. The pASK-60 vector was from Biometra, Maidstone, Kent UK. HE 101 
cells were from Stratagene, Cambridge UK. TG 1 cells were the generous gift of Dr. P. 
Alefounder, University of Cambridge UK. Large scale fermentations (tOL) were 
performed at SmithKline Beecham Phannaceuticals, Great Burgh, Surrey by Helen 
Edwards and Bob Imrie. Factor Xa was purchased from Denzyme Aps, Aarhus, 
Denmark. IgG Sepharose was from Pharmacia. Agar, yeast extract and bactotryptone 
were from Difco Labs, Molesy, Surrey, UK. Agarose was from Gibco BRL Ltd, Paisley, 
UK. DNA ligase, all restriction enzymes and restriction buffers were from Boehringer 
Mannhei'll UK, Lewes. Sussex. Mini gel apparatus was from International 
Biotechno]ogies Inc. Connecticut USA. Perip]asmic extraction kit was from Biometra, 
Maidstone, Kent UK. Mini-prep spin kits were from QIAGEN, Dorking, Surrey, UK 
Oligonucleotides were supplied by the Dept of Molecular Medicine Kings College 
London School of Medicine. Phosphoramidon, aprotinin, PM SF and ampicillin were 
from Sigma Chemical Company, Poole Dorset, UK. IPTG was from Northern 
Biologicals Ltd, Cramlington, UK. Falcon 2059 tubes were from FSA Lab Supplies, 
Loughborough, UK 
pEZZ181'ector for TIMP-l and ATIMP-l. 
The pEZZ 18 vector used is shown as figure 4·1. 
pASK-60 vector for TIMP-l. 
The pASK60-strep vector used is shown in figure 4·2. 
8] 
pEZZ18 
Clal 
4642bp 
Asn Ser Ser Ser Val Pro Gly Asp Pro Leu Glu Ser Thr Cys Arg His lila S'!r I.eu 
~G AGC TC~C GG~T CTA GAG TCG ACe TGC AGG CAT GCA IICC TTG 
£coRI SstI KpnI-s;;:;;;r- Bamltl Xbal Sal! Pst! SphI HindIlI 
~RI J;indlIl 
ZZ- IEGR- L-I C_] _______ A_I_84-1~ (ZZ-TfMP-l) 
E~RI .j;indIII 
ZZ- IEGR-I~C_l ___ E_l_26.....J~ (ZZ-!J. TfMP-I) 
IFactor Xa cleavage site 
Figure 4·1. Diagrammatic representation of the pEZZ 18 Expression Vector and 
the TIMP-lI.1TIMP-1 Construct. 
The vector contains two IgG binding domains (ZZ), a multiple, restriction site (shown 
expanded below the vector), the bla gene which confers ampicillin resistance, an origin of 
replication, the lacZ structural gene and the gene for F I protein which is the recognition 
sequence for packing the DNA into phage particles after M13 or fl infection. The lIMP 
constructs shown beneath the vector are inserted between the EcoRl and HindUI sites. 
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~~~ ..... ~:StullBsal 
pASK60-Strep 
3832 tJp 
RES )'~! F.ES 
CA~CAGCTAT~CCATGA~ACGAA7rTC~AGAT~:~L;S~~TGAAhAAGACAGCTATCGCG 
~cZ: MetTb.~etJleThrAsnPbeEnd DmpA: MetLYSLysTbrAlaIle~la 
Stu! Bsal EcoR! SstI Kpn! Sma! BamHI 
A'rTG::AGTGGCAC"K:GCTGG'!'T':'C'GCTACCG';'AGCG:;"9gcC~::;AATTCGAGC'!'CGGTACCCGGOOAT 
J 1 eAla valAlaLeuAlaGlyi'l1eAl a ThrValJ.laGlr..Ala1::'ld 
Y':'lC: Sa:I PStI ECO'-'III Hin~r!l 
CCC':'CGA:;GTCGACCTG~a9cGC'T'l""~CGTCA::CCGc:.:.:l'!'TCG3':'GGTTAATAAG~:C'!'GTGA.z,GTG 
Srrep-tag: SerAlaT~rgHisproG1r.PbeGlyG1YEnd 
StuI HindllI 
ompA--1r~_c_I _______________ A_I_8-J~ (TIMP-I) 
sru~c I H~lII 
ompA ---1~_-1 --E-12-6..3t'1 ( Ll TIMP-I) 
Figure 4·2. Diagrammatic representation of the pASK60-strep Expression Vector 
and the TIMP-l LlTIMP-I Constructs. 
The vector contains an origin of replication (ori); the ampicillin resistance gene (bla); the 
lac repressor gene (lad); an expression cassette under the control of the lac promoter, 
containing a multiple restriction site (shown expanded below the vector), the ompA 
leader sequence and the strep tag, and an f1 origin as in figure 4· I. Here the TIMP-l or 
Ll TIMP-I construct is inserted between the Stul and HindllI sites in the multiple 
restriction site so that when the ompA leader sequence is cleaved in the peri plasm the N-
terminal amino acid is Cys I of TIMP-l. 
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4.2.2. Experimental Details. 
All modifications of TIMP-I eDNA, vectors, PCR, and DNA sequencing was 
carried out by Dr. Mary 0' Hare (at the Rheumatolob'Y Research Unit, Cambridge) and 
will not be discussed in detail here. To generate a truncated d TIMP-l sequence a stop 
codon and an r,l.:oR 1 site were insel1ed at base pair 379 using PCR. For the pEZZ 18 
vector, the TIMP-l cDNA was modified to create a factor Xa cleavage site just before 
the first cysteine residue at the N-terminus of the TIMP-l/ d TIMP-l coding sequence. 
The modified TIMP-l cDNA was cloned in to the pEZZ18 vector between an EcoRl 
site and a HindIlI site and the truncated TIMP-J between a pair of EcoRl sites. For the 
pASK60-strep vector TIMP-l and ~ TIMP-I cDNAs were c1on<::d into the vector 
between a SluI site and a HindIII site. The orientation and sequences were confirmed by 
double stranded dideoxy sequencing methodology. The pEZZ 18 and pASK60-strep 
vectors containing the TIMP-l cDNAs were initially introduced into the HB 10 I E.coli 
strain. 
Cell cultures of up to lL in volume were prepared by inoculating the relevant 
volume ofLB (1% w/v bactotryptone, 1% w/v NaCI, 0'5% w/v yeast extract) at 1-2% 
v/v with an overnight preculture (in LB). All media was autoclaved and ampicillin added 
to 50 J..lg /ml before use. Some cultures included 0·4% w/v glucose. This was to reduce 
premature expression from the lac promoter. Cultures for the pEZZ 18 expression vector 
and all overnight pre-cultures were grown at 37°C with shaking at 250 rpm. Cultures for 
the pASK60-strep vector were grown as close to 22°C as possible shaking at 250 rpm. 
Expression was induced by the addition ofIPTG to 1-2 mM. Cells were harvested from 
the media by centrifugation at 5000g for 10 minutes. Larger volumes (IOL) were 
prepared at SB in either LB or minimal media (M9, 6'8g Na2HP0.J, 3'Og KH2PO"" 0'5g 
NaCI, l'Og NH.JCl, I L H20). 
TIMP-I and ,1 TIMP-I cDNAs were ligated into the pASK60-strep vector. 
Transformation of TG 1 and HB 1 0 1 cells was carried out in pre-chilled Falcon 2059 
tubes. 100 III of competent cells were transferred to the tubes with I- 7 ~d p-mercapto-
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ethanol. The cells were incubated on ice for 10 minutes with occasional swirling. 5 ~tl of 
the ligation mixture was added to each tube, separate vector only controls were also 
prepared. The transformation mixture was incubated on ice for 30 minutes then suhjected 
to a heat shock of 42°C for 45 seconds. The tubes were cooled on ice for 2 minutes then 
0·9 ml of SOC medium added (20% w/v bactotryptone, 5% w/v yea.st extract, 0·5% w/v 
NaCl, 2·S mM KCl, 20 mM glucose, 50 ~I 1M MgCI2). The cells were incubated at 
37°C, 225 rpm for 1 hour then centrifuged for lO minutes at 4000 rpm. The cell pellet 
was resuspended in 1 00 ~I of the supernatant and plated out onto L-Amp plates and 
grown at 37°C overnight. 
L-AMP plates were prepared using 15 gil bacto-agar dissolved in LB medium. 
Ampicillin was added to 50 ~g/rn1 before pouring the plates. 
Plasmid preps (mini-preps) were prepared using the QIAprep spin kit which uses 
the NaOH SDS-lysis method [293]. 
Restriction digests were prepared using 10 units of each enzyme and its buffer, 
10 Jll of DNA from a mini-prep and 6 III of water. The restriction mix was incubated at 
37°C for 2 hours. 4ml of 6x sample buffer (0·25% (w/v) bromophenol blue, 40% (w/v) 
sucrose) was added to each sample then run out on an 8% agarose gel containing 50 ~JIL 
of a 10 mg/mJ solution of ethidium bromide. Gels were run overnight at 25V in T AE 
running buffer (40 mM Tris-acetate, I mM EDT A, pH 8·0) 
Periplasmic extraction was carried out on ice. The cell pellet was initially 
resuspended in sucrose buffer (0·5M sucrose, O·IM Tris, I mM EDTA, pH 8·2). The cell 
pellet from a 10L fermentation was resuspended in 250 ml of sucrose buffer. 4ml of 
lysozyme (lOmg/ml) was added with 250 ml of ice cold water and the cell slurry mixed 
and incubated on ice for 5 minutes. 9 ml of I M MgSO~ was added and the material 
centrifuged at lO,OOO rpm for 20 minutes to remove cell debris and intact cells. For 
smaller culture volumes of the pASK60-strep expression systems the peri plasm was 
extracted using a Biometra kit form of this procedure which omits the MgSO~. 
Cytoplasmic extracts were obtained by sonication of the cell pellet resuspended in 50 
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mM Tris, 100 mM NaC'l followed by centrifugation for 10 minutes at 37000 rpm to 
pellet remaining cell debris. 
Purification of TIMP-I containing material was carried out USIng either the 
CNBr-activated Sepharose-P3G6 column (as described in chapter 3), or an IgG 
Sepharose column for some preparations from the pEZZ 18 vector. Where material was 
to undergo cleavage by factor Xa after purification the CNBr-activated Sepharose-P3G6 
column was washed, eluted and the eluted fractions dialysed against Xa buffer (50 mM 
Tris, 100 mM NaC'l, I mM Cael2, pH g·O) instead of the previously described buffers. 
F or purification using IgG-Sepharose, material was loaded onto a 10 ml IgG-Sepharose 
column at 100 mllhr. The column was washed with a 50 mM Tris, 100 mM NaCI buffer 
pH 8·<) containing 1 roM EDTA and 1 roM PMSF. Protein was eluted using a two step 
elution of acetate buffer at pH 5·0 and then at pH 3·4. Fractions were returned to neutral 
pH by the addition of sufficient 3M Tris. Proteinase inhibitors (aprotinin to lOIlg/ml, 
phosphoramidon to I mM, PMSF to 1 mM, and EDT A to 1 mM) were added to some 
samples during the purification process. 
Cleavage of the fusion protein domain from TIMP-l was attempted using the 
proteolytic enzyme, factor Xa. Protein samples were typically at 0'5-1 mg/ml. Factor Xa 
was stored as a 1 mg/ml solution in 50% glycerol and used at a range of working 
concentrations of 1: 10 (enzyme:protein) to I :200. The cleavage reaction was carried out 
in Xa buffer at temperatures of 4°C, room temperature and 37°C. Incubation times 
ranged from 3 hours to 24 hours. 
Western blotting to identifY bands containing an IgG binding domain were carried 
out as described in the general methods, omitting the initial anti-TIMP-I antibody 
incubation. 
N-terminal sequence analysis was carried out at the microchemical facility at the 
Institute of Animal Physiology and Genetics Research, Babraham, Cambridge, UK by Pat 
Barker. 
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4.3. Results. 
4.3.1. Assessment of the pEZZ 18 vector system for TIMP-I and L\ TIMP-l. 
DNA sequence analysis of the vectors showed that the TIMP-I and L\TIMP-I 
cDNAs had been correctly modified and inserted into the vector. The factor Xa cleavage 
site wa& a'so correct. 
Expression tests were carried out using approximately 100 ml of medium from 
the cell cultures. The media from both the TlMP-I and L\ TIMP-l fermentations was 
passed down a (NBr-activated Sepharose-P3G6 column, and bound protein eluted as 
described (chapter 3). For the full length TIMP-I system, TIMP-I was detected (by 
ELISA) in the original medium, and in the material eluted from the column. TIMP-l was 
also detected in the periplasm. The same pattern was seen for the .1 TIMP-l. None of this 
material showed any inhibitory activity in a bioassay. 
Large volumes of media were produced to provide sufficient material to 
determine the conditions for cleavage of the fusion protein using factor Xa. Initial assay 
of the media by ELISA could not detect either the full length or the truncated molecule. 
Analysis of the medium by SDS PAGE, did not identifY any protein overexpression in 
either the full length, or truncated TIMP-I expression systems (figure 4· 3). 
Purification of full length ZZ-TIMP-I from the media using CNBr-activated 
Sepharose-P3G6 gave a yield of 14 mg of material from a 10L fermentation. This 
purified material still showed several bands on a Western blot, although one band, at a 
little under 45 kDa was dominant (figure 4·4). 
To determine the optimum conditions for cleavage of the full length ZZ-TIMP-I 
fusion protein by factor Xa. The cleavage reaction was carried out using different 
temperatures and enzyme concentrations. For the lower temperatures no change was 
seen in the bands present on SDS-PAGE (figure 4·5). At higher temperatures (37°C and 
room temperature with higher enzyme concentrations) all of the bands present appeared 
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Figure 4·3. SDS-PAGE of Media From the ZZ-TIMP-I and ZZ-.1TIMP-l 
Expression Systems. 
Lane 1: Molecular weight markers. Lane 2: 15 III ZZ-TfMP-l media. Lane 3: ]5 III ZZ-
L\ TIMP-l media. Lane 4: 5 III ZZ-TIMP-J media. Lane 5: 5 III ZZ-.1 TIMP- J media. 
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Figure 4'4. Western Blot of ZZ-TIMP-l Purified By CNBr-activated Sepharose-
P3G6 Chromatography. 
Lane 1: Molecular weight markers. Lanes 2-5 : Purified ZZ-TIMP-l. Lane 6: Wild type 
TIMP- J. The purified ZZ-TIMP-l has a higher molecular weight than wild type TIMP-l 
as would be expected. 
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Figure 4-5. SDS-PAGE of Factor Xa Cleavage ofZZ-TIMP-l. 
A. Lane 1: Molecular weight markers. Lane 2 : Purified ZZ-TIMP-l . The remaining lanes 
contain ZZ-TIMP-l treated with the following enzyme:protein ratios and incubation 
temperatures; Lane 3: 1:10, 4°C. Lane 4: 1:50, 4°C, Lane 5: 1 :100, 4°C. Lane 6: 1:10, 
RT. Lane 7: 1;50, RT. Lane 8: 1: 100, RT. 
B. Lane 1: Molecular weight markers. Lane 2: Purified ZZ-TIMP-l . The remaining lanes 
contain ZZ-TIMP-l treated with the following enzyme:protein ratios and incubation 
temperatures; Lane 3: 1: 10, 37°C, Lane 4: 1 :50, 37°C. Lane 5: 1: 1 00, 37°C. The samples 
show signs of general proteolytic degradation at the higher temperatures. 
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to be degraded (figure 4,5) This degradation occurred more rapidly in material that had 
not been purified 
This breakdown is thought to be the result of proteinases from l~'.c(}1i that are 
present in the media. Although the sample had been purified, t'esidual contamination was 
sufficient to ensure total degradation of the protein. 
No ~ TIMP-I could be detected in the medium of the ~ TIMP-I IOL culture (by 
ELISA), or the fraction eluted from the affinity column. Analysis by SDS-PAGE showed 
that no intact proteins remained in the sample. It can be assumed that a short delay in 
processing this material resulted in complete degradation prior to assay. To prevent the 
breakdown of further samples, the proteinase inhibitors aprotinin and phosphoramidon 
were added to all subsequent preparations, other than those that were to be assayed for 
activity. These inhibitors were chosen because they do not inhibit factor Xa. Where a 
bioassay was necessary PMSF was added and allowed sufficient time to hydrolyse before 
any assays were performed. 
The peri plasm was extracted from the cell pellets (both approximately 70g in 
weight) harvested from the TIMP-I and ~TIMP-I 10 L fermentations described above. 
The periplasmic extract was found to contain TIMP-I/~TIMP-I (ELISA). There was 
some inhibitory activity found in the crude preparations, and no inhibitory activity was 
seen in fractions purified by CNBr-activated Sepharose-P3G6 chromatography (full 
length system) or purified using IgG Sepharose (~TIMP-l system). A total of 1·9 mg of 
material was obtained from the purification of the TIMP-J periplasm, and a yield of ] 1·8 
mg of protein was obtained from the ~ TIMP-I periplasm. A similar quantity of periplasm 
was obtained from both cell pellets. 
The peripiasmic preparations and column fractions from ZZ-TIMP-l and ZZ-
~TIMP-J were analysed by SDS-PAGE and Western blotting. Both ZZ-TIMP-Iand ZZ-
~ TIMP-l show many bands in the periplasmic extracts. In the ZZ-TIMP-I sample a 
strong band is seen close to 45 kDa (4'6 A). No significant bands were seen in the ZZ-
8 TII\1P-I sample (Figure 4·6 C). After purification the ZZ-TIMP-I sample shows one 
major band at 45 kDa and a number of 
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Figure 4·6. SDS-Page of Periplasmic Extracts and Purified ZZ-TIMP-l. 
A. SDS-PAGE of peri plasm from ZZ-TIMP-I . Lane 1: Molecular weight markers. Lane 
2: Peri plasm from ZZ-TIMP-l. Lane 3: Flow through from purification using CNBr-
activated Sepharose-P3G6 Chromatography. 
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Figure 4-6. Western Blots of Periplasmic Extracts and Purified ZZ-TIMP-l. 
B. Western blot (developed with 4-chJoronaphthol) of purified ZZ-TIMP-1. Lane 1: 
Molecular weight markers. Lane 2: Concentrated pool eluted from CNBr-activated 
Sepharose-P3G6 column. Lane 3: Eluted pool prior to concentration. Lane 4: Wtld type 
TIMP-l. 
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Figurt' 4'6. SOS-Page of Peri plasmic Extracts and Purified ZZ-~T1MP-1. 
C. SDS-PAGE of peri plasm and samples from the IgG-Sepharose purification of ZZ-
d TIMP-I . Lane 1: Molecular weight markers. Lane 2: Periplasm from ZZ-~ TTMP-l . 
Lane 3: Flow through pool from IgG-Sepharose column. Lanes 4 to 8: Fractions eluted 
from IgG-Sepharose column. Lane 9: Wild type TIMP-l . 
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weaker bands (4'6 B) The ZZ-j TIMP-l sample has a strong doublet at approximately 
2 I kDa and some weak contaminant bands (4'6 C) 
ZZ·TIMP-I \\as treated with factor Xa at enzyme:protein ratios of 1: 10 to 1 :200 
at 4°C, room temperc~ture and 37°C, for up to 6 hours. No change was detected in any 
sample until after 3 hour~ (figure '~'7), when the band at 45 kDa could no longer be seen 
on a Western blot for any of the different temperatures or enzyme concentrations. This 
was not accompanied by the appearance of any additional bands. 
ZZ-.1 TIMP-I was treated with factor Xa at a ratio of 1:200 for 3 hours at room 
temperature and re-purified on IgG Sepharose. The flow through pool contained 3'53 
mg of protein and the eluted pool contained 4'6 mg of protein. Analysis of the t1 TIMP-I 
material by SDS PAGE and Western blotting shows a strong band at approximately 21 
kDa that decreases in size after treatment with factor Xa (figure 4'8). However, after the 
second pass down IgG-Se~harose, both the original, and new bands are found in the 
eluted fraction. On assay, none of this material was found to have inhibitory activity. 
Further 10L fermentations in LB, and minimal media were prepared for the ZZ-
TIMP-l system. Purification of this material by CNBr-activated Sepharose-P3G6 
chromatography gave a yield of 18·5 mg protein for the LB culture and 12'8 mg from the 
cells in minimal media. A Western blot of the purified material is shown in figure 4·9. 
None of this material showed any inhibitory activity. 
The cleavage reaction of the ZZ-TIMP-I with factor Xa was carried out using 
enzyme: protein ratios of 1: 50, J: 100 and 1:200 at room temperature and 37°C for a 
minimum of 3 hours for the preparations from minimal media and LB. Analysis by 
Western blotting (figure 4·9) and bioassay showed that there had not been a decrease in 
the molecular weight of any band on the gel, nor was any inhibitory activity generated. 
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Figure 4·7. SDS-PAGE of Factor Xa Cleavage of ZZ-TIMP-I (containing 
proteinase inhibitors). 
Lane I : Molecular weight markers. Lane 2: Purified ZZ-TTMP- I. The remaining lanes 
contain ZZ-TlMP-] treated with the following enzyme:protein ratios incubation 
temperatures and incubation times; Lane 3: I: JO, RT, I hr. Lane 4: 1: 50, R T, 1 hr. Lane 
5: 1: 100, RT, ] hr. Lane 6: 1:200, RT, I hr. Lane 7: 1: J 0, RT, 3 hrs. Lane 8: 1:50, RT, 
3hrs. Although the band at 45 kDa is absent in the longer incubations, no additional band 
is seen to indicate the release of the ZZ domains or the TIMP- J . 
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Figure 4'8. SDS-PAGE of ZZ-ATlMP-l Periplasm, Purification and Factor Xa 
Cleavage. 
Lane] : Molecular weight markers. Lane 2: Peri plasmic extract from ZZ-ATIMP-I . Lane 
3: Flow though pool after IgG-Sepharose. Lane 4: Eluted pool from IgG-Sepharose. 
Lane 5: IgG pool treated with factor Xa (1 :200) at RT for 3 hrs. Lane 6: Flow through 
from IgG-Sepharose column run ofXa treated ZZ-ATIMP- 1. Lane 7: Eluted pool from 
second IgG-Sepharose column. Lane 8: Wild type TIMP-l . 
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Figure 4·9. Western BJot~-chloronaphtholstained) ofZZ-TIMP-l purified from 10 
L of LB, and minimal media and treated with factor Xa. 
Lane 1: Molecular weight markers. Lane 2: ZZ-TIMP-I from LB. Lane 3: ZZ-TIMP-l 
from LB treated with factor Xa (I :200), RT. 3hrs. Lane 4: ZZ-TIMP-I from minimal 
media. Lane 5: ZZ-TTMP-l from minimal media treated with factor Xa (1:200), RT, 
3hrs. Lane 6: Wild type TIMP-l . 
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The cleavage reaction was also carried out in the presence of o· 5 M urea, again to no 
effect. Treatment of the sample with thrombin also did not affect the molecular weight or 
activity observed. 
Western blots of the culture media and peri plasm extracted from both TIMP-I 
and ~ TIMP-l cultures, were preI=ared using only the second (HRP-linked anti-IgG) 
antibody. These blots showed the same pattern of bands as those prepared including the 
specific, anti-TIMP-l first antibody (data not shown). This suggests that several different 
gene or processing products were present in the media, and that all of these products 
contain IgG binding domains. This was also seen for the ~ TIMP-l sample that had 
shown an altered pattern of bands after treatment with factor Xa. This would imply that 
any cleavage that occurred was not generating free ~ TIMP-l. 
4.3.2. Assessment of the pASK60-strep Vector System for TIMP-l and L\ TIMP-l. 
Several clones (15-20 of each) were tested for both the full length and the 
truncated TIMP-l protein. Cultares of 10 ml were used for screening clones and larger 
cultures (up to lL) were used for assessment of yield and N-terminal sequencing. 
During initial expression tests of the full length pASK60-TIMP-l vector 10 
HB 101 cells it was found that the cells grew very slowly at 22°C. Cultures inoculated at 
2% required up to 10 hours to reach an Asso of 0·5 (suitable for induction by IPTG). 
Growth after induction was also very slow, normally requiring an overnight growth to 
reach a final A550 of between 1·0 and 2·0. Subsequently the vector+insert was 
transferred to competent TG 1 cells where the induction p0int was reached in 2-4 hours 
and cells could be harvested after a further 6 hours. 
plasmids from 
Restriction digests oicells transformed with the ligated vector identified II 
clones containing restriction products of the expected sizes. Analysis of periplasmic 
extracts of 10 ml cultures identified 5 clones that showed strong bands of approximately 
21 kDa on a Western blot (figure 4·10). The two strongest of these were chosen for 
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Figure 4'10. Western Blot (stained using alkaline phosphatase system) to Screen 
for TIMP-l producing pASK60 clones. 
A. Lane I : Molecular weight markers. Lane 2 : Clone 1. Lane 3 : Clone 2. Lane 4 : Clone 
5. Lane 5: Clone 6. Lane 6: Clone 7.' Lane 7: Clone8. Lane 8: Wild type TIMP-1. 
B. Lane] : molecular weight markers, Lane 2: Clone 9. Lane 3 : Clone 10. Lane 4 : Clone 
II. lane 5: Clone 12. Lane 6: Clone 13 . Lane 7: Periplasm from cells containing the 
vector alone. Lane 8: Wild type TIMP-I . 
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further assessment of yields, activity and N-terminal sequence (clones numbered 5 and 
8). 
The medium, peri plasmic extract and cytoplasmic extract from 50 ml cultures of 
both clones were assayed for the presence of TIMP-l (by ELISA). TIMP-I was found in 
both the periplasm and the cytoplasm but not in the medium. The periplasmic and cellular 
extra(:ts were compared on Western blots against de-glycosylated wild type TIMP-l (see 
chapter 6). The band at approximately 21 kDa ran alongside the de-glycosylated material 
indicating that the gene product was of a similar weight to that expected (figure 4'11). 
Large cultures (I L) were produced to obtain sufficient material for N-terrninal 
sequence analysis and assessment of yields. Parallel Western, and PVDF blots were 
prepared for clone 8 to identifY clearly the band of interest on the PVDF membrane 
which was very faint. Clone 5 was not sequenced because the correct band could not 
easily be picked out on a blot. Sequence analysis of clone 8 did not produce a clear result 
(table 4'1). 
Sequence Position J 2 3 4 5 6 
Sequencing Result Ala Asp Gly Asp Glu Arg 
Glu lie Glu Pro Pro 
Thr Gin Thr Gly 
Possible Identity X Thr X X Pro Pro 
Table 4'1. N-terminal sequence analysis of clone 8. Multiple options for each 
sequence position may be due to the presence of contaminating proteins of a similar 
molecular weight. Alternatively, weak signals from small quantities of protein for analysis 
can make distinguishing different residues difficult (cysteine does not appear as a possible 
residue identity because it cannot be detected by the sequencing methodology). Residues 
that agree with the expected sequence are shown on the last line of the table. 
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Figure 4-11. Western Blot (stained using alkaline phosphatase system) showing the 
comparison between the molecular weight of clones 5 and 8, and deglycosylated 
wild type TIMP-l. 
Lane 1: Molecular weight markers. Lane 2: Periplasm from clone 5. Lane 3: Periplasm 
from clone 8. Lane 4: Deglycosylated TlMP-l. Lane 5: Cellular extract from clone 5. 
Lane 6: Cellular extract from clone 8. Lane 7: Wild type TIMP-l. 
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Of the different sequence options presented, threonine was indicated at position 2 
and proline at position 5 and 6. This could indicate that the N-terminal sequence is 
cleaved correctly, but the sample used for sequencing probably contained other 
contaminating proteins, making the result mort: complex. 
Low inhibitory activity was detected in both tht:: periplasm, and cell extracts from 
clones 5 and 8. For a 50 ml culture with a final Asso of 2·0 a tota1 of 1·5 ml of periplasm 
was extracted. The peri plasm from clone 5 had an activity of 0·5 unit s/ml , and the cell 
extract, 1·44 units/ml. Clone 8 had 0·55 units/mt in the peri plasmic extract and 1·13 
units/mi. 
The peripJasmic material from 1 L preparations of clones 5 and 8 were passed 
down a 10 ml CNBr-activated Sepharose-P3G6 column and eluted as described in 
chapter 3. Analysis of the column fractions by ELISA showed that some of the TIMP-l 
came off in the flow through, whilst some bound to the matri~ and could be released in 
the elution step. Clone 5 gave a yield of 780 ngIL from the purified periplasm and 2Jlg/L 
from the cytoplasm (not purified). Clone 8 gave 43 Jlg/L from the purified peri plasm and 
0·3 Jlg/L from the cytoplasmic extract (not purified). This gives the overall yields 
(extrapolated to llitre) shown in table 4·2. 
Truncated TIMP- I was cloned into the pASK60 vector and introduced into 
HB 101 cells. Restriction analysis of a selection of clones identified eleven that showed 
the correct plasmid and insertion profile. 10 mI cultures were prepared of each of these 
and the periplasm analysed by Western blotting. This identified five clones that appeared 
to produce an excess of protein of approximately 14 kDa Mw. One, (t12a) appeared to 
be producing a large quantity of protein (figure 4·12). A 100 ml culture was prepared 
and the peri plasm used for blotting onto PVDF for protein sequencing. The N-terminal 
sequence analysis is shown in table 4· 3. 
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Figure 4· 12. Western Blot (stained using alkaline phosphatase system) to Screen 
for .1 TIMP-1 producing pASK60 clones. 
Lane 1: Molecular weight markers. Lane 2: Clone .110. Lane 3: Clone .111. Lane 4: 
Clone .12a. Lane 5: Clone .13a. Lane 6: Clone .16a. Lane 7. Clone .19a. Lane 8: 
Deglycosylated TIMP-l . Lane 9: Wild type TIMP-I . 
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Sample Inhibitory activity Protein Yield Specific activity 
unitsllitre mgllitre units/mg 
clone 5 peri plasm 15 0·00078 19230 
clone 5 cytoplasm 43·2 0·002 21600 
-
clone 8 peri plasm 16·5 0·043 384 
clone 8 cytoplasm 33·9 0.0003 113000 
Table 4·2. Analysis of specific activities of protein extracted from domes 5 and 8. 
The material from clone 5 has a specific activity close to what would be expected from 
conventional purifications. The periplasm from clone 8 has a low specific activity, which 
might be attributable to a low purity. The activity of the cytoplasm of clone 8 is 
unusually high, and may be due to other factors than the presence of TIMP-l . 
Sequence position 1 2 3 4 5 6 
Sequencing Result lie Thr Gin Gly Pro Pro 
Glu Val Val 
Possible identity X Thr X Val Pro Pro 
Table 4·3. N-terminal sequence analysis of clone &2a. The sequencing results are 
shown with residues that agree with the expected TIMP-l sequence shown on the 
bottom line (cysteine does not appear in the result since it cannot be detected by the 
sequencing methodology). The sequence is almost certainly that of TIMP-l, showing 
that the ompA peptide was cleaved correctly. 
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4.4. Discussion. 
The initial attempt to produce an expression system for TIMP-l and .1 TIMP-I 
was not successful. Sequence analysis of the vector inserts showed that the cDNA, 
fusion protein and engineered factor Xa cleavage site were all correct. Western blotting 
found that several proteins were being produced that could be detected by a polyclonal 
anti-TIMP-I antibody. The crude media and to a lesser extent the partially purified 
material was sensitive to E.coli proteinases. This was avoided by the addition of 
inhibitors, carefully chosen to avoid inhibiting the factor Xa. 
The purification methods used did increase the homogeneity of the samples. 
Interestingly a greater yield was obtained for the .1 TIMP-I, purified on IgG Sepharose 
than was obtained for TIMP-l purified by CNBr-activated Sepharose-P3G6 (see chapter 
3). The difference in yield between these two samples may be due to a simple difference 
in the levels of expression in each vector. Alternatively the IgG binding domains might 
reduce the affinity of the recombinant TIMP-J for the CNBr-activated Sepharose-P3G6, 
IgG Sepharose was binding other proteins or the antibody was being removed from the 
matrix in the elution process. 
Some slight inhibitory activity was seen in cytoplasmic material from all of the 
cultures studied, but was absent from the affinity purified material. Since the inhibitory 
activity is lost after affinity purification of TIMP-l, or .1 TIMP-l from the cytoplasmic 
extracts it is unlikely to be due to the action of active TIMP-l or .1 TIMP-I . This activity 
was also seen in preparations of cytoplasm from cells containing the vector only, and so 
could be due to the action of E.coli proteinases degrading the collagenase used in the 
assay. 
The increased purity of the material could be detected by SDS PAGE and 
Western blots, but on no occasion was a single clear band produced. However bands of 
the expected molecular weight were seen for both the ZZ-TIMP -I (- 45 kDa) and ZZ-
L\TIMP-I (- 30 kDa) suggesting that the desired fusion product was being expressed. 
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The presence of the IgG binding domains made accurate assessments of the presence of 
TTMP- l / ~ TIMP- J particularly difficult. ELISA assays were not reproducible and it is 
possible that false positives or negatives would be found as a, result of interference by the 
fusion protein. 
Attempts to remove the fusion protein using factor Xa were not successful. No 
inhibitory activity was generated in treated samples and in only one preparation was any 
change in molecular weight observed where the band assumed to be the correct fusion 
product for the ~TIMP-l system, decreased in size by close to the expected amount (14 
kDa). By using the second antibody alone as a control for IgG binding domains in a 
Western blot, no band was identified that could correspond to free ~ TIMP-l . Urea was 
used in an attempt to unfold the protein sufficiently, to allow access to the cleavage site. 
Thrombin, which does not cleave TIMP-1 , was also used to try and partially degrade the 
fusion protein to increase access to the Xa site. Neither strategy appeared to aid the 
successful release of the fusion protein from TIMP-I . At no point was inhibitory activity 
seen for any of the samples of media or periplasm. 
This vector system is not suitable for the production of TIMP-I or ~ TIMP- J . 
Although the overall protein yields are not acceptable, under fermentation conditions, 
with further work, the growth conditions could have been optimised to improve the 
yield. The greatest difficulty lay with cleaving the fusion protein. It is possible that the N-
terminus of TIMP-l is sufficiently buried to prevent access by the factor Xa. The 
structure of the N-terminal fragment of TIMP-2 published recently [J41] suggests that 
the N-terminus is at least partially buried and the same may be true for TIMP-I . Another 
possibility is that the presence of the fusion protein prevents the correct folding ofTIMP-
I and L1 TIMP- l molecules. In particular Cys-I , and the formation of its correct 
disulphide bond with Cys-99 could be affected by the presence of N-terminal protein. If 
the cleavage did occur correctly as it may have done ~or . the ~ TIMP-l sample, the 
resulting protein may have still been incorrectly folded, hence the lack of activity. 
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For the second expression system tried, the factor Xa cleavage site was not 
included. For both the full length and the truncated TIMP-I there were a greater number 
of clones available for assessment than for the pEZZ 18 system. The two most promising 
clones for the full length TIMP-l were assessed in detail. 
The material produced could be recognised on a Western blot, appeared to be the 
correct molecular weight (2 I kDa), and was recognised in a TIMP- I ELISA. Low levels 
of inhibitory activity were detected in both the periplasm and the cytoplasm. 
Interestingly, more inhibition was seen in the cytoplasm than in the periplasm, in 
particular for clone 8. Although TIMP-l was detected in the cytoplasm (by ELISA) it 
would not be expected to be folded, or active under the reducing conditions present. The 
activity detected was most prcbably due to the proteinase activity described in the 
pEZZ 18 vector tests. 
The protein produced appears to be non-glycosylated recombinant TIMP-l . The 
product from clone 8 is the correct molecular weight (- 21 kDa). Although the N-
telminal sequence could not be clearly defined due to the presence of contaminating 
bands on the PVDF blot, it contains elements that indicate it may be correct (in particular 
Pro-5 and Pro-6). The protein binds to a CNBr-activated Sepharose-P3G6 column, is 
detected by a specific TIMP- I ELISA and shows inhibitory activity against collagenase. 
From these results it can be said that TIMP-1 has been expressed successfully in the 
periplasm of E.coli. However the yields obtained were very low. Were the cells to be 
grown under fennentation conditions a higher yield would be expected. For this 
expression system to be viable for the production of large quantities of TIMP-l for 
structural studies, a yield in the order of 20 mg IL would be an acceptable minimum. To 
reach this level of expression an increase in yield of 500-1000 fold is required. This 
would be exceptionally difficult to achieve. 
Truncated TIMP-I was also produced in the same system. Again, a gene product 
of the expected molecular weight and with the correct N-tenninal sequence was 
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produced. However, as for the full length molecule the protein yield was exceptionally 
. protein 
low. Although not assayed (an ELISA usmgmonoclonalantibodies to the ful1lengt~wl1l 
not necessarily be reliable for a truncated protein) the appearance of the bands on SDS 
PAGE and Western blots indicated a similar yield to that obtained for the full length 
molecule. 
This yield is simjlar to that obtained by Cocuzzi et al [285J using a similar method 
of refolding the protein from inclusion bodies as that described by Kohno et al [287J 
(indicating that the overall yield obtained by both groups was probably low). The most 
successful method published to date also uses a cytoplasmic expression system and a 
different refolding process [286]. The yields quoted are up to 10 mgIL which is an 
encovraging sign that it should be possible to produce large enough amounts of TIMP-J 
using relatively low volumes of media. 
4.4.1. Alternative strategies 
Obviously it is necessary to try an alternative approach to the production of large 
quantities of whole or truncated TIMP-] in E.coli. Although periplasmic expression did 
result in the expression of the correct protein, none of the available vectors have the 
strong promoters and subsequent high levels of expression that are seen for conventional 
cytoplasmic expression systems. Since the most successful approaches have used 
cytoplasmic expression followed by denaturation/renaturation, it is probable that a similar 
method will be the most productive. By varying the refolding conditions, and including 
different agents to aid the correct formation of disulphide bonds, it should be possible to 
obtain acceptable yields from a cytoplasmic expression of TIMP-I . 
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Chapter 5. 
Secondary Structure and Tbermostability of TIMP-l. 
5.1. Introduction. 
The secondary structure content of a protein is a measure of the relative 
quantities of sheet, helix, tum and coil that are present. This information provides a 
useful indication of the structure that could be expected from more detailed studies. For 
TIMP-l in particular the secondary structure content gives an idea of how difficult 
assigning the structure by NMR might be. A protein with a high alpha helical content 
tends to be more difficult to analyse because the signals arising from alpha protons are 
less dispersed. In beta sheet structures the chemical shifts of these protons are often 
further downfield, away from resonances of ~-, and other protons. This increases the 
dispersion in a potentially very crowded region of the spectrum. 
Spectroscopic techniques such as Fourier transform Infra-red spectroscopy 
(FTIR) and Circular dichroism spectroscopy (CD) can be used to study the secondary 
structure of proteins. The recorded spectra from a sample can be compared to spectra 
from control samples with a known secondary structure content. From this a reliable 
approximation of the secondary structure can be made. 
These techniques are particularly sensitive to changes in the secondary structure 
of a protein, allowing analysis of the changes that occur during temperature variations or 
under different concentrations of denaturants such as guanadinium chloride and urea. 
Subsequently they can be used to study folding pathways and thermally induced 
structural changes. Studying the thermal stability of a sample under these conditions 
gives a useful indicator of how the protein will behave under the more demanding 
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conditions required for NMR (higher temperatures, higher concentrations, low pH and 
long experiments). In particular, for studies by FTIR, the protein concentration required 
is similar to that for NMR although the sample volume is much smaller. Consequently an 
unstable protein can be identified before large quantities of precious materia] are 
committed. 
There are now large numbers of algorithms that attempt to predict the secondary 
structure of proteins using a range of methods. Some use the probability of a residue 
being in any particular secondary structural feature based on analysis of a database of 
known structures [294]. Another uses the context of an individual residue to characterise 
its most probable environment [295]. The most recent advance in structure prediction 
has been the development of neural networks that claim to have a much greater ac.:uracy 
than other methods. As we learn more about the structures of proteins and the way in 
which sequence influences structure it is possible such programs will become more 
accurate. 
This chapter discusses the secondary structure content of TIMP-l and compares 
the results to those obtained using structure prediction programs. The thermal stability of 
TIMP-l and the effects of temperature on its secondary structure are also discussed. 
] 1 I 
5.2. Methods. 
5.2.1. Materials. 
Wild type TIMP-l was purified as described in chapter 3. Infra-red spectra were 
recorded on a Perkin-Elmer I 760X FTIR spectrometer. The sample cell was a Specac 
20500 cell fitted with a CaF2 window and a 50 11m Teflon spacer for experiments in 
D20, and a 6 11m tin spacer for H20 experiments. °20 was 99-9 atom %0 from Aldrich 
Chemical Company. CO spectra were recorded on a Jasco J-600 spectropolarimeter. 
5.2.2. Experimental Details. 
The differential binding ofTIMP-l to Concanavalin A (see chapter 3) implies that 
there is more than one glycosylation pattern. One or more of these forms is unable to 
bind strongly to the Concanavalin A lectin. This may be due either to composition or 
structure. To incn~s(! the homogeneity of samples used for spectroscopy the 
Concanavalin A binding formes) of wild type TIMP-I was used for this study. 
Fourier-Transform Infra-Red (FTIR) Spectroscopy_ 
Samples were prepared in 100 mM KH2P04 buffer (pH 7-0), using either H20 or 
020 at 9-8 mglmJ and 7-5 mg/ml respectively. Sample temperature was maintained at 20 
°C ± 0-1 °C using a cell jacket of circulating water. The spectrometer was continuously 
purged with dry air to eliminate water vapour. A sample shuttle was used to allow the 
background spectrum to be signal-averaged over the same time period as the sample 
spectrum. In all cases, 256 scans were co-added, apodised with a Norton-Beer function 
and Fourier transformed to give a resolution of 2 cm-J . 
Spectra of the appropriate buffers were recorded in the same cell and under the 
same instrument conditions as the sample spectra. Difference spectra were generated by 
an interactive difference routine to subtract the appropriate solvent spectrum from the 
spectrum of each protein solution. Proper subtraction of water should yield an 
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approximately tlat baseline from 1900 to 1 720 em-I , avoiding negative side lobes and the 
removal of the water band near 2130 em-I . When required, an infrared spectrum of 
water vapour was also interactively subtracted from the difference spectra. Subtraction 
of 020 was adjusted to optimise the removal of the D-O-D bending absorption near 
1220 em-I . Second derivative spectra were genera.ted from the difference spectra using 
the Perkin-Elmer DERlV routine. 13 or 19-data point (13 crn- I or 19 em-I) windows 
were selected. 
For the thennal denaturation study, the temperature was raised in lOoe 
increments, allowing approximately 15 minutes for equilibration before recording the 
spectra. Secondary structure calculation was carried out using the Perkin-Elmer 
CIReOM program, which is based on factor analysis of a data set of the spectra of 
known structures [296]. 
Circular Dichroism (CD) Spectroscopy. 
Solutions of TIMP-J of known concentration, in the range 0-3 - 0- 5 mg/mJ, were 
prepared in 100 rnM KH2PO~ buffer (pH 7-0).in H20 . CD spectra of the solutions were 
recorded in both the near-UV (340-240 run) and the far-UV (260-180 run) regions using 
cylindrical cells of pathlengths 1-0 em and 0-02 cm respectively. A temperature of 200 e 
was maintained for the secondary structure determination using a circulating water bath. 
F or the thennal denaturation study, the temperature was raised in 100 e increments, with 
an equilibration time of approximately 15 minutes, before recording spectra. Solvent 
baselines were recorded at 200 e using the same cells. These were subtracted from the 
spectra, which were then converted to 6 based on the molar concentration of residues 
(mean residue weight of TIMP-l = ISS). Secondary structure content was calculated 
using the method of Provencher and Glockner by analysis of the far-UV eo spectra 
using the eONTIN program (version 2DP) [297]. 
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NMR 
All experiments and subsequent processing were performed on a Bruker AMX 
500 spectrometer running standard Bruker UXNMR software. Samples were prepared at 
40 mg/mJ, equivalent to 1-4 mM, in 500 ~I of D20. The sample is self-buffering at pH 
4-2. All spectra were acquired at a probe temperature of 32
0 C. For the 10 spectrum, 
1024 Fills were acquired into 16 K data blocks with a 60 degree excitation pulse of 6 
J,lS, a spectral width of 7042 Hz, an acquisition time of 1-16 s and a relaxation delay of 
1-S s. The phase-sensitive, double-quantum-fiItered (DQF) COSY spectrum [298, 299, 
300, 301] was acquired by accumulating 512 FIDs into 2 K data blocks using the same 
spectral width as for the 1 D accumulations. 2D data were zero-filled once in F 1 and 
Fourier transformed with the application of a Tt/3 shifted sine bell function in both 
dimensions. In all experiments the solvent peak was suppressed using a low power pre-
irradiation pulse of 1 -S s, corresponding to the relaxation delay. 
Secondary Structure Prediction. 
The secondary structure content of TIMP-I was predicted using Protein Predict 
[302], SOPM [303]and nnpredict [304] programs via the MSU mail server facility [305]. 
The Robson-Garnier and Chou-Fasman structure predictions used the peptide structure 
program (part of the GCG package, Genetics Computer Group, University of 
Wisconsin). 
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5.3. Results. 
5.3.1. Secondary Structure Determination 
Fourier-Transform Infra-Red (FTIR) Spectroscopy. 
Difference and second derivative FTIR spectra of both the H20 and the D20 
samples are shown as figures 5'1,5'2,5'3 and 5'4. The difference spectrum ofTIMP-1 in 
H20 (figure 5· I) shows the amide I band at J 643 cm- I and the amide II band at 1550 
em-I . The amide I band is assigned principally to C=O stretching and the amide II band 
principally to N-H bending of the peptide bonds. When dissolved in D20 buffer, the 
amide II band shifts to lower wavenumbers as a result of isotopic exchange ofN-H to N-
D. This exchange was complete after 48 hours to give bands at 1637 cm- I and 1456 cm-
1 respectively (figure 5'2). In all cases, the amide bands are broad and composed of 
several ove~rlapping components; these are revealed in the second-derivative spectra. In 
H20 (Figure 5'3), the major components in the amide I region are assigned to ··sheet at 
J 63 7 em-I, a-helix and/or turns at 1659 cm- l and anti-parallel ~-sheet and, or turns at 
]684 em-I . 
In D20 (Figure 5'4), the major amide r components are assigned to p-sheet at 
1638 em-I, a-helix at 1656 cm- I and anti-parallel ~-sheet and, or turns at 1685 em-I . 
The absorptions of several amino-acid side chains are also revealed in the second 
derivative. These are aspartate at 1585 em-I, glutamate at 1562 cm- 1 and tyrosine at 
ISIS em-I . 
Quantitative analysis of the secondary structure content was made by factor 
analysis of the difference spectrum of TIMP-l in H20 [296]. This gave 42% p- sheet, 
24% a-helix and 22% turns. The Mahalonobis' statistic [296] was 0·83, indicating that 
the spectrum of TIMP-l is within the range of variation of the reference spectra in the 
data set. 
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Figure 5·1. FTIR difference spectrum of TIMP-l in H20. The protein concentration 
was 9'8 mg/mJ in 100 mM KH2P04 buffer (pH 7'0), 256 scans were recorded at a 
resolution of 2 cm- I, The characteristic amide I and amide IJ bands are seen at 1643 and 
1550 cm- I respectively, 
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Figure 5'2. FTIR difference spectrum of TIMP-I in D20. The protein concentration 
was 7·5 mg/ml in 100 mM KH2P04 buffer (pD 7'0). 256 scans were recorded at a 
resolution of2 em-I . The amide bands have shifted to1637 em-I and 1456 em-I . The 
shoulder around 1575 em- J may reflect a population of non-exchangeable amide protons. 
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Figure 5·3. Second-derivative spectrum of TIMP-l in H20 using a 19 data point 
window. The major peaks of interest in the spectrum are marked and have been 
identified as: 1637 em-] - sheet, 1659 em-] - a-helix and/or turns and 1684 em-) - anti-
parallel B-sheet and/or turns. 
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Figure 5·4. Second-derivative spectrum of TIMP-l in D20 using a ]3 data point 
window. Again the major peaks have been marked, along with others that derive from 
individual amino acids whkh absorb in this region. These are aspartate at 1585 em-I , 
glutamate at 1562 em- l and tyrosine at 1515 em-I . The amide peaks have been assigned 
as 1638 em-I - ~-sheet, 1656 em-1 - a-helix and 1685 em- i - anti-parallel p- sheet 
and/or turns. 
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Circular Dichroism (CD) Spectroscopy. 
The overall shape of the far-UV CD spectrum (figure 5'5) would indicate that (1.-
helix is present, with a negative maximum at approximately 208 nm and a positive band 
below 200 nm, although not as the predominant structural type. The quantity of each 
secondary structural type, as determined from the far-UV CD spectrum using the 
CONTIN program, is 53% p- sheet, 13 % a- helix and 34% remainder (turns and coil); 
these values are the averages from six spectra. 
Thermal Denaturation 
To determine the thermostability of TIMP-J, the sample temperature was raised 
in 10°C increments from 20°C to 80°C for the CD and 70°C for the FTIR studies. The 
maximum temperature for the infrared spectroscopy was limited by the buffer 
evaporating from the cell at high temperatures. 
The CD spectra are shown in figures 5'6 and 5·7. The far-UV CD shows no 
significant change up to 60°C. At 80°C, however, the height of the maximum around 
190-195 nm decreased noticeably compared to the same peak at 20°C (figure 5'6). 
Maintaining the temperature at 80°C for a total of 4 hours caused the spectrum to 
change markedly. The broad negative band between 200 nm and 230 nm decreased 
sharply and the overall shape of the spectrum changed significantly. This effect was not 
reversed on cooling to 20°C, suggesting that the protein had denatured or precipitated. 
An identical sample studied in the near-UV region (figure 5·7) shows some small 
changes. The intensity of the positive maximum at 290 nm (which is due to tryptophan 
side chains) varies with temperature, decreasing as the temperature increases (by 
approximately 50% at 60°C). This can be explained as a result of the protein structure 
becoming less tightly packed, allowing the tryptophans greater freedom of rotation 
(mobile tryptophans have a much weaker signal in CD than those that are spatially 
confined). 
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Figure 5-6. Far UV CD spectra of TIMP-l showing the changes occurring through 
a temperature variation. Spectra were acquired for the same sample using a 0·02 cm 
pathlength cell and a 2 nm bandwidth. No significant changes were observed in spectra 
recorded at temperatures between 20°C and 80aC. 
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Figure 5·7. Near UV CD spectrum of TIMP-l at 20°C and 60°C. These spectra were 
acquired for the same sample, during the same temperature study as in figure 5'6. The 
effect of increased temperature is observed in the absorbance of the tryptophan side 
chain before any change is observed in the overall structure. 
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The same procedure using FTIR shows broadly the same effects. There are very 
minor changes up to 50°C, with no major changes in the appearance of the second 
derivative spectra (figure 5'8). The most notable change is an increase in the relative 
intensity of the component at 1675 cm- I and the appearance of a band at 1690 cm-1 as 
the temperature is incn:ased from 20°C to 30°C. Examination of the corresponding 
difference spectra (not shown) indicates that the:re is no difference in the extent of 
isotopic exchange. These high wave number components are usually assigned to p- sheet 
and/or turns. However, the absence of a corresponding change in the major p-
component at 1638 em-I suggests that the band at 1675 cm-) should be assigned to 
turns. There are no further changes in the spectra at 40°C and 50°C. 
At 60°C, a shoulder becomes visible at 1623 cm-1, this becomes stronger on 
cooling to 20°C. Also at 60°C, the intensity of the band at 1690 cm-) decreases sharply 
and that at 1676 cm-) (originally at 1674 em-I) increases. Reheating the sample from 
20°C to 70°C dramatically alters the spectrum. An intense band is seen at 1616 cm- I , and 
many of the bands in the spectrum of the unheated protein are lost entirely, being 
replaced with bands at 1682 cm- t, 1659 cm- I , 1647 cm- l (shoulder) and a greatly 
reduced band at 1639 cm- I . This effect was also seen at 50°C in a sample that was 
heated to 40°C and then cooled to 20°C for 48 hours before continuing the temperature 
variation study (data not shown). 
NMR Analysis 
The aromatic regIOn of a DQF-COSY and accompanymg one-dimensional 
spectrum is shown in figure 5·9. It is possible to identifY a number of through bond 
connectivities in this region. There are a number of downfield shifted a.-proton signals 
between 5 and 6·2 ppm, which are clearly devoid of COSY connectivities to aromatic 
protons, and which are characteristic of p-sheet regions [306]. 
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Figurf' 5·8. The effect of temperature on the second-derivative FTfR spectrum of 
TIMP-l. AU spectra were recorded under the same conditions as for the structure 
determination and calculated using a 13 data point window. The temperature was raised 
in 10°C increments allowing sufficient time for equilibration before recording the spectra. 
(a) FTIR spectrum ofTIMP-l at 20°C as used for structure determination. (b) Spectrum 
at 30°C. (c) Spectrum at 60°C. (d) Spectrum at 70°C. 
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Figure 5-9. DQF COSY spectrum of TIMP-l. Aromatic region with a few 
characterised spin-spin coupling systems traced out in the accompanying one dimensional 
spectrum. A number of peaks in the ID spectrum do not show any cross peaks indicating 
that they may be downfieJd shifted N-H protons. 
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5.3.2. Secondary structure Prediction. 
The TIMP-I protein sequence was analysed using a range of different structure 
prediction programs. The prediction for each residue is shown in table 5·) . The relative 
quantity of each secondary structure type was either taken directly from the program 
output or calculated from the numbers of residues defined as being in a particular 
conformation (table 5'2). When the prediction gave a relative probability of a residue 
being in a particular structure type (Chou-Fasman and GOR), all residues of any single 
type were grouped together to allow comparison with other methods. 
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Table 5·1. Secondary structure prediction from five different programs, Helix is 
indicated by H, sheet by E, tum by T and coil or loop by C, Less certain predictions for 
some programs are in lower case and residues for which a structural type was not 
assigned are marked as a point. 
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a-helix % f3-sheet % other % turn % 
Chou + Fasman 35·9 29·9 22,8 11'4 
GOR 12'5 8·2 33·6 45·7 
-
SOPM 21·74 33·7 44·57 nd 
nnpredict 21-7 8-2 70·1 nd 
protein predict 10'3 38,6 51-1 nd 
Table 5'2. Results drawn from the structure prediction of TIMP-l by five different 
algorithms; tr.e methods of Chou and Fasman [294J, Gibrat et al [295] (GOR), the self 
optimised prediction method (SOPM) [303], the nnpredict [304] and protein predict 
[302] neural network programs. Where a program could not assign an individual residue, 
or assigned it as coil it has been included as 'other' structural types. Some programs do 
not produce figures for tum structures, so for the neural network predictions the 'other' 
category includes turns. 
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5.4. Discussion. 
This work (with the exception of the structure prediction) is the first study to 
provide data on the structural content of TIMP-] (307]. 
The secondary structure content of TIMP-1 has been determined by two 
complementary methods: circular dichroism and Fourier transfonn infrared spectroscopy. 
The far-UV CD spectrum identifies a structure containing 53% ~-sheet, 13% a.-helix 
and 34% as remainder (turns and coil). The FTIR spectrum of TIMP-l in H20 gives a 
result of 42% ~-sheet, 24% a.-helix and 22% turns. This quantitative analysis is 
supported by the assignment of the bands in the second-derivative FTIR spectrum. The 
CD and FTIR analyses are in reasonable agreement. FTIR general1y gives a more 
accurate determination of the p-sheet content than does CD. 
Previous studies of TIMP-l have indicated that it has a high thermal stability 
[308J, which is consistent with the high number of disulphide bonds in relation to its size. 
However, to follow the stability using biological assays, the samples had to be cooled, 
precluding any analysis of possible reversible changes at higher temperatures. For the 
current experiments, the temperature was limited by the constraints of the equipment to a 
maximum of 60-80°C. The effects of temperature on the secondary structure are not 
extensive up to 60°C. FTIR spectra indicate that there are changes in tum structures at 
lower temperatures. The ~-sheet structure is unaffected until a threshold temperature of 
60°C is reached. The appearance of the band at 1616 cm- J has been associated with the 
aggregation of anti-parallel f3-sheets in other proteins [309]. The native f3 - sheet structure 
is lost at higher temperatures (greater than 60°C) and the denatured protein interacts 
irreversibly to form multimeric complexes. Aggregation also occurs on heating to lower 
temperatures, followed by long periods at room temperature. 
There was no significant change in the far-UV CD spectrum up to 60°C. When 
the sample is held at 80°C, irreversible changes occur as described above. By comparison 
with the FTIR experiment, the change is probably not due to structural alterations but is 
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caused by sample aggregation. Although aggregation occurs at different temperatures in 
the two techniques, this is probably due to the higher sample concentration that had to be 
used for the FTIR technique. 
The near-UV CD spectrum of TIMP- I shows an increase in the mobility of the 
tryptophan residues as t he temperature is increased. These changes could imply that the 
tertiary structure surrounding the tryptophan rings becomes less closely packed as the 
temperature increases, which is in agreement with the FTIR and far-UV CD results. The 
results of the secondary structural analysis, combined with the thermal stability study, 
suggest that TIMP-I could be similar to many other inhibitors in having a generally 
stable structure based around an exceptionally stable core of anti-parallel ~-sheet. 
NMR experiments were carried out as part of a general assessment of the 
suitability of TIMP-I for further structural analysis. The presence of several downfield 
shifted a-proton signals supports the conclusions drawn from the CD and FTIR studies. 
From the DQF-COSY experiment, it was possible to identify a number of scalar 
connectivities through several very clear cross peaks in the aromatic region. 
Secondary Structure Prediction. 
Of the five structure prediction methods tried, none predicted a secondary 
structure content that agreed entirely with the experimental evidence. The Chou and 
Fasman method significantly overpredicted the a-helical content of TIMP-l . All of the 
other methods gave helical predictions that were in line with the results obtained from 
CD and FTIR. In all the predictions the p-sheet content was underestimated. The GOR 
and nnpredict programs both predicted a sheet content of 8'2 %. These values are 
entirely different to the experimental ones and indicate that although structure prediction 
methods have improved they are by no means reliable in all cases. The GOR prediction in 
particular has designated almost half of the protein as .being in a tum conformation, 
which would be very unusual . 
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Table 5'1 shows the predictions by the different programs for each residue in the 
TIMP-l sequence. For the first fifteen residues there is no agreement between the 
different methods. The next block of ten shows some consensus towards sheet. The next 
section where the results are in general agreement is between Gln-36 and Asp-57, where 
the prediction is mostly helix. Residues Glu-81 - Ala-86 are also predicted as being 
helical. The section, Lys-93 - Ala-1OJ was predicted as being in a p-sheet conformation. 
There are no other long regions where all five predictions are in good agreement. Some 
individual residues were given the same assignment by all five methods such as I1e-96 
(sheet). There are also some where four have given the same assignment and the fifth not 
given a prediction such as GIn-50 (helix) . Overall there is not a great deal of agreement 
between the different methods 
These m~thods can give accurate predictions of secondary structure. The protein 
predict algorithm claims an accuracy of greater than 70 %, whilst the nn predict program 
has been accurate to 79 %. SOPM claims an overall accuracy or 69 %, with the most 
accurate predictions being for loop or coil (74 %), a.-helix is predicted to 66·3 % 
accuracy and f3-sheet to only 60·9 % accuracy. For structure prediction in general it 
appears that accurately estimating the quantity of ~-sheet is much less reliable than any 
other structural class. For a protein with a high p-sheet content, such as TIMP-I , it is not 
surprising that the predictions do not tie in with the experimental evidence. The best 
overall predictions were from the protein predict and SOPM programs, both of which are 
more recent developments. Future programs may be more accurate but extreme caution 
should be exercised when inte!J>reting the results. 
Comparison between Secondary Structure of TIMP-J anti the Structure of the N-
terminal Domain ofTIMP-2fI41J. 
Although TIMP- J and TIMP-2 do not have an extremely high sequence 
homology, from the complete conservation of the cysteine residues and their similar 
function it is probable that the two molecules share the same overall topology. According 
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to the NMR data, the N-terminal domain of TIMP-2 contains 40 % /3-sheet, most of 
which is anti-parallel. This is very similar to the high quantity of p-sheet and the 
indication that much of it is anti-parallel obtained by CD and FTIR for TIMP-l . The 
relatively low helical content also appears to be similar. However it is neither easy, nor 
valid to draw conclusions from this comparison, since the C-terminus of TIMP-2 was not 
studied and further data may alter the picture entirely. The general impression given by 
the data is one of a protein with a large amount of anti parallel ~-sheet. 
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Chapter 6. 
Some Surface FeatUlres ofTIMP-I. 
6.1. Introduction. 
Although the interior of a protein is essential to its overall structure, it is the 
surface that is most important in its solubility and interactions with other molecules. 
Studying the composition of the surface, in particular for any unusual residues, such as 
exposed hydrophobic patches and charged residues lost on interaction can give an insight 
into the mechanism of inhibition when no structural data is available. 
Wild type TIMP-l is known to be glycosylated at two sites, Asn-30 and Asn-78 
which do not appear to have any function in terms of biological activity [141]. However 
they may have a role in the behaviour of TIMP-l in vivo, possibly determining the 
accessibility to particular regions of the tissue and its stability in the blood. 111 vitro, the 
glycosylation may affect the solubility of TIMP-l in concentrated solutions which will 
have implications for the study of recombinant protein. There are also other points at 
which a protein may be gJycosylated. There can be a-linked glycosylations at serine and 
threonine residues which can not be predicted directly from the sequence. These might 
also not be detected after removal of the N-linked carbohydrate, particularly if the 
modification is not very large. 
In NMR spectra the majority of protons from the sugar residues have proton 
resonances which are overlapped with those of the protein side chains (between 2 and 4 
ppm). However, cross-peaks from the anomeric protons of the sugars are often' found in 
a relatively uncrowded region of a COSY spectrum. Studies of carbohydrates have 
identified characteristic chemical shifts for different sugar residues in particular 
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oligosaccharide environments [310, 311]. The chemical shifts of cross-peaks between 
anomeric, and vicinal C2 sugar protons can be compared with published data. It is then 
possible to make a tentative identification of the sugar type and position in the 
carbohydrate chain. 
There are a number of paramagnetic molecules, which have a large (electronjc) 
magnetic moment and can bind to various groups on the surface of proteins. The result 
of this binding is that the relaxation rate of any nuclei close to the introduced 
paramagnetic molecule is increased. Tills increases the Iinewidth of signals seen from the 
surface groups in NMR spectra. This is observed as the broadening of peaks in a ] 0 
spectrum and the reduction or cancellation of cross-peaks in a 20 COSY spectrum 
[3] 2]. The COSY experiment is particularly sensitive to line broadening. This is because 
the cross peak lobes are antiphase and if they become broader, will cancel themselv,es out 
as well as dropping down to the level of the noise. 
Careful choice of the compounds used will allow the composition of a proteins 
surface to be probed. Unusual surface residues can be identified, as can residues that 
become protected in protein-protein interactions. One of the most widely used probes is 
4-hydroxy-2,2,6,6-tetramethylpiperidinyl-N-oxy (OH-TEMPO). This is an organic free 
radical with an unpaired electron wruch does not cause a substantial change in the 
chemical shift of protein side chains on binding. OH-TEMPO interacts with hydrophobic 
side chains such as tryptophan, valine, leucine and isoleucine. Identirying exposed 
hydrophobic residues can be important in identifying and mapping protein-protein and 
protein-ligand interactions [3] 3]. 
8-anilino-l-napthaJene sulphonate (ANS), is a fluorescent probe that binds non-
covalently to hydrophobic regions of proteins. When this probe binds to proteins its 
fluorescence alters. The total fluorescence will increase and the wavelength of the 
emission can shift towards a lower wavelength. By titrating against ANS and calibrating 
the titration using a factor derived from a protein titration it is possible to determine the 
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number of ANS binding sites and their affinity [314]. As with the NMR probes, ANS can 
be used in studying protein-protein interactions when changes in conformation, or 
hydrophobic exposure occur. 
Tills chapter describes three analyses of surface features of TIMP- ) using these 
techniques. 
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6.2. Methods. 
6.2.1. Materials. 
Carbohydrate Analysis. 
Glycopeptidase F (PNGaseF) and Neuraminidase was from Boehringer 
Mannheim UK, Lewes, Sussex. Biotin-conjugated Concanavalin A was from Sigma 
Chemical Company, Poole, Dorset UK. Isogel- agarose plates for iso-electric focusing 
were from FMC BioProducts, Denmark. Biophoresis horizontal electrophoresis cell was 
from Bio-Rad Laboratories Ltd, Hemel-Hempsted, Herts, UK. Western blots were 
prepared using a Bio-Rad trans blot cell and Kodak EZE buffer formula 1 (0'025 M Tris-
HCI, 0'192 M glycine pH g'3, 20% methanol). IEF markers were from Pharmacia Fine 
Chemicals, Uppsala, Sweden. Analysis of sugars was carried out on a Dionex Dx500 
HPLC system with a PAl-4x250mm CARBOPAK. Data was processed using Dionex 
Peaknet software. 
NMR Probes. 
All experiments were carried out on a Bruker AMX 500 spectrometer. 4-
hydroxy-2,2,6,6-tetramethylpiperidinyloxy, free radical (OH-TEMPO) and MnCI2'4H20 
were from the Sigma Chemical Co., Poole, Dorset, U. K. 
ANS Binding Study. 
ANS was purchased from Molecular Probes Inc. NC AB TIMP-I was purified as 
described in chapter 3. The N-terminal fragment of porcine fibroblast collagenase was 
purified as described by O'Hare et al [315]. Fluorimetry was carried out on a Perkin-
Elmer LS2 filter fluorimeter. 
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6.2.2. Methods. 
Carbohydrate Analysi.'1. 
0,) mg of NCAB TIMP-I at 0'06 mg/ml was incubated at 37°C for a minimum of 
7 hours with I unit of PNGase F in 0'2M phosphate, 1 mM EDT A buffer, pH 8'6, to 
remove N-linked sugars. SDS PAGE was as described. Western blotting was carried out 
essentially as described in chapter 2. Molecular weight markers (both pre-stained and 
unstained), and untreated TIMP-I were included as controls. After the transfer 
procedure, the nitrocellulose was blocked with a solution of 1 % BSA in TBS-TWEEN 
for I hour. The blot was given a first incubation of 16 hours with biotinylated 
Concanavalin A at 2mg/m1 in TBS-TWEEN, then washed as described. The second 
incubation was for 2 hours with horse-radish peroxidase linked streptavidin at 1'6 mglml 
followed by extensive washing with TBS-TWEEN. The blots were developed using 4-
chloro-napthol (chapter 2). 
Iso-electric focusing was carried out according to the manufacturers' instructions 
using 10-100 J..I.g of protein per lane. Gels were run at 20 rnA until the current dropped 
towards lOrnA. Standards of known pI were included. Gels were stained in 0'1 % 
Coomassie and destained in 25 % ethanol, 9 % acetic acid. Alternatively they were silver 
stained according the manufacturers' instructions. 
Neuraminidase was used to remo' /e the free sialic acid residues from the 
carbohydrates. Both CAB and NCAB TIMP-l were at approximately 1 mglmJ. The 
buffer was adjusted to 50 mM acetate pH 5'0, neuraminidase added and samples 
incubated overnight at 37°C. 
CAB and NCAB TIMP-l were prepared for monosaccharide analysis by 
preparative SDS-PAGE and Western blotting. Img of CAB and 0'65 mg of NCAB 
TIMP-l were loaded across the top oflarge (3mm thick) SI?S ·PAGE gels and run at 300 
V for 3-4 hours, then blotted onto nitrocellulose using a 30 rnA current overnight. 
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Acid hydrolysis of attached carbohydrates was carried out on strips, up to 3mm 
wide, cut from the western blots of both CAB and NC AB TIMP-I . Strips from each 
were immersed in 200 J..l1 of either 6M HCI or 2M trifluoroacetic acid (TF A). Control 
strips from regions of the blots containing no protein were also included. These samples 
were incubated at 105°C for 4 hours, the strips removed and the remaining material dried 
in a rotavap. 
The hydrolysis products were rtsuspended in 20 J..l1 of H20 and centrifuged to 
remove residual Coomassie stain and precipitated material. PNGase F treated samples 
and controls were also centrifuged to remove precipitates and analysed without further 
treatment. 5 III of each sample were loaded onto the HPLC, pre-equilibrated, and run 
with 25 rnM NaOH. Detect ion of monosaccharides was with an electochemical detector 
sampling at a rate of 1 s-l. To identify the peaks and give a quantitative measure of the 
monosaccharides present, standards of a known concentration were used to calibrate the 
results. 
Glycosylated samples for analysis by NMR were prepared at 40 mg/mJ, 
equivalent to 1·4 mM in 500 ~I of 100 % °20. The sample is self buffering at pH 4·2 . 
The experim~nta1 details for the acquisition of DQF-COSY spectra are as described in 
chapter 5 (methods). 
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NMR Paramagnetic Probe-Experiments. 
The same TIMP-I sample was used for the OH-TEMPO experiments and for the 
sugar analysis. 20·1 mg of OH-TEMPO were dissolved in 500 /ll of D20 and the pH 
adjusted to 4'4 using DCI. One-dimensional spectra were recorded as described above 
for samples containing 0, 0'75, 1'5, 6, 9'75, and 13'5 mM OH-TEMPO. A OQF.COSY 
spectrum was recorded for the final sample under the conditions described above using a 
9/ls, 90° pulse. 
For experiments using MnCI2, a fresh sample was made up at 24 mglmJ (0'85 
mM) in DzO. MnClz was dissolved in OzO to a final stock concentration of I mM. One 
dimensional spectra were recorded as described above for samples containing 0, 2·5 ~lM, 
5 ~lM, 12·5 /lM, 25 /lM, 37'5 /lM, 87'5 /lM, 330 /lM, 2·83 mM, 5·33 mM and 7·83 mM. 
Again a DQF-COSY spectrum was recorded for the final sample. 
ANS Binding Experiments. 
ANS was dissolved in HzO to give a 10 mM stock solution. This was diluted as 
necessary and the actual concentration determined from the absorbance of solutions at 
350 run (a 0'1 mM solution has an A350 of 0'5). All experiments were carried out in a 
buffer of 0-1 M Tris-HCI, 0'1 M NaCI, 2 mM CaClz, pH 8-0. Sample tubes were foil 
wrapped and exposure to light minimised. All samples were incubated with ANS in the 
dark at room temperature for two hours prior to recording the fluorescence. When TIMP 
and collagenase fragments were used together an additional two hour incubation was 
used prior to the addition of ANS. An excitation wavelength of 340 nm was used and 
emission spectra recorded between 390 and 560 nm. Wavelength scans were run 
automatically, other readings were made individually. After each reading, the fluorimeter 
was washed with buffer until the emission returned to zero. 
Samples prepared for wavelength scans were 3 /lM TIMP-l , 100 mM ANS; 2·5 
J.lM each of TIMP-l and collagenase fragment, 100 mM ANS; 0·5 mM collagenase 
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fragment, 200 mM ANS and 200 mM ANS only. Samples for the more accurate 
assessment of A max used 2 mM protein and 200 mM ANS. Samples for titrations used 
protein concentrations of 0 - 3 mM and 0 - 500 mM ANS. For the protein titrations ANS 
was kept constant at 100 rnM and for the ANS titrations the protein concentrations were 
kept constant at 1 mM. 
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6.3. ResuJts. 
6.3.1. Carbohydrate Analysis. 
Analysis of Endog/ycosidase Treated TIMP-l. 
NCAB TIMP-l treated with PNGase F was analysed by SDS PAGE and 
Concanavalin A Western blotting. The gel and blot are shown as figures 6'1 and 6'2 
respectively. SDS PAGE (figure 6'1) shows that the PNGase F treatment has reduced 
the molecular weight of the TLMP-1 . Two bands are present in lane 2 of this figure, the 
higher is at approximately 26 kDa and the lower is at 21 kDa. Western blotting (figure 
6'2) using a Concanavalin A based detection system, picked out the glycosylated 
molecular weight markers (lane 1) and the untreated TlMP-1 controls (lane 3). A smaller 
quantity of TIMP-l was loaded into lane 3 resulting in the faint band observed. The same 
pair of bands seen in the SDS PAGE analysis of the treated sample is also seen on this 
western blot (lane 2). This shows that in both forms a Concanavalin A binding capacity 
has been retained after PNGase F cleavage of the N-linked carbohydrate. 
IEF Analysis of CAB and NCAB TIMP-l. 
Figure 6·3 shows the IEF profile of CAB TIMP-l. A range of sample loadings 
has been used in lanes 2 to 6. A large number of different pIs are present. The major 
forms have pIs of approximately 9'2, 9'0, 8'9, 7'9, 6'7, 5·9 and 5·6. Figure 6·4 shows the 
IEF profile of NCAB TIMP-I (lane 6) and both CAB (lane 3) and NCAB TIMP-] (lane 
5) after treatment with neuraminidase. The CAB and NCAB forms of TIMP-l have 
different profiles that can be clearly distinguished on the IEF gel. The NCAB TIMP-l 
(lane 6) has pIs of8'4, 8'2, 7'3, 6'5, 5'6, 5'3 and 5'0. 
After treatment with neuraminidase, the large number of widely distributed bands 
is reduced to one or more bands with a narrow range of pIs (figure 6'4, lanes 3 and 5). 
Even after neuraminidase treatment some differences are apparent between the CAB and 
NCAB forms. The NCAB form of TIMP-J (lane 5) shows at least five different pIs 
between 8·2 and 9,2, whilst the CAB form (lane 3) has reduced to a single band with a pf 
of approximately 9·0. 
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Figure 6-1. SDS PAGE of PNGase-F treated TIMP-l. Lane 1: molecular weight 
markers, Lane 2: PNGase-F treated TIMP· J, Lane 3: wild type TIMP-l . The molecular 
weight of the lower band in Jane 2 is approximately 21 kDa showing that all N-Iinked 
sugars have been removed . The upper band of approximately 25 kDa is partially 
deglycosylated. 
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Figure 6·2. Western blot of PNGase F treated TIMP-1. Biotinylated Concanavalin A 
is used to detect proteins with bound sugars. Lane I: molecular weight markers, Lane 2: 
PNGase F treated TIMP-l, Lane 3: wild type TIMP-1. The Concanavalin A detection 
system has picked out some of the molecular weight markers, the untreated TIMP-] and 
both bands of the treated sample. This suggests that other forms of gIycosylation may be 
present. 
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Figure 6·3. IEF gel of CAB TIMP-1. Lanes 1 and 7 contain markers of known pI. 
Lanes 2 through 6 contain a range of protein quantities ( I 0 ~Lg - I 00 ~g) . The IEF profile 
shows that wild type TIMP-l has an extremely complex mixture of pIs. 
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Figure 6·4. IEF gel showing CAB and NCAR TIMP-I before and after treatment 
with neuraminidase. Lane 1: pI markers, Lane 2 CAB TIMP, Lane 3: CAB TIMP 
treated with neuraminidase, Lane 4: neuraminidase, Lane 5: NC AB TIMP treated with 
neuraminidase, Lane 6: NCAB TIMP, Lane 7: pI markers. NCAB TIMP-l has a 
different pattern of pIs to CAB TIMP-I , both before and after neuraminidase treatment. 
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Monosaccharide Composition. 
Data from the HPLC chromatograms was converted into relative percentage 
composition using the calibration from the set of known standards. This data is shown in 
tables 6'1, 6'2, 6·3 and 6·4. The results from both the TF A and Hel hydrolysis of the 
monosacchalides are 3hown for CAB TIMP-l and NC AB TIMP-I. 
Monosaccharide Concentration/mM Relative % 
fucose 0·039 4'1 
galactosam ine 0·021 2 
glucosamine 0'552 59 
galactose 0'238 25 
mannose 0'08 8'5 
Table 6'1. Monosaccharide composition of CAB TIMP-l (HCI hydrolysis). 
Monosaccharide Concentration/mM Relative % 
fucose 0'12 8 
galactosamine 0·002 0·2 
glucosamine 0'609 40 
galactose 0·576 38 
mannose 0'199 I3 
Table 6'2. Monosaccharide composition of CAB TIMP-l (TFA hydrolysis). 
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Monosaccharide Concentration/mM Relative % 
fucose 
-
-
galactosamine 
-
-
glucosamine 1·081 79'68 
galactose 0'277 20'4 
mannose 
- -
Table 6'3. Monosaccharide composition of NCAB TIMP- t (HCI hydrolysis). Very 
small peaks could be observed at retention times indicative of fucose galactosamine and 
mannose (slightly larger peak). However, these were not identified as peaks by the 
software and their concentration was not determined. 
Monosaccharide Concentration/mM Relative % 
fucose 0·121 8'67 
galactosamine - -
glucosamine 0'676 48'64 
galactose 0·371 25·59 
mannose 0'227 16'72 
Table 6'4. Monosaccharide composition of NCAB TIMP-t (TFA hydrolysis). No 
significant peak was observed for galactosamine. 
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Both HCI and TF A were used for chemical deglycosylation because slightly 
different results are obtained using the different acids (as can be seen in the tables above). 
However, the differences between the two acid hydrolyses are not large and the overall 
picture for each TIMP-I form (CAB and NCAB) is very similar. For all four analyses the 
chromatograms recorded for the blank controls showed only glucose at higher 
concentrations than in the samples. From this it was concluded that glucose was not 
present in the samples. The composition of both glycoforms is very similar. 
Galactosamine is present at trace quantities « 2%) and fucose makes up 4-8% of the 
total. Although complete data was not obtained for mannose it appears to be very similar 
for both glycoforms and is present at slightly greater than 10% of the total. The primary 
difference is the relative quantities of galactose and glucosamine. In the NCAB form 
there is more glucosamine and less galactose (by percentage) than the CAB form. Since 
the material for these analyses was obtained from Western blots it was not possible to 
quantify the amount of each sugar, only the relative proportions. 
NMR Analysis 
The one-dimensional spectrum of CAB TIMP-I in 020 is shown as figure 6·5. 
Some of peaks in the amide N-H region (downfield of approximately 7 ppm), may be due 
to signals from N-acetylated sugars. A dominant feature of the spectrum is a number of 
sharp peaks due to mobile sugar residues, the majority being found in the region between 
3·5 and 4·5 ppm. These are due to the sugar ring protons, with the exception of the 
anomeric proton signals which are shifted to the region between 4·5 and 5·5 ppm. At 
higher field (about 2 ppm), resonances from the methyl group of N-acetylated sugar 
residues such as N-acetylglucosamine and sialic acid are evident. 
The region containing the majority of the sugar signals of a DQF-COSY is shown 
in figure 6·6. Cross peaks due to the anomeric protons of different sugars have strongly 
characteristic chemical shift coordinates in a 2D spectrum. These have been recorded for 
synthetic polysaccharides in 020 and H20, and, although these could differ slightly in a 
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Figure 6·5 1 D NMR spectrum of TIMP-l in D20. The sharp peaks indicated are from the sugars which are both very abundant and 
have greater mobility. The result of this is that much of the protein spectrum is obscured. 
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Figure 6·6. Section of COSY spectrum of TIMP-1. Non-methyl sugar region, with 
assigned cross peaks labelled as referred to in the text, except peak f. which is only 
apparent at a much higher plot gain, 
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glycoprotein spectrum, the difference in most cases will be only a few hundredths of a 
ppm. By referring to the published resonance frequencies, it was possible to identitY 
some of the monosaccharide types in TIMP-I. The cross peaks of interest in figure 6'6 
are labelled a to g. Cross-peak (a) is ambiguous: it may be from mannose, although it 
does not fit any of the tabulated shifts closeiy The appearance of the cross-peak suggests 
a small JH }-H2 consistent with the axial-equatorial interaction expected in a j3-linked 
mannose residue. However, it may also be a-linked fucose. Cross-peak (b) may reflect 
the HI j3-H2 connectivity of galactose at the non-reducing end of an oligosaccharide 
chain. Cross peak (c) is also due to the HI j3-H2 protons of galactose, which in this case 
is located in the backbone. Cross-peak (d) is consistent with connectivities between the 
HI j3 and H2 protons of glucosamine or glucose. Cross-peak (e) could be due to the 
connection between the H4 and H5 protons of galactose, this time at the reducing end of 
the oligosaccharide. Cross-peak (f) between resonances at 4·716 and 3·812 ppm is much 
weaker than the others. It may be a connectivity between the HIJ3 and H2 protons of a 
backbone glucosamine at a branch point in the oligosaccharide. Cross-peak (g) 
corresponds exactly to the connectivity between the H3 equatorial and H4 protons of 
sialic acid. Further cross-peaks would have been expected for the H3ax-H4 and H3ax-
H3eq connectivities, but they occur in regions of the spectrum that are extremely 
crowded, thus preventing unambiguous assignment. 
6.3.2. NMR Paramagnetic Probe Experiments. 
The series of 1-D spectra recorded for the OH-TEMPO study is shown in figure 
6'7. In these spectra line broadening can be seen as the concentration of the 
paramagnetic probe is increased. Certain signals were particularly affected by the 
presence of the probe. A large number of signals between 0 and 3'5 ppm show evidence 
of line broadening, in particular, those between 0 and 2 ppm. The highfield signals 
between 0 ppm and 0·5 ppm are usually associated with methyl groups located above the 
plane of aromatic rings in a folded protein structure. Further downfield, signals between 
6 and 7 ppm also broaden in response to the probe. Sections of a COSY 
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Figure 6-7. Series of ID spectra of TIMP-l showing the effect of the spin probe, 
OH-TEMPO. The concentration of OH-TEMPO is marked next to each spectrum. A 
number of peaks show clear line broadening as the concentration of OH-TEMPO is 
increased. Those at highfield could be attributed to the side chains of residues such as 
Val, Leu or lie. The downfield peaks may be associated with tryptophan side chains. 
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Figure 6.8. COSY spectra of TIMP-l. without (A) and with (8) 13.5 mM OH-
TEMPO. The section shown is part of the aromatic region. A number of cross peaks are 
absent from spectrum B. These may be due to Tyr, Phe or Trp. 
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Figure 6·9. Series of to spectra of TIMP-l showing the effect of the spin probe, 
MnCI2• A large number of peaks in the spectrum exhibit line broadening as the 
concentration of MnCI2 is increased. 
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spectrum recorded with the highest OH-TEMPO concentration are shown alongside 
COSY spectra recorded for the sample prior to the addition of the probe (figure 6-8). 
These clearly show where line broadening has occurred in the aromatic region. Cross 
peaks associated with two separate spin systems have been broadened such that they 
have effectively been removed from the spectrum. One spin system has observable peaks 
at 6-24 and 6-67 ppm. From these chemical shift co-ordinates, these resonances are 
tentatively assigned as being from the aromatic ring of a tyrosine residue. The other spin 
system has peaks at 5-94, 6-12 and 6-58 ppm. These may be from the aromatic ring of 
either tryptophan (with some resonances overlapped) or phenylalanine. Alternatively they 
may also be due to a tyrosine ring which is flipping slowly. 
A similar series of I D spectra is shown in figure 6-9, for the experiments using 
increasing concentrations of MnCI2. Here, extensive line broadening can be seen for 
many signals as would be expected from the binding of Mn ions to charged surface 
groups (Asp arId Glu). 
6.3.3. ANS Binding Study. 
Preliminary wavelength scans of the emission spectra were recorded for each 
sample and an ANS only control to approximate the wavelength where emission was the 
greatest (A max). This was found to be close to 520 rim for all samples. Table 6-5 shows 
fluorescence measurements made at 510, 520 and 530 nm for ANS, TIMP, porcme 
collagenase fragment and TIMP + porcine collagenase fragment. 
From the evidence in table 6-5, it would appear that the N-terminal fragment of 
collagenase does not have any binding sites for ANS and no further study was made of it. 
For TIMP-l two titrations were performed in an attempt to determine the 
number and affinity of the ANS binding sites that are present. The first used a varying 
concentration of protein and a fixed concentration of ANS, in the second, the protein 
concentration was kept fixed and the ANS concentration varied. 
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510 nm 520nm 530 nm 
ANS 37·3 39'85 38'0 
TIMP-l 0·5 0·4 0·3 
Collagenase Fragment 0·3 0'3 0·2 
ANSffIMP 43·65 45·9 42'1 
ANS/Collagenase Fragment 38'05 40'05 38'3 
TIMP/Collagenase Fragment 0·7 0·6 0'45 
ANSrrlMP/Collagenase Fragment 47·05 48·2 44'65 
Table 6'5. Fluorescence of TIMP-l, Porcine Collagenase N-terminal fragment and 
ANS in combination. The figures given are in arbitrary units. The protein alone makes 
little contribution to the total fluorescence of samples and the increase on the addition of 
ANS is small for TIMP containing samples. There is effectively no change in the 
fluorescence when ANS is added to collagenase fragment alone. When TIMP and 
collagenase fragment are present (with ANS) the fluorescence is higher than that of 
either component alone. 
The protein titration was used to generate a calibration factor giving the units of 
fluorescence change per micromole of ANS bound. This figure was obtained from the y 
intercept of a plot of I/fluorescence against \/[protein] (figure 6'10). For TIMP-I the 
calibration factor is 10·3. The ANS titration was used to find the difference in 
fluorescence (.1F) between the sample + ANS and ANS alone (figure 6'11). The 
calibration factor and .1F were used to create binding isotherms for the sample (figure 
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Figures 6·10 to 6·14 show the stages involved in analysing the protein and ANS 
titration data to give final Klotz and Scatchard plots. Values are derived from these plots for 
the number and average affinity of any ANS binding sites present on TIMP-I. Curve fitting 
was carried out using the Kaleidagraph analysis package for Apple Macintosh. Data for 
figure 6·10 was fitted to a curve with the equation y=m 1-(m2/(m3+mO», all other data could 
be fitted to conventional formats (i.e. smooth, exponential or linear). rnO represents the x values. 
Figure 6·10 is used to calibrate the experiment by determining the maximum increase 
in fluorescence/J..lM ANS bound. This is taken from the y intercept of the plot (at infinite 
protein concentration, where no ANS is free in solution). Figure 6·11 shows the titration of 
ANS alone, ANS plus protein and the third curve, and the difference between them (M', the 
change in fluorescence caused by ANS binding). This set of values (~F at different ANS 
concentrations) is converted into moles of ANS bound per mole of TIMP-l by 
multiplication with the calibration factor (10·3) derived from figure 6·10. Figure 6·12 shows 
the amount of ANS bound (v) plotted against the concentration of free ANS. The 
concentration of free ANS is derived by calculating the total amount of ANS bound to the 
TIMP-I (from v and the protein concentration) and subtraction from the total amount of 
ANS in the sample. This plot shows the equilibrium between free and bound ANS. The data 
was fitted to an exponential curve with an R factor of 0·95. However the majority of the 
data would also fit linearly in the absence of the point at 0 moles of ANS bound. This point 
was included to represent zero ANS binding and was not used in subsequent calculations. 
To calculate the number and affinity of ANS binding sites on TIMP-1, the amount of 
ANS bound (v) and the amount of free ANS are presented as a linear Scatchard plot in 
figure 6·13. The x intercept indicates the presence of one, and one partial binding site and 
the gradient shows an average Ka of 2·6 xI04M. Although linear, the fit to the data is not 
good (the R factor of 0·8 where an R factor of 1 indicates a perfect fit). A better fit was 
obtained from a Klotz analysis of the data (figure 6·14). Here the data is presented as a 
double reciprocal plot of lIv (moles of ANS bound per mole of TIMP-I) against lithe 
concentration of free ANS. In this case the linear fit had an R factor of 0·98. The value at 
the y intercept shows that one binding site is present with aKa of 3·3 x 1 04 M -I (from the 
gradient). 
6' J 2). This was achieved by multiplying the values for L1F by the calibration factor to 
give v. The resulting curve shows the number of moles of ANS bound per mole of 
protein. This can then be used to generate either Scatchard [316] or Klotz [3 I 71 plots for 
the data ~ figures 6·13 and 6'14) from which the number of binding sites and an average 
Ka can be calculated. 
From the linear Scatchard plot, one complete and one partial binding site was 
indicated with an average Ka of 2·6 xl04 M-I The R factor of 0·8 indicates that the 
results drawn from this plot are not very accurate. When a Klotz plot was used it was 
found that a single binding site was present with a Ka of 3· 3 x 104 M-I. In this case the R 
factor was close to 1, (0'98) indicating an excellent fit to the data. 
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Figure 6·11. ANS Titration for TIMP-l. 
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Figure 6·13. Scatchard Analysis of ANS Binding to TIMP-1. 
The plot is linear indicating that the binding is non-cooperative. The x intercept 
shows one complete and one partial binding site present. The Ka (- gradient) 
is 2·6 x IO~ M- 1• The R factor is 0·8. 
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Figure 6'14. Klotz-Plot Analysis of TIMP-ANS Binding. 
The number of binding siles is taken from II) intercept. The Ka is 
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6.4. Discussion 
In this chapter a number of different techniques have been used to study some of 
the surface features of TIMP-]. A short study has also been made of the N-terminus of 
collagenase, and how it might interact wit" TIMP-]. 
To date there has been no detailed analysis of the carbohycirate present on the 
human form of TIMP-]. Two sites for N-linked glycosylation are apparent from the 
amino acid sequence and treatment with endoglycosidases gives a two stage 
deglycosylation showing that both available sites are occupied [129]. Previous studies 
have also been made of the charge of the sugars. TIMP-l has a large number of pIs 
which generally reduce to a single band on removal of sialic acid residues using 
neuraminidase [134]. Other than an estimate of the number of sugar residues present and 
evidence from the lectin binding behaviour, no analysis has been made of the 
carbohydrate composition. 
A detection method for use on Western blots has been devised to identify 
glycoproteins. Biotinylated Concanavalin A was chosen as the detecting agent because it 
has an affinity for the type of sugars likely to be found at an O-linked site. The 
biotinylated form was used to detect and amplify the signal. The results show that even 
after treatment of wild type TIMP-l with PNGase F, a band is still present at 21 kDa on 
the blot after staining for carbohydrates. This band is also seen in Western blots using the 
TIMP-l polyclonal detection method (chapter 4). This result indicates that TIMP-l may 
have more glycosylation sites than have previously been identified. Since these additional 
sugars are not removed after extended treatment with PNGaseF, it is likely that they are 
not N-linked. The next most common type of glycosylation is at an O-linked site, where 
the initial sugar is attached to an amino acid with a free hydroxyl group (i.e. serine or 
threonine). 
It is also possible that the bands seen in this experiment are an artifact. There may 
be a non-specific interaction occurring between the proteins present and the lectin, 
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possibly as a result of using an excess of Concanavalin A. Since only a few of the 
proteins in the marker lane, and none of the BSA used in the blocking step responded, it 
is unlikely to be a general protein-lectin binding. 
However, the nature of this additional glycosylation remains to be determined. 
Since recombinant TIMP- J is known to have normal inhibitory activity against the 
MMPs, it is unlikely to be important for function. It is possible that this additional 
glycosylation is a spurious feature of TIMP-I produced by cultured cells. A similar study 
of TIMP- J purified from human tissues would be required to confirm whether this is the 
case. 
Human TIMP-l is known to have heterogeneous glycosylation. Multiple pIs and 
differential binding to Concanavalin A-Sepharose have been observed. Both CAB and 
NCAB TIMP-I were purified and studied by IEF. The patterns of bands seen on ihese 
gels confirm that TIMP-I has a hcteroger. eous mix of carbohydrates present. The CAB 
and NCAB forms show different IEF patterns, which collapse to patterns which still 
differ after treatment with neuraminidase. This shows that there is heterogeneity in both 
the composition and charge of the carbohydrates, and that the apparent separation of 
glycoforms by Concanavalin A-Sepharose is genuinely separating two different pools of 
material. 
HPLC analysis of monosaccharides removed from both CAB and NC AB TIMP-I 
by acid hydrolysis confirms the heterogeneity seen in IEF. CAB TIMP-l has relatively 
less glucosamine and relatively more galactose than NC AB TIMP-I. This differs from 
the composition of the bovine TIMP-J [132], which has a much greater mannose (25% 
of the total compared with 8% for human TIMP-I) content. The glucosamine content of 
bovine TIMP-l is similar to CAB TIMP-l whilst the galactose content is similar to 
NC AB TIMP-I. 
A similar picture was obtained in the NMR study of the carbohydrates. It was 
possible to identifY certain individual sugar residues from the chemical shifts of the 
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anomeric and H2 protons of the carbohydrate groups. Galactose Has been identified in 
the backbone and at both the reducing and non-reducing ends of the carbohydrate chains, 
while glucose or glucosamine (more probable in view of the HPLC analysis) may be 
present at a branch-point in a chain. Sialic acid is present, but no other sugar tyP(: was 
specifically identified. Mannose was not unambiguously identified, with no clear 
resonances from mannose protons in the 20 spectra. Unfortunately it is not possible to 
quantify the sugars from the intensities of the COSY cross-peaks. 
Since sialic acid does not participate in the binding to Concanavalin A, one 
explanation for the differential binding to this lectin lies in the different proportions of 
galactose and glucosamine. This might be due to the loss of galactose or addition of 
glucosamine residues in NCAB TIMP. Concanavalin A binds a-mannose, a-glucose and 
sterically related residues. Subsequently the differential binding may reflect a different 
spatial arrangement of sugars that does not expose sufficient sterically correct hydroxyl 
groups for a strong interaction with Concanavalin A. 
NMR was also used to study another aspect of the surface of TIMP-I. In this 
study spin probes were used to identify signals from charged, or hydrophobic surface 
residues. As would be expected, the MnCI probe caused a large number of signals to 
broaden. Most of these were in the region where signals from acidic side chains would 
normally be seen. 
When the hydrophobic spin probe, OH-TEMPO was added to the TIMP-l 
sample, a number of peaks in the aromatic and highfield (above 1 ppm) regions of the 
spectrum broadened. This indicates that one or more hydrophobic residues are exposed 
on the surface of the protein. From the chemical shift of the aromatic signals it is possible 
that at least one of these residues is a tyrosine. The identity of the second susceptible spin 
system is less clear. The signals are more dispersed than those expected from the 
aromatic ring of Phe, but a complete tryptophan ring system is not observed. It is 
possible that the additional tryptophan peaks are very weak or overlapped with others. 
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Both of these spin systems are found at a low chemical shift. This may indicate that each 
lies close to another aromatic ring in an unusual (possibly exposed) environment. 
The broadening effect seen with the high field signals may be related tC' the 
exposed aromatic residue(s). These highfield signals are probably from methyl groups on 
side chains that lie close to an aromatic ring. Since they are affected by the OH-TEMPO 
they may be close to an exposed hydrophobic residue. Interestingly, in another 
experiment [131 J TIMP-I was treated with the reagent, 2-nitrophenylsulphenyIchloride 
(2-NPSCI) which modifies tryptophan residues. It was found that the use of a 5'6 fold 
excess of2-NPSCI resulted in a 55% decrease in inhibitory activity ofTIMP-1. 
Data from the solution structure of the N-terminus ofTIMP-2 [141] shows that 
several hydrophobic residues are exposed on the surface of the molecule. These are Phe-
103, Leu-85, Trp-107, Leu-lIS and Tyr-I22. They form part ofa concave face that also 
includes His-7. The evidence presented here suggests that TIMP-I also has a number of 
exposed hydrophobic residues. In TIMP-I all but one of these residues is homologous to 
TIMP-2 (Leu-l 18 is substituted by Phe-116). It is possible that this concave site will also 
be found on TIMP-l. 
Experiments studying the effects of ANS binding on TIMP-I also indicate that 
one or more hydrophobic groups may be exposed on the surface. The increase in 
fluorescence on the addition of ANS to TIMP-l shows that the ANS molecule is binding 
to the protein surface. The titration against ANS indicates that there is probably only a 
single low affinity binding site present. An additional study with the N-terminal fragment 
of recombinant porcine collagenase found that no ANS binding sites were present on the 
enzyme. When the collagenase fragment. and TIMP-I were incubated together prior to 
the addition of ANS, the fluorescence seen was greater than for TIMP-I alone. This 
suggests that an interaction between the two molecules had altered the hydrophobic 
surface of one, or both proteins. 
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Although a titration analysis was carried out using a I: I ratio of TlMP and 
collagenase fragment, the analysis is complicated by the fact that a large excess of TlMP-
1 (50 fold) is required to inhibit the N-terminal fragment of collagenase [28]. Such large 
q 'Jantities of TIW-l (in the order of 15 mg per sample) ar~ not available. 
The increased fluorescence in the presence of collagenase fragment could suggest 
that a confonnational change has occurred on binding, increasing the accessibility of the 
ANS binding site. It cannot be assumed that the ANS binding site on TIMP-\ is the same 
one that is present in the TIMP-l-collagenase fragment complex. It is possible that the 
first site is blocked by the interaction with the collagenase fragment and a second site 
becomes available as a result of conformational changes. Another explanation is that 
additional sites have been exposed on one or both proteins. To fully investigate this 
phenomenon it will be necessary to determine the proportion of protein found as a 
complex in the mixture. Also the rate at which the complex forms and dissociates may 
affect the results seen. If an ANS binding site is buried on interaction and additional sites 
exposed the data will be further complicated by a heterogeneous mix of the two species. 
A simpler, and more biologically relevant study would be made using intact 
porcine collagenase, adding the ANS both before and after the TIMP-I. Sufficient 
quantities of full length enzyme have been made available and these studies are now in 
progress. 
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Chapter 7. 
Study of a Peptide Derived From the N-terminus of TIMP-l. 
7.1. Introduction. 
The inhibitory activity of TIMP-I has been shown to be primarily in the N-
terminus [230]. Consequently a great deal of attention has been focused on this region, 
to identify residues that are important for inhibition of the MMPs. Of particular interest 
are the first 23 residues, which show a high degree of conservation throughout the 
TIMPs. As discussed in the introduction, a high degree of homology may be an 
indication of either a structurally, or a functionally important feature. Deletion of the 
VIRAK (residues 18-22) sequence results in virtually no protein production [244] 
suggesting it has a structural role (confirmed on the publication of the TIMP-2 N-
terminal structure). The region between Cys-3 and Cys-13 has been implicated in the 
inhibition of the MMPs. Mutants where His-7 and Gln-9 were substituted have reduced 
inhibitory activity [244]. Also modification with DEPC indicated that a histidine residue 
was involved in the inhibition of the MMPs. However, the evidence pointed more to His-
95, rather than His-7 in this experiment. 
By analysing the N-terminal sequences of all the known TIMP sequences a clear 
consensus is seen for the first thirteen N-terminal residues. This consensus is 
CXCXHPQXAFC. A search of the EMBL database using this consensus sequence 
identified all the TIMP sequences, as would be expected. Interestingly another family of 
proteins was also shown to have a strong homology to this consensus sequence. This 
was the Bowman-Birk family of proteinase inhibitors. These are a group of small serine 
proteinase inhibitors found in plants (i.e. soybean, adzuki bean and cowpea). They are 
able to inhibit both trypsin and chymotrypsin, using different regions of the molecule. 
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This type of inhibitor is known as "double headed". The region of homology between the 
soy bean inhibitor and the TIMP consensus sequence is shown below. 
10 
TIMP consensus CXCXPXHPQXAFC 
I : I :: I:: I I 
Soybean BBI homologous sequence CICALSYPAQCFC 
40 50 
This homologous region includes the residues that are involved in the inhibition 
of chymotrypsin (Tyr-44 and Ser-43). The solution structure of this protein has been 
determined [318]. This region is found as a loop, disulphide bonded at the base (Cys-41 
Cys-49), which exposes the inhibitory residues. When this loop was isolated from the 
rest of the protein it retained inhibitory activity, although the Ki was reduced [319]. It 
was postulated that, although these are two very different families of inhibitors, they may 
be using a similar structure to expose crucial residues for the inhibition of their respective 
enzyme 
The high conservation of the N-t~rrninal sequence of the TIMPs, the sensitivity of 
His-7 and Gln-9 to mutation, and the intriguing similarity to the Bowman-Birk inhibitors 
suggested it may be possible for a peptide based on t~e N-terrninal sequence of a TIMP 
to show inhibitory activity. A peptide was produced, based on human TIMP-l, with the 
sequence: 
c~v P P H P Q T A F C 13 I -' I 
s _________ ---.;s 
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The residues are numbered according to their position in the original TrMP-1 
sequence for clarity. The peptide was initially obtained with the two cysteines joined by a 
disulphide bond, creating a cyclised molecule. This was to ensure that no free sulphydryl 
groups were available to interact with the active site of the enzymes assayed. Any 
interaction between the enzymes and free thiol groups may have given a false impression 
of inhibitory activity. 
In this chapter the peptide Cys-3 - eys-I3 is assayed for activity against a number 
of different enzymes in both cyclised and linear (reduced and methylated) form. The 
cyclised form was also studied by NMR in both H20 and the structure stabilising solvent 
TFE-d2. 
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7.2. Methods. 
7.2.1. Materials. 
The II-mer peptide CVPPHPQT AFC was purchased in oxidised form from 
Bachem Ltd, California. TFE-d2 was from Fluorochem, Glossop, Derbyshire UK. 
Methyl iodide (Mel), DFP and OTT were from Sigma Chemical company, Poole, Dorset 
UK. Enzymes for assays were either purified in the Rheumatology Research Unit or 
purchased from Sigma. 
7.2.2. Experimental Details. 
Preparation and storage. 
The freeze dried peptide was made up to 1 mM in H20 for assays and stored in 
200 III aliquots at -20°C. Samples for NMR were made up in either 90% H20/1O% O2° 
or 100% TFE-d2 at 31'4 mg/ml and stored at -20°C. 
To reduce and methylate the peptide, Sill of 2M Tris buffer pH 8.0, and 5111 3M 
DTT were added to a 200 III aliquot of the peptide (1 mM) and incubated for a minimum 
of3hrs at 37°C. The Mel stock solution was diluted to 1M (J1l6 dilution) in sterile H20 
and both the sample and Mel were chilled on ice. 5~L1 of Mel (1M) was added and the 
mixture incubated at 4°C for I hour. To remove residual reagents, the samples were 
passed down a PD-1O desalting column using H20 as the eluting buffer. Fractions of 
200-250 III were assayed for the presence of the peptide using the BC A assay and also 
assayed for inhibitory activity. 
Assays. 
Inhibitory activity against collagenase was assayed using the diffuse collagen fibril 
assay (chapter 2). Inhibitory activity against gelatinase was assayed using a similar 
method. 3H-gelatin was prepared by denaturing 3H collagen for a minimum of 30 
minutes at 56°C in the presence of 2 mM DFP. 72 kDa gelatinase was used as the 
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equivalent of the active enzyme in the collagenase assay. Trypsin (10111 at I mg/ml) is 
used as a control for total degradation of the gelatin. The assay tubes contain I 00 ~1I of 
Tris buffer (as for collagenase), 100111 of 3H gelatin, 10111 of gelatinase, up to 40pl of 
sample and sufficient cacodylate buffer (as for collagenase) to make the volume up to 
250111. Samples are incubated for 20 hours at 37°e, then 50111 of 90% TeA is added. 
Samples are incubated on ice for 30 minutes, centrifuged at 37000 rpm for 10 minutes 
then counted. The assay for inhibitory activity against bacterial collagenase was adapted 
from the collagenase assay, using sufficient bacterial collagenase to give 70-80% lysis of 
the 'active enzyme control'. The assay for inhibitory activity against trypsin was a similar 
modification of the gelatinase assay. 
NMR Stud;e~: 
All NMR experiments were carried out on either a Bruker AMX 360 or a Bruker 
AMX 500 spectrometer. The sample was prepared at a concentration of 30 mM in 90% 
H20l1 0% D20, and the pH adjusted to 5·32 with He!. On completion of the H20 
experiments, the sample was Iyophillised and re-dissolved in 100% TFE-d2· All spectra 
for the H20 sample were recorded at a temperature of 300K. One dimensional (I D) 
spectra were recorded for the TFE-d2 sample over a range of temperatures and 2D 
spectra were recorded at either 273K or 283K. 2D spectra were acquired with 512 t I 
increments and 2048 t2 data points. For TOCSY spectra [320] a total mixing time of 60 
ms was used for the sample in H20 and 63 ms for the sample in TFE-d2· A DIPSI-2 spin 
lock [321] was found to give the best quality spectra. ROESY spectra [322] were 
acquired with a mixing time of 200 ms. Most NOESY [323, 324] spectra were acquired 
with a mixing time of 25 ms. Solvent suppression was achieved by a 1·5s saturation 
pulse. 2-D data were zero-filled once in FI and Fourier transformed with the application 
of a 1[/3 shifted sine bell function in both dimensions. 
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7.3. Results. 
7.3.1. Inhibitory Activity. 
No inhibitory activity was seen against porcine fibroblast collagenase, tJypsin or 
bacteria! collagenase (data not shown). 72 kDa gelatinase however, was inhibited, 
although the effect was only seen at relatively high peptide concentrations. A thousand-
fold excess is required to give a 10% reduction in the activity of gelatinase in a bioassay 
(sample activity of 13800 dpm compared to 15270 for the enzyme alone). The reduced, 
methylated fonn of the peptide does not show any activity against any of the enzymes 
assayed. 
7.3.2. NMR studies of the Cyclised form of Cys-3 - Cys-13. 
Since the cyclised form of the peptide showed a weak inhibitory activity against 
72 kDa gelatinase a series of NMR experiments were performed to determine its 
structure. 
Cys-3 - Cys-13 is a stable monomer under the conditions used. No evidence of 
aggregation or deterioration of the sample was observed in either solvent, even after 
extended periods at room temperature. 
Cys-3 - Cys-13 in H20. 
The 1 D spectrum of this sample is shown in figure 7·1. Figures 7'2, 7'3, 7·4 and 
7·5 show the TOCSY and ROESY spectra of Cys-3 - Cys-13 with the assigned cross 
peaks marked. The number of cross-peaks was far greater than would have been 
expected from a peptide of this size. The I D spectrum shows a large number of relatively 
broad, low intensity peaks in the NH region, which correspond with the TOCSY cross-
peaks. This indicates that there may be large number of conformers present. The spin 
systems were assigned primarily from the TOCSY experiment shown in figures 7·2 and 
7·3. Where it was not possible to uniquely assign a particular spin system (i.e. 
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Figure 7·1. ID spectrum of CJ-C13 in H20. The spectrum was recorded on a 360 MHz spectrometer at 300K on a 30mM sample 
The high sample concentration and small molecular weight produce sharp lines and good resolution. The amide region shows a large 
number of peaks, an indication of multiple conformers. 
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Figure 7.3. TOCSY of C3-C13 in H20. Region taken from the diagonal to show the 
proline 8-<i cross peaks and demonstrate the isomerisation occurring (t-trans, c-cis). The 
intensities of all of these cross peaks are very similar indicating increased stability of the 
cis form. 
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differentiating the His, Phe and Cys residues) from the TOCSY, the ROESY spectrum 
was used to find NH-Ha NOEs from adjacent residues and thus give a sequence specific 
assignment [320). 
The large number of cross-peaks provides evidence that the p(~ptide, Cys-3 .. Cys-
13 adopts a large number of contormers which are in slow exchange on the proton NMR 
timescale. In most cases the cross-peaks from each residue are clustered around similar 
chemical shift co-ordinates. A few are shifted away from the main cluster, such as the 
cluster of signals from the alanine ~-protons which has one or two shifted strongly 
downfield. With the exception of Ala-II and Thr-I2, most of the residues show evidence 
for only three or four conformers (every residue has at least two distinguishable 
conformers) which can be subdivided into two sets on the basis of their chemical shift. 
Two conformers are very similar, with shifts not far removed from the random coil 
values, the third shows a strong shift away from random coil (appendix 5 shows random 
coil values for the amino acids). Other conformers coincide with either of these groups. 
This could imply that there are three dominant conformations. 
Figure 7·3 shows the region of a TOCSY spectrum showing cross-peaks 
associated with the proline residues. For the three proline residues in the peptide there 
are a total of six 8-<) cross-peaks. This shows that each of the proline residues is present 
in both cis, and trans form. These conformers do not adhere to the statistical distribution 
of approximately 80% trails - 20% cis [325]; most of the proline 8-8 cross peaks are of 
equivalent intensity. In particular the ratio is reversed for Pro-6, where the cis 
conformation is dominant. An exact quantification of the relative abundance of each 
isomer is not possible since cross peak intensity is a function of many factors including 
relaxation times. However the dominance of the cis form of Pro-6 is clearly seen in the 
data. 
Assignments of these spm systems were made on the basis of NOEs from 
adjacent residues. The conformation of each isomer was deduced from the presence of 
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NOEs that would be unique to that conformation NOEs between proline 8 and the HN 
or Ha of the preceding residue indicate the frans conformation, NOEs between a proline 
a-carbon proton and the a-carbon proton of the preceding residue indicate a cis 
conformation The assignments are shown in table 7·1, 
NOE data was collected to obtain structural information for this peptide, 
However, it was not possible to distinguish between individual conformers, nor could 
sufficient data be obtained for a single conformer to calculate a structure. There are 
inter-residue NOEs between the His-7NH proton in all conformations, and the methyl 
protons of Ala-II and Phe-12. There are also weak or ambiguous NOEs suggesting that 
the His-7NH proton may also be close to the side chain of Thr-l O. In addition there are 
NOEs seen from the Phe-12NH to either the Ha or Hf3 protons of His-7. It is unfeasible 
that all of these conditions would be found in a single conformation. There are no NOEs 
to the side chain of Gln-9 suggesting that in all conformations this residue is exposed. A 
similar 5.ituation is found for the histidine ring protons. The C-terminal cysteine (Cys-13) 
NH shows NOEs to the His-7 alpha proton and Thr-IO methyl protons in both 
confi)rmations. Prog also shows NOEs to Thr-l 0 or Ala-II dependent on conformation. 
Figure 7·6 summarises of the NOE data (NOEs are tabulated in appendix 6). 
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Residue NH CaH Cf3H Others 
C3 4·907 3'217, 3·040 
V4a 8·545 3·901 1·940 0'806, 0·851 
.-
V4b 3'464 3·989 1·936 0'819, 0·865 
V4c 8·693 4·498 2·102 0'920, 1'023 
V4d 8·727 4'461 1'949 0·863 
PSt 4'448 2·200 1'987, 1'810, 3'609, 3·8 \0 
PSc 4·507 2'184 2'094, 3'486, 3·574 
P6t 4·507 2'191,2·093 1'875 ,3'311, 3'438 
P6c 4·427 2'288, 2·052 1'770, 3'670, 3·973 
H7a 7·728 4·298 3·041 
H7b 7·791 4·644 2'932, 3·138 
H7c 7·683 4'660 2·9533'138 
P8t 4·353 2'287 
1'951, 3'553, 
3.739 
P8c 4·419 2'273 
1'933, 1'879, 
3'408, 3·744 
Q9a 8·828 4·212 2.092, 2·200 2.349 
Q9b 8'809 4·200 2'051,2'142 2'327 
Q9c 8·7570 4·275 1'961, 2·030 
2·359 
Q9d 8·689 4'147 2'004, 2·094 2'311 
TlOa 7·731 4·835 4'114 
1·093 
TIOb 7·664 4·400 
4·060 1·088 
TIOc 7·983 4·602 
4·239 1·223 
TtOd 7·569 4'447 
1·134 
A1la 8'314 4'081 
1·085 
Allb 8·254 4'192 
1'168 
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Aile 8·237 4·255 1·200 
Alld 8·225 4·255 1·192 
Alle 8·176 4·085 1·104 
Allf 8·235 3·752 
AIlg 8·203 3·812 
Allh 8'179 3·864 
Fl2a 7·952 4'612 3'192, 2'868 
Fl2b 7'888 4·750 2,907, 3·222 
Fl2e 8·000 4·612 3'096, 
Cl3a 7·375 4·981 3'224, 3'015 
Cl3b 8·428 4·933 3'224, 3·044 
Cl3e 8·770 3'130 
Table 7·1. Assignments for the peptide, C3-(' J) in H20. Complete assignments have 
been made for the majority of spin systems identified. Different conformers of the same 
residue are distinguished by letter. Where a system is not completely assigned it is 
because it is a very minor conformer and TOCSY or ROESY cross peaks were too weak 
to be observed. Chemical shifts were measured to ± 0'001 ppm. This level of accuracy 
was used in an attempt to distinguish some closely overlapped signals. 
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Figure 7'6. Representative diagram showing NOE contact!l found in the family of 
conformers adopted by Cys-3 - Cys-13 in H20. NOEs are represented as a line 
beginning and ending beneath the relevant residues. The protons involved are shown on 
the left of the figure. Cis/trans isomers are designated as t or c. Some NOEs are 
duplicated where they were observed for more than one conformer. 
Cys-3 - (ys-13 in TFE-tl2. 
The 10 spectrum of Cys-3 - Cys-13 in TFE-d2 is shown in figure 7'7. There is 
less dispersion when compared with the spectra in H20. Figures 7·8, 7·9, 7·10 and 7'11 
show selected regions of a TOCSY spectrum and a NOESY spectrum of Cys-3 - Cys-13 
in TFE-d2. These spectra are much less complex than for the sample in H20, with only 
two residues showing evidence of any conformational heterogeneity (figure 7'8). There 
are only three clearly observable proline spin systems (figure 7·9), indicating that the 
TFE-d2 has reduced the extent of the cis-trans isomerisation. One dominant form is 
observed, although two sets of signals from Val and Tht are seen. This has made for a 
more straightforward assignment. 
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Figure 7·7. ID spectrum ofC3-C13 in TFE-d2. The spectrum was recorded on a 500 MHz magnet at 300K Sample is at 30mM. 
This spectrum shows less dispersion and less complexity than when the sample was in H20 (figure 7-1). 
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Figure 7.9. TOCSY of CJ-C13 in TFE-d2. Upfield region showing the proline spin 
systems. 
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Figurr 7·10, NOESY spectrum C3-CU in TFE-d2. A number of NOEs are observed. 
However these spectra were interpreted cautiously since TFE can aid solvent mediated 
magnetisation transfer. The clearest examples of this are provided by the downfield 
shifted histidine which has a string of NOEs over a large range of chemical shifts, and the 
phenylalanine, which is almost entirely obscured by noise. 
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Figure 7'11. NOESY spectrum C3-C13 in TFE-d2. The same spectral region as 7·9, 
showing the proline systems. The spectral quality is not ideal; a lot of noise is present 
making interpretation complex. 
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Residue NH Ca.H CPH Others 
V4a 7'859 4'315 2'072 I . I 73, I ·084 
V4b 7·576 4'181 2'008 0·928 
P5a 4'535 2'304, 1·985 2'132, 4'210, 
3·719 
P6 4·392 2'515,1'627 2'080, 3·476 
H7 8·877 4·458 3'352,3'149 
P8 4·433 2'322, 1·928 2'013, 3'826, 
3'036 
Q9 7·998 4·344 2,171,2,025 2'524, 2·457 
TlOa 7'686 4·570 4'302 1·289 
TIOb 7·584 '~'622 4·295 
All 7·669 4'122 1'285 
F12 7'301 4·775 3'357, 3'115 
C13 7·521 4·434 
Table7·2. Assignments for the peptide C rC l.1 in TFE-d2. Assignments have been made 
for all residues other than C J which was not assignable due to the absence of an N-H -
a.H TOCSY connectivity. Where a chemical shift is not recorded for an individual proton 
it may be due to overlap, or its signal may not have been observable in the spectra. 
Different conformers of the same residue are distinguished by letter (a,b). 
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The same assignment procedure was used as for Cys-3 - Cys-I J in H20 Cross 
peaks are shown labelled in figures 7·8 and 7·9 and the full assignment list is shown in 
table 7·2. 
Analysis of NOESY spectra was approached with caution. Given the high 
conc~ntration of TFE-d2, it is possible for magnetisation transfer to occur via the 
solvent, giving spurious NOEs. Consequently relatively few NOEs were recorded. The 
NOE data are summarised in a representative diagram (figure 7'12)and tabulated in 
appendix 7. 
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Figure 7'12. Representative diagram showing NOE contact for Cys-3 - Cys-13 in 
TFE-d2. 
The pattern of NOEs seen here is very different to that seen for the sample in 
H20. There are no contacts seen between His-7 and Thr-IO, Ala-l or Phe-12. Instead, 
NOEs between His-7HN and Val-4 methyls indicate a sharp tum around the two prolines 
(Pro-S and Pro-6). Also seen is a contact between the NH proton of Val-4 and the D 
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protons of Pro-8 which might be expected were there to be a tight turn as described. The 
absence of Pro-5a-Pro-6& NOEs may indicate that Pro-6 is again in a cis conformation. 
Weak NOEs between the NH proton of Thr-lO and B-protons of Pro-8 suggest that the 
chain turns back on itself around Gln-9. There are also contacts between the Cys-13 NH 
proton and the a, and methyVmethylene protons of Ala-II and Phe-12. 
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7.4. Discussion. 
The peptide, Cys-3 - Cys-13 was found to be a weak inhibitor of 92 kDa 
gelatinase, but not of any other enzyme tested. This activity was not seen in the reduced, 
methylated form of the peptide, suggesting that the inhibitory activity may be associated 
with the cyclised conformation. An attempt was made to determine the solution structure 
of this peptide and subsequently to explain its mechanism if possible. 
However, it has proved very difficult to determine the structure of Cys-3 - Cys-
13 in H20. Were the peptide to be linear, only a single apparent conformer, with 
chemical shifts close to random coil, might be expected as a result of conformational 
averaging. Alternatively a (small) number of slowly interconverting structures migh~ be 
seen due to local effects from proline isomerisation. Since no study was made of the 
reduced form of the peptide, this assumption cannot be confirmed. The presence of the 
disulphide bond would be expected to reduce the number of accessible conformations by 
reducing the overall flexibility. However the peptide remains sufficiently flexible for 
proline isomerisation to occur resulting in a large number of observable conformers in 
slow exchange. Because of the presence of multiple conformers a detailed structural 
analysis was not attempted. Consequently it is not possible to infer the presence of any 
elements of stable secondary structure. 
It was found that all three of the proline residues were exhibiting cis-lrans 
isomerisation. The rarer cis form (cis:tram ratio is normally 20:80) had an increased 
stability as shown by the similar intensities of all the cross-peaks in a TOCSY 
experiment. The permutations of all three proline residues being in either the cis or Iralls 
form is at least in part responsible for the large number of different peptide 
conformations. Since the peptide is cyclised via a disulphide bond, either the local, or the 
overall structure will have to alter to accommodate the isomerisation, giving rise to the 
different conformations. It is noteworthy that His-7, which is flanked by proline residues, 
only shows evidence of three different environments. This may be an indication that the 
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proline isomerisation only results in a small amount of conformational variation and the 
remainder is due to larger structural flexibility. 
Ideally the structure of each conformer would be determined. However in 
ROESY spectra only intra-residue NOEs could be found for many of the residue 
conformers. Unfortunately, the few sequential inter-residue NOEs identified only 
extended over two residues. Also very few NOEs were found for either Cys-3 or Val-4, 
making analysis of the N-terminus of the peptide very difficult. 
The overall picture of Cys-3 - Cys-13 in H20 is of families of structures that 
although constrained by the presence of a disulphide bond, are able to adopt a large 
number of rapidly interconverting conformations in solution. These conformations are 
such that the cis form of the proline residues is stabilised, in particular at Pro-6. Another 
peptide study involving a Pro-Pro unit in a short, disulphide bonded peptide also shows 
the second Pro is in a cis conformation [326]. 
Some of the of the hydrophobic residues (Ala-II and Phe-12, possibly Thr-IO) in 
Cys-3 - Cys-I3 appear to cluster around the histidine NH or Cex protons, although there 
is no single, clearly defined arrangement. The side chains of both His-7 and Gln-9 are 
solvent exposed. The small number of NOEs from the N-terminus of the peptide could 
suggest that in the majority of conformers, this region has very few contacts with the 
remainder of the molecule. The presence of backbone-sidechain NOEs between Val-4 
and Pro-5IPro-6, and the dearth of NOEs to other residues, implies that these residues 
may be forming a small cluster, remote from the rest of the structure. The schematic 
diagram (figure 7-13) attempts to summarise the general features observed in the NOE 
data. 
On transfer to TFE-d2, Cys-3 - Cys-13 is found to adopt an entirely different 
conformation to that seen in H20. The overall impression is of an elongated molecule 
with a sharp tum at one end (Pro-Pro turn) and a more open turn at the other. Residues 
that were distant from each other in H20, are close together when in TFE-d2. 
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Figure 7'13. Representative figure indicating the possible general arrangement of C 1-(' 11 
in H20. This diagram is intended only to create an impression of the spatial arrangement 
of the residues and for comparison with its equivalent for C 3 -C 13 in TFE-d2. Some key 
longer range NOEs arl~ marked as dotted lines. 
p-p 
/ / 
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<; A / \ / \ P, 
F T-Q 
Figure 7·14. Simplified Schematic diagram showing the general arrangement of C 3-C 11 
in TFE-d2. The presence of TFE-d2 has allowed greater exposure of the hydrophobic 
residues than in H20, and the overall structure is more open. Some key longer range 
NOEs are marked as dotted lines. 
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Although there is no direct observation of proline isomerisation (only three prolinc ()-() 
cross peaks are seen), there is other evidence of isomerisation. Minor conformers are 
observed for Val-4 and Thr-IO suggesting that some isomerisation is occurring for at 
least one Pro residue. An inten:sting feature is that the peptide bond of Pro-6 remains in 
the cis conformation It is possible that in certain protein~, and peptides, the cis form of 
the Pro-Pro amide bond is favoured over the trails form. The schematic diagram shown 
in figure 7·14 summarises the main points drawn from the NOE data. Although using 
TFE-d2 as a solvent for the peptide has allowed for a simple assignment it is unlikely that 
this structure has any biological relevance since the same solvent cannot be used for 
assays. 
Examples have been published where a peptide based on the parent protein 
exhibits inhibitory activity. This was found for soybean Bowman-Birk inhibitor and for 
chymotrypsin inhibitor-2 (CI2) [327]. In this case the inhibitory residues are sequentially 
close, and exposed on a long flexible loop that was produced as a disulphide bonded 
peptide. Other inhibitors have a more complex mechanism, using sequentially distant 
residues, and large regions of the molecule. 
Recent data from structural, and antibody/peptide competition studies of TIMP-I 
and TIMP-2 indicate that large regions of the protein are involved in the inhibition of the 
MMPs. The N-terminus of TIMP-2 has been shown to be an extended loop, finishing in a 
single turn helix (TIMP-I is likely to be very similar). Although no detailed structures 
were obtained for the peptide, Cys-3 - Cys- 13, the structures suggested by the NMR 
analysis are entirely unlike those seen in the intact protein. This is not surprising since the 
disulphide bond in the peptide draws residues which are normally distant, close together. 
Were this peptide not to have been disulphide bonded it would not necessarily have 
adopted a similar conformation to the same sequence in the context of its parent protein. 
Higher order interactions are often essential to function. This may well explain the 
complete absence of activity seen for the reduced form of Cys-3 - Cys-13. 
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The very weak inhibition seen in the cyclised form is almost certainly due to a 
property unique to the peptide. It may be due either to a weak property of many 
conformers, or a stronger effect restricted to a minor conformer. This inhibition may be 
due to the histidine being able to co-ordinate with the active site zinc atom, or a weak 
interaction with the active site cleft that reduces substrate access. 
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Chapter 8. 
The Suitability of TIMP-I for Further NMR Stud~es. 
8.1. Introduction. 
The overall a\m of this research project is to obtain as much structural 
infonnation about TIMP-l as possible. Previous work in the Rheumatology Research 
Unit had found that although wild type TIMP-l did form crystals on one occasion, they 
were very small and the crystallisation could not be reproduced. A recent publication has 
shown that TIMP-l which has had the giycosylation sites removed by site directed 
mutagenesis does fonn crystals of a quality suitable for X-ray crystallography [278]. 
Although NMR studies have been made of many proteins, full structural determination 
has been limited to relatively small proteins (up to ~30 kDa [328]). As the size of the 
protein increases, the spectra become increasingly complex, making them harder to 
assign. In addition, larger molecules tumble more slowly in solution which increases 
transverse, or spin-spin relaxation rates arid hence the line widths, decreasing the 
resolution of the spectra [329]. One of the most effective ways of increasing the 
resolution of complex spectra is to incorporate stable isotopes (commonly 13C and 15N, 
although deuterium and fluorine may also be used) into the protein during expression. 
These isotopes can be detected by NMR and allow the use of more complex, n,ulti-
dimensional experiments which distribute the data and provide information on the spatial 
arrangement of all atoms within the proteiri. At 184 residues, TIMP-I is close to the 
maximum desirable size for NMR studies. The combination of higher field strength 
spectrometers and more versatile software should allow the structure of isotopically 
labelled TIMP-l to be detennined. 
This chapter presents preliminary data from experiments carried out using the 
wild type protein. This work was done to assess the suitability of TlMP-l for further 
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NMR studies and complements the NMR data that has been described in prevIous 
chapters. Before embarking on a potentially costly project to produce tens of milligrams 
of isotopically labelled protein it is important to assess how the protein will behave under 
the conditions used for NMR studies. Although TIMP-l is known to be exceptionally 
stable, NMR experiments are typically performed at room temperature or above, ur-Ing 
protein concentrations of greater thm 1 mM in a low pH solution. These conditions are 
necessary to obtain spectra of sufficient quality for structural analysis. Thus it is 
important to have data on solubility, sensitivities to temperature and pH and how the 
protein withstands extended periods under these conditions. 
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8.2. Methods. 
8.2.1. Materials. 
Wild type TIMP-I was purified as described ill chapter 3. NaOD, DCI and D~O 
were from the Sigma Chemical Co. (Poole, Dorset, UK) 
8.2.2. El.perimental Procedures. 
All NMR spectra were recorded on either a Bruker AMX 360 or a Bruker AMX 
500 spectrometer. Lyophilised wild type TIMP-I was dissolved in H20 at a 
concentration of 40·2 mglml (1'4 mM). The sample was Iyophilised again, and 
resuspended in D20 for some experiments. Samples have been kept for over a year 
stored at 4°C in the absence of bacteriostatic agents. Before any experiment, a I 0 
spectrum is acquired to determine the condition of the sample. For ID spectra at 500 
MT-Iz, 1024 FIDs were acquired into 16 K data blocks with a 60 degree excitation pulse 
of 6 ~s, a spectral width of 7042 Hz, an acquisition time of 1·16 s and a relaxation delay 
of 1·5 s. The temperature is the same as subsequent experiments. 
For the pH titration, NaOD was added in small quantities (up to I 0 ~ll), and the 
sample mixed by inversion of the tube. The pH was recorded inside the 5mm NMR tube 
using a 3·7mm outer diameter Russel (Auchtermuchty, Scotland) glass electrode and 1 D 
spectra acquired at 305K. 
For NOESY spectra TIMP-I was dissolved to 30 mglml in 90% H20110% D20 
at pH 3'8. Sample temperature was 305K. A total mixi.ng time of 100 ms was used. 2D 
data were zero-filled once in FI and Fourier transformed with the application of a rel3 
shifted sine bell function in both dimensions. The solvent peak was suppressed using a 
low power pre-irradiation pulse of 1·5s. 
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8.3. Results. 
8.3.1. Solubility, Stability and I D Spectra. 
Wild type TIMP-I is readily soluble, with protein solutions of over 40 mg/ml 
showing no visible sign of degradation over long periods of time. Fi!,TUre 8'1 shows aID 
spectrum of TIMP-I in H2O. As would be expected, the spectrum in H20 ~hows a large 
number of peaks in the amide N-H region (downfield of approximately 7 ppm), some of 
which may be due to signals from N-acetylated sugars. There is no evidence of 
significant aggregation in solution over several months at 4°C, with the linewidths 
remaining unchanged. In addition there are no changes seen over the course of 48 hour 
experiments at higher temperatures. There are five well resolved peaks between 0'6 and 
0·0 ppm that are only usually observed as a consequence of methyl or methylene groups 
being located above the plane of aromatic rings. This feature is usually indicative of a 
folded protein structure. 
A dominant feature of the spectrum is a number of sharp peaks due to mobile 
sugar residues, the majority being found in the region between 3·5 and 4·5 ppm. These 
are due to the ring protons, with the exception of the anomeric protons which are shifted 
to the region between 4·5 and 5·5 ppm. At higher field (about 2 ppm), resonances from 
the methyl groups of N-acetylated sugar residues such as N-acetylglucosamine and sialic 
acid are evident. 
On transfer to D20, most exchangeable proton signals disappeared very rapidly, 
within one hour, although some amide signals remained for longer periods (see figure 6' 5 
for I D spectrum in O2°). This is an indication that these protons are buried within the 
protein, protected from exchange with the solvent. The H2 protons from the six histidine 
residues coincide to give a sharp, well-resolved signal at 8'53 ppm. 
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Figure 8·t. ID Spectrum or\Vild Type TIMP-l in H20. Sample conditions are 1·4 mM, pH 4·3, 30SK. The signals from the 
protein portion are dwarfed by the sharp, intense signals from the sugars. Highfield signals (between 0 and 1 ppm) indicate that 
the protein is folded in solution. 
8.3.2. pH Stability. 
A pH titration experiment was carried out to assess the stability of TlMP-1 under 
differing conditions. This experiment was also intended to identify c. pH at which the 
histidine signals could be resolved from each other. Figure 8·2 shows a series of I D 
spectra recorded at different pH values. The peak of the histidine H2 protons moves 
upfield from 8·53 to 8·0 without resolving any individual peaks. As the pH is raised from 
5·78 to 6·15, extensive line broadening is seen as the protein precipi£ates. This process is 
reversible on returning the sample to a more acid pH. 
8.3.3. 20 Spectra. 
Some 2D COSY data has already been presented in chapter 5 and is not included 
here. Figure 8·3 shows selected regions of a NOESY spectrum of TlMP-1 in H20 
Although the sample concentration used was low in comparison with that typically used 
for studies of other proteins, a large number of NOEs are seen. 
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Figure 8·2. The aromatic region of the TIMP-l, ID spectrum recorded at differing 
pH. The histidine H2 proton signals are moving upfield with increasing pH. As the 
sample approaches pH 6 the spectra give evidence of protein aggregation (broad lines 
and decreased resolution). pH 6·52 t was recorded after 16 hours at this pH. The 
uppermost spectrum is of the sample on return to pH 4'3 showing complete recovery. 
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Figure 8.3. NOESY spectrum of wild type TIMP-l at 0·8 mM. This spectrum 
contains too much data to attempt any analysis. This region does show that the data is 
well dispersed, and the spectrum is of good quality. This is a good indication for future 
studies. 
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8.4. Discussion. 
Preliminary spectra of wild type TIMP-I show that it is very suitable for further 
NMR studies. It is soluble to a desirable concentration (greater than 1 mM), and may be 
soluble to higher concentrations, although this was not determined Samples of TIMP-I 
have remained stable in solution for many months at 4°('. The solubility of TIMP-I may 
be affected by the glycosylation. It ig possible that the solubility and long term stability 
may differ in a recombinant protein. One possibility is that the sagars are masking a 
hydrophobic or charged part of the surface that may enhance aggregation when exposed. 
Reports of the formation of crystals of non glycosylated mutants of TIMP-I suggest that 
this may not be a problem. In H20 the pH of the prepared sample is low (4'3) which 
slows the exchange rate of the amide protons with water, improving the quality of the 
spectra. It is not yet known whether recombinant, non-glycosylated TIMP-] can 
withstand low pH at high protein concentrations. 
It is not unsurprising that the pH titration did not resolve the histidine H2 protons 
since they do not normally separate until a more basic pH (up to pH 9). The aggregation 
between pH 5·78 and pH 6·15 may be due to the protein reaching its pI. Recorded pIs 
for bovine and rabbit TIMP-l are between 5·5 and 6'5, whilst pIs determined for human 
TIMP-I include 6'7, 5·9 and 5'6. Computer prediction of the pI gives a result close to 7, 
but is not necessarily reliable. It is possible that in this case, the aggregation was 
mediated by the charged sugar residues and the situation may differ in a recombinant 
sample. Fortunately this process appears to be reversible, unlike the aggregation that 
occurs at high temperatures. 
The spectra obtained of TIMP-I are of good quality, with good dispersion in two 
dimensions. Triple resonance techniques and high field magnets allow assignment of 
proteins with a molecular weight of up to 30 kDa, with structural determination of 
proteins with molecular weights approaching 20 kDa. A full assignment and subsequent 
structure determination of a 184 residue (20'5 kDa) protein should be feasible if the 
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quality of spectra and dispersion in heteronuclear dimensions is good 1320, 3291 
Techniques such as automated spectral assignment, improved structure calculation 
protocols and low level isotopic labelling (i.e. 10% 13(' for stereo-assignment of Val/Leu 
methyls) will also aid the analysis. 
Since the partial structure of TIMP-2 was published a useful model has been 
obtained to aid in the assignment of TIMP-l. Homology modelling, and comparison with 
published data will assist in the identification of NOEs and may lead to a high quality 
three dimensional structure. 
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Chapter 9. 
Concluding Discussion. 
The extracellular, connective tissue matrix forms the scaffolding for all other 
tissues and it is essential that it is maintained correctly. Connective tissue turnover is an 
ongoing process which begins during fot!tal development and continues throughout life. 
The primary agents of connective tissue breakdown are the MMPs, which are tightly 
regulated at many levels. Too little activity leads to a build up of tissue as in fibrotic 
conditions. Too much or inappropriate activity is associated with a host of common 
diseases such as arthritis, cancer and osteoporosis. 
The TIMP family is an extremely important group of MMP inhibitors. They have 
been found in many species and a strong conservation of key residues has been seen. 
Particularly notable are the 12 cysteines, forming the disulphide bonds that contribute to 
the high stability of these proteins. TIMPs have been identified as products of a great 
number of cell lines and appear in many tissues. TIMP-I in particular seems quite 
ubiquitous, whereas to date TIMP-3 has only been found in stromal tissue. 
The TIMPs may provide an important key for regaining control of the MMPs in 
disease states. By understanding how the inhibition process works it may be possible to 
design compounds to mimic this activity. The aim of this project is to obtain structural 
data on TIMP-I, which will contribute to our understanding of the TIMP-MMP 
interactions 
The work presented here forms part of a continuing project of structural and 
functional studies of human TIMP-I. Obviously this type of work requires a reliable 
supply of protein. The source used for the majority of the work so far has been wild type, 
human TIMP-l purified from bulk cultures of foetal lung fibroblasts (WI-38 cells) 
Producing and processing this volume of media is costly and time consuming. The 
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conventional purification scheme has been used successfully for many years, giving very 
acceptable yields. However, it does require a large amount of processing, utilising several 
column chromatography steps, with the accompanying need for concentration and 
dialysis between stages. This makes the purification of bulk quantities of protein a velY 
slow process. Given thn recombinant TIMP-I produced in E.cvli will have a different 
molecular weight, no glycosylation, and possibly a differem surface charge, it is unlikely 
that the accepted protocol would be as suitable as for wild type protein. 
Affinity purification of proteins using monoclonal antibodies attached to a 
support matrix is a very effective method of purification, which has already been used 
successfully for TIMP-J by other workers. A number of monoclonal antibodies have 
been produced in the Rheumatology Research Unit which had previously been assayed 
for their ability to bind TIMP-I when bound to a Sepharose matrix. One of these, P3G6, 
was selected for further tests, having been the most effective in preliminary columns. 
P3G6 was bound to different types of Sepharose matrix and tested for its ability to bind 
TIMP-l. The most effective of these was found to be CNBr-activated Sepharose-P3G6. 
The original elution protocol using low pH buffer was only effective for small column 
volumes. 3M NaI was found to be a suitable alternative for larger column volumes (up to 
760 mI). This affinity column was used to rapidly purifY most of the TlMP-l used for the 
experiments described. 
The monoclonal affinity column is now used for all purifications of wild type 
TIMP-I in the Rheumatology Research Unit. It is hoped that it will also be suitable for 
the large scale purification of recombinant TIMP-l. This matrix can also be used to 
remove TIMP-I from samples where it is not required (i.e. to remove traces that may 
contaminate an MMP preparation). 
Since it is intended to carry out NMR studies of TIMP-l, production in human 
cell culture is completely unsuitable. To a spectroscopist, glycosylated material is an 
undesirable product of expression in human cells. In addition, isotopic labelling is not 
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feasible in this system, since to ensure homogenous labelling all nitrogen or carbon 
sources must be labelled. This is only realistic in organisms that can flourish on a simple 
single source of nutrient. Thus it was necessary to develop a bacterial expression system 
to meet the demands of this project. 
The disulpbide bonds in TIMP-l make expres:,ion in Ecoli H non trivial task. The 
reducing environment of the cytoplasm causes the protein to be produced as unfolded, 
insoluble aggregates in the cytoplasm. To retrieve the protein it must be solubilised and 
denatured, then refolded. Whilst this is a successful approach for many proteins, the need 
to reform all six disulphide bonds correctly makes this procedure exceptionally difficult in 
this case. Early reports in the literature indicated that this approach was not very 
successful, with very low yields of under lmg/L. To avoid the pitfalls of refolding TIMP-
1 from cytoplasmic inclusion bodies, two alternative Ecoli expression systems were 
assessed. 
Expression vectors were tested that directed the.: protein to either the medium or 
the periplasm. Both of these environments allow the formation of disulphide bonds. The 
extracellular matrix is not a reducing environment, whilst the periplasmic space contains 
a disulphide isomerase which aids the correct formation of disulphides by shuffling 
disulphide pairs until a stable (hopefully correctly folded) conformation is obtained. 
The first vector used, directed the protein out into the medium. This was pEZZ 18 
which included a pair of IgG binding domains at the N-terminus of the protein. An 
engineered factor Xa site should have allowed the TIMP-l to be cleaved from the fusion 
protein. However this proved- not to be possible, even under mildly denaturing 
conditions. Analysis of the sequence, taking into account the positions of the disulphide 
bonds, suggested that the N-terminus might not be very accessible. The regions around 
Cys-l and Cys-99 contain a large number of hydrophobic residues and prediction of the 
surface accessibility indicated that this site may be partially buried in the protein. In the 
partial TIMP-2 structure [141] the N-terminus does not appear to be significantly buried. 
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However, the exact positions of some of the loops (ie. Cys-72 - Cys-IO I) remain 
undetermined, and these may prevent access to the N-terminus. 
Although active TIMP-I with the correct N-terminal sequence was produced 
using the second vector system a problem was encountered. pASK-60 use') an ompA 
signal seque,1ce to direct the protein to the periplasm, where disulphide bond formation 
can occur. Unfortunately the yields were very low, in spite of attempts to reduce 
premature expression and using a rich medium. In order to achieve a reasonable level of 
expression (20 mgIL or greater) the yield would have to increase by at least SOO-fold. 
The few peri plasmic expression vectors produced so far do not have a very strong 
promoter (such as T7). This suggests that although high yields are reported by the 
manufacturers for some proteins, it is not necessarily true for all proteins. 
It appears that the most effective way to obtain sufficient recombinant protein 
may be to design an improved protocol for refolding TIMP-l from cytoplasmic 
aggregates To do this will require a careful assay of protocol for removing the 
denaturant, different redox buffer systems and folding catalysts (such as chaperones and 
protein disulphide isomerase). Further studies are being made of Ecoli expression 
systems and refolding protocols. 
Although the absence of a bacterial expression system meant that it was not 
possible to carry out a full NMR study of TIMP-I, a number of biophysical studies were 
made of the wild type protein. 
The first of these studies was an analysis of the secondary structure content of 
TIMP-I using CD and FTIR spectroscopy. Both methods showed that TIMP-I is 
comprised mostly of anti-parallel p-sheet with 20-25% of the structure as a-helix. 
Evidence from NMR spectra of the wild type protein also indicated that there were a 
substantial number of backbone alpha protons in regions of p-conformation. This was the 
first study to provide any data on the structural content of a TIMP. 
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In the initial absence of any other structural data for comparison, the 
experimental results obtained for the secondary structure content of TIMP-I were 
compared with the theoretical contents obtained using a number of structure prediction 
programs. This exercise demonstrated that, although structure prediction programs are 
becoming increasingly sophisticated, it is still possible to obtain results that bear little 
resemblance to experimental data. The relatively high homology of the TIMPs, and the 
constraints imposed on the structure by the presence of the disulphide bonds, suggest 
that the overall fold of all members of the family is likely to be similar. This appears to be 
borne out by the recent publication of the solution structure of the N-terminal domain of 
TIMP-2 which also shows a molecule with a high proportion of J3-sheet. However, since 
only the N-terminus has been studied and no tertiary structural data exists for TIMP-I 
the two proteins may yet prove to have substantial differences. 
One of the notable features of TIMP-I is its hjgh thermal stability, which has 
been so well documented tha.t it is often used as one of the criteria for identifying a 
TIMP. Much of this stability has been attributed to the six disulphide bonds which 
presumably prevent the complete unfolding, and subsequent aggregation at higher 
temperatures. The effect of temperature on the secondary structure of TIMP-I was 
studied by both CD and FTIR. This showed that the secondary structure was also heat 
stable, with no dramatic changes seen in the spectrum until the protein aggregated. This 
high structural stability might indicate that much of the structure of TIMP-I is in a 
compact form, with an extensive hydrogen bonding network that requires relatively high 
temperature to disrupt. For the high concentrations of protein used in this study, thermal 
denaturation is accompanied by rapid, irreversible aggregation. When biological assays 
have been performed after heating TIMP-I in more dilute solutions, some activity has 
been restored on cooling It is possible that TIMP-I can undergo complete denaturation 
at high temperatures and only intermolecular interactions prevent the full restoration of 
inhibitory activity. 
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A number of different surface features of TIMP-I have been described herc. 
Although TIMP-l is a glycoprotein, very little is known about the attached carbohydratc 
chains (at Asn-30 and Asn-78). They do not appear to have any function in the inhibitory 
activity of TIMP-l, but may have some other role in vim. This function is unknown but 
may be involved with the stability of the protein. 
Concanavalin A is sensitive not only to the composition, but the structure of a 
carbohydrate, making it fairly selective. During purification CAB and NC AB forms were 
identified. These were analysed by iso-electric focusing to identify any differences in the 
charge composition, and by HPLC to quantify the relative concentrations of 
monosaccharides present in each form. It was already known that human TIMP-I had a 
range of pIs [13 4 ]. This study showed that for CAB and NCAB TIMP-I, different 
subgroups of charged molecules appeared to be distinguished by the Concanavalin A 
lectin. Monosaccharide analysis has also shown that the composition of the two pools is 
different. The two are very similar, with only a small quantity of mannose, and the 
majority made up from glucosamine. The primary difference is that the CAB forms have 
relatively more galactose than the NC AB forms. This compositional difference may be 
responsible for the differential Concanavalin A binding. It would be desirable to obtain 
the structure of the polysaccharide to explain the differential binding in terms of the 
accessibility of carbohydrate ligands. 
This' study has identified an additional carbohydrate feature. By probing a 
Western blot with biotinylated Concanavalin A it is possible to detect those glycoproteins 
which bind the Concanavalin A lectin. Unsurprisingiy wild type TIMP-I was revealed on 
development of the blot. More unexpected was the observation of a 21 kDa band 
associated with TIMP-I that had been treated with an endoglycosidase. The nature of 
this small additional glycosylation was not explored further and its function is unknown. 
It may be possible to identify it by acid hydrolysis'ofPNGase treated TIMP-I and HPLC 
analysis of the products 
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To accompany the biochemical analysis of the T1MP-1 carbohydrate, some of the 
carbohydrate features in a COSY NMR spectrum were analysed. By comparison with 
tables of published chemical shift data tentative assignments were made of some sugar 
anomeric protons, which have chemical shifts separating them from the rest of the sugar 
resonances. The inferred composition is close to the biochemical ob5ervations, with little 
evidence of mannose present. Since the use of chemical shift data alone is not a reliable 
method of confirming the identity of peaks in a spectrum, this data serves only to support 
the HPLC analysis. 
NMR was also used to identify surface residues of TIMP-I. The titration using 
Mn('J2 shows a large number of peaks broadening with increasing Mn concentration. The 
Mn ion binds to negative charges on the proteins surface. In this sample it may also 
interact with the sugar groups. Information from this titration can aid the assignment of 
the TIMP-I spectrum by identifying peaks from acidic residues. 
A number of side chain methyls and the side chains of two aromatic residues 
(probably a tyrosine, and either a phenylalanine or tryptophan) showed line broadening 
caused by binding of the spin probe OH-TEMPO. This is a particularly interesting 
observation indicating that the surface of TIMP-l has one or more exposed hydrophobic 
regions. The majority of hydrophobic residues are normally found at the protein core. 
Exposed regions may be involved in protein-protein interactions. 
The evidence for an exposed hydrophobic region was strengthened by a study 
using the fluorescent probe ANS. A titration of TIMP-I against ANS was used to 
determine the number of ANS binding sites and the average Ka. A single binding site 
with a low Ka (3·3xlO~ M-l) was identified. Further studies using the N- and C-terminal 
domains of TIMP-I may help to locate this site. Although the N-terminal fragment of 
collagenase did not bind ANS, when TIMP-I was added the fluorescence increased. In a 
titration experiment identical to that performed for TIMP-I alone very similar results 
were obtained. Because the fraction of enzyme-inhibitor complex is not known it is not 
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possible to determine whether this represents a small change occurring across the entire 
population, or a more extensive change restricted to a few molecules 
A role for a hydrophobic, or aromatic, residue in the interaction between TIMP-I 
and the MMPs has been suggested by kinetic data of TIMP-I mutants [330} This 
suggested that Trp- I 05 may be part of a large interface between TIMP-I and matrilysin 
This residue (Trp-l 07) is seen at the edge of a large concave region in the N-terminw. of 
TIMP-2 [14 I ] along with a tyrosine (Tyr - I 22) and a phenylanine (phe-I 03) The data 
presented in this study provides additional evidence for the exposure of hydrophobic 
and/or aromatic residues in TIMP-I. 
The inhibition of the MMPs by the TIMPs is of enormous interest to those 
wishing to design novel therapeutics for the treatment of those diseases where MMP 
activity is unchecked. Identifying the residues involved in the interaction and their 
conformation will provide an important a,d to drug development A useful key to 
functionally important residues is the extent of conservation both within members of the 
TIMP family and between TIMPs in different species. The homology between all TIMPs 
identified at the time of compilation is shown in Appendix 3. The regions of high 
homology are likely to be important for function or for the maintenance of the overall 
structure of the protein. Substitution, or deletion mutants of TIMP-I may identifY 
structuraIlly or functionally important residues. A reduction in the amount of protein 
produced can indicate that the mutation has affected the structure of the protein If the 
inhibitory activity of TIMP- I is reduced, the mutant or absent residues may be involved 
in the inhibition of the MMPs. 
In this way, the N-termini of the TIMPs have been indicated as potentially 
important for inhibition. Subsequently a peptide base on the sequence of TIMP-I was 
produced. Some weak inhibitory activity was observed towards gelatinase at high 
concentrations of peptide. NMR studies of this peptide showed that it had a structure 
entirely unlike that found for TlMP-2. The inhibitory activity seen may be due to a weak 
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interaction with the active site of the enzyme, possibly involving the histidine in the 
peptide. 
NMR studies of this peptide in H20 found that it adopted a large number of 
slowly interconverting conformations as a result of the isomerisation of the three prolines 
present. The most interesting feature of this was that the cis form of all ~hree prolines 
had been stabilised sufficiently for the isomerisation to be observed in the NMR 
timescale. Also interesting was the extensive effect of the isomerisation on residues some 
distance away in the sequence. In TFE-d2, the structure seen was entirely different to 
that observed in H20. TFE is often used as a structure inducing solvent. Sometimes the 
structure produced is very similar to that of the peptide in the context of its parent 
protein. It is also possible for TFE to induce structure that it entirely unlike the parent. 
Interestingly, the stabilisation of the cis form of Pro-6 was retaint:d when the 
peptide was studied in TFE-d2. This feature has been observed in other peptides and may 
prove to be a common feature of proline-proline units under certain conditions. It may be 
present in whole TIMP-I and have a function in the structure of this region of the 
protein. Since TIMP-2 does not have this unit no predictions can be made by comparison 
with the known structure. 
Further experiments may be able to provide data of sufficient quality to identify 
individual conformers and determine their structures. From this it may be possible to 
explain the increased stability of the cis form of the prolines in Cys-3 - Cys-13. 
The complete structure of TIMP-l remains to be solved. Some of the work 
presented here is a preliminary study of wild type TIMP-l to determine how it behaves 
under the conditions required for NMR spectroscopy. The evidence so far indicates that 
wild type human TIMP-l is very stable at high concentrations and low pH for many 
months. Although it is possible that the non-glycosylated, recombinant protein may be 
destabilised it is unlikely since mutants of human TIMP-l, without the essential 
216 
asparagine residues have been shown to crystallise successfully. Once the structure is 
known a great deal may be revealed about the mechanism of MMP inhibition. 
In the bture our knowledge will be greatly enhanced by a complete structure for 
each enzyme aad inhibitor. The difficulty of producing sufficient quantities of enzyme or 
inhibitor has hampered the study of structure-function in the MMPs and TIMPs. As 
solutions to the difficulties presented by instability and complex folding are found more 
structural data for individual proteins will become available. More infonnation will come 
from studies of enzyme-inhibitor complexes and dynamics measurements. It might also 
be possible to use synthetic substrates that are held at the active site but are either 
uncleaved, or partially cleaved allowing a dissection of the cleavage reaction. 
The matrix metalloproteinases and their specific inhibitors are an extremely 
important and expanding area of study. The many roles they have to play in both normal 
and disease processes make them of interest to researchers in many fields from cancer 
and arthritis to dentistry and reproductive biology. Many of these proteins are relatively 
recent discoveries and there is still much to be learnt about their regulation, structure and 
function. 
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Appendix I. 
CLllSTAL V multiple sequence alignment of nine human MMPs and one mouse MMP. 
MMP-l 
Ml1P- 3 
MMP-8 
MMP-9 
MMP-2 
MMP-3 
MMP-10 
MMP-ll 
MMP-7 
MMP-14 
MMP-12(murine) 
MH--------------sFP-------pL-LLLI,~WGVVSHSFPATLET---Q----EQDV 
KM--------------HPG-------VLAAFLFLSWTHCRALPLPSGG---D----EDDL 
MF--------------SLK-------TLPFLLLLHVQISKAFP--VSS---K----EKNT 
M-----------------SLWQPL---VLVLLVLGCCFAAPRQRQSTLVLFP----GDLR 
ME--------------ALMARGALTGPLRALCLLGCLLSHAAAAPSPIIKFP----GDVA 
M-----------------K-------SLPILLLLCVAVCSAyPLDGAA---R----GEDT 
M-----------------M-------HLAFLVLLCLPVCSAyPJ.SGAA---K----EEDS 
M--------APAAWLRSAAARALLPPMLLLLLQPPPLLARALP-----------------
M-------------------------RLTVLCAV-CLLPGSLALPLPQ---E----AGGM 
SSVPTEDKGAPREWRCDPRAWARPRSHTARLTRWSRTMSPA-PRPSRCLLLPLLTLGTAL 
KF--------------TMK-------FL-LILLLQATASGALPLNSST----------SL 
N 
'J> 
W 
MMP-l 
MMP-3 
MMP-8 
Ml1P-c) 
Ml1P-2 
Ml1P- -) 
Ml1P-l () 
Ml1P-ll 
Ml1P-7 
------DLV----QKyLEKyyNLKNDGRQVEKRRNSGPVV-EKLKQMQEFFGLKVTGKPD 
SE-EDLQFA----ERyLRSyyH-PTNLAGILKENAASSMT-ERLREMQSFFGLEVTGKLD 
------KTV----QDyLEKFyQLPSNQyQSTRKNGTNVIV-EKLKEMQRFFGLNVTGKPN 
TNLTDRQLA----EEyLyRy-----GYTkVAEMRGESKSLGPALLLLQKQLSLPETGELD 
PK-TDKETA----VQYLNTFyGCPKESCNLF-------VLKDTLKKMQKFFGLPQTGDLD 
:3----MNLV----QKyLENyyDLKKDVKQFVRRKDSGPVV-KKIREMQKFLGLEVTGKLD 
N----KDLA----QQyLEKyyNLEKDVKQF-RRKDSNLIV-KKIQGMQKFLGLEVTGKLD 
PDVHHLHAERRGPQPW----------HAALPSSPAPAPATQEAPRPASS-----------
SE-LQWEQA----QDyLKRFYLyDSETKNAN-------SLEAKLKEMQKFFGLPITGMLN 
MMP-14 ASLGSAQSSSFSPEAWLQQYGYLPPGDLRTHTQkSPQS-LSAAlAAMQKFYGLQVTGKAD 
MMP-12(murine) EK-NNVLFG----ERYLEKFyGLEINKLPVTKMKySGNLMKEKIQEMQHFLGLKVTGQLD 
MMP-l 
MMP-3 
MMP-8 
MMP-9 
MMP-2 
MMP-3 
MMP-10 
MMP-ll 
AETLKVMKQPRCGVPD---------VAQFVLTEGNPRWEQTHLTyRIENyTPDLPRADVD 
DNTLDVMKKPRCGVPD---------VGEYNVFPRTLKWSKMNLTyRIVNyTPDMTHSEVE 
EETLDMMKKPRCGVPD---------SGGFMLTPGNPKWERTNLTyRIRNyTPQLSEAEVE 
SATLKAMRTPRCGVPD---------LGRFQTFEGDLKWHHHNITyWIQNYSEDLPRAVID 
QNTIETMRKPRCGNPD---------VANYNFFPRKPKWDKNQITYRIIGYTPDLDPETVD 
SDTLEVMRKPRCGVPD---------VGHFRTFPGIPKWRKTHLTYRIVNYTPDLPKDAVD 
TDTLEVMRKPRCGVPD---------VGHFSSFPGMPKWRKTHLTYRIVNYTPDLPKuAVD 
------LRPPRCGVPDP-SDGLSARNRQKRFVLSGGRWEKTDLTYRILRFPWQLVQEQVR 
t...l 
'J'I 
""" 
MMP-7 SRVIEIMQKPRCGVPD---------VAEYSLFPNSPKWTSKVVTYRIVSYTRDLPHITVD 
MMP-14 ADTMKAMRRPRCGVPDKFGAElKANVRRKRYAIQGLKWQHNEITFCIQNYTPKVGEYATY 
MMP-l=(murine) TSTLEMMHAPRCGVPD---------LHHFREMPGGPVWRKHYITYRINNYTPDMNREDVD 
t-11-1 P - 1 
MHP- -~ 
MMP-8 
HHP-9 
MHP-2 
MMP-3 
MMP-10 
**** ** * * 
HAl EKAFQLWSNVT PL T FTKV - - - - - - - -5 EGQP.[' 1M IS FVRGDHRDN5 P FDGPGGN LAH 
KAFKKAFKVWSDVTPLNFTRL--------HDGIADIMISFGIKEHGDFYPFDGPSGLLAH 
RAIKDAFELWSVASPLIFTRI--------5QGEADINIAFYQRDHGDNSPFDGPNGILAH 
DAFARAFALWSAVTPLTFTRV--------YSRDADIVIQFGVAEHGDGYPFDGKDGLLAH 
DAFARAFVVWSDVTPLRFSRI--------HDGEADIMINFGRWEHGDGYPFDGKDGLLAB 
SAVEKALKVWEEVTPLTFSRL--------YEGEADIMISFAVREHGDFYPFDGPGNVLAH 
SAIEKALKVWEEVTPLTFSRL--------YEGEADIMISFAVKEHGDFYSFDGPGHSLAH 
MMP-ll QTMAEALKVWSDVTPLTFTEV--------HEGRADIMIDFARYWDGDDLPFDGPGGILAH 
MMP-7 RLVSKALNMWGKEI PLHFRKV--------VWGTADIMIGFARGAHGDSYPFDGPGNTLAH 
MMP-14 EAIRKAFRVWESATPLRFREVPYAYIREGHEKQADIMIFFAEGFHGDRTAFDGEGGFLAH 
MMP-12(murine) YAIRKAFQVWSNVTPLKFSKI--------NTGMADILVVFARGAHGDFHAFDGKGGlLAH 
MMP-l 
MMP-3 
* * ** * *** * * *** *** 
AFQPGPGIGGDAHFDEDERWTNNFR-----------------------------------
AFPPGPNYGGDAHFDDDETWTSSSK-----------------------------------
t-J 
'J> 
'J> 
MMP-8 AFQPGQGIGGDAHFDAEETWTNTSA-----------------------------------
MMP-9 AFPPGPGIQGDAHFDDDELWSLGKGVV1PTRFGNADGAACHFPFIFEGRSYSACTTDGRS 
MMI'-~~ AFl\PGT(3VGGDSHFDD[iELWTLGEGQWRVKYGNADGEYCKFPFLFNGKEYNSCTDTGRS 
HHP- j lI."{]\l.'r;PC I W;[IAHFDDDEQWTKDTT- - - -- - - - - - - - - - --- - - - - - - - -- - -- - - - - --
;-1MP-:C (J A,{PPcJPGL '{(J[II HFDDDEKWTEDA:3- ------ -- - - --- ------- -- --- -- -- -----
:vn1P-: : AFFPKTHFE:;DVHFDYDETWT IGu- - - --- - - - - - --- - ---------- - -- -- - - -- --
t-1t1P- -/ JI.FAPGTGLGC;DAHFDEDERWTDGS :)LG IN--- - - - - -- - --- - FLYA-------------
t-TI1P-:C 4 AYFPGPN I GGDTHFDSAEPWTV-- - - - ----- -- - ---- ----- ---------- -- -- RN 
MMP-12(murine) AFGPGSGIGGDAHFDEDEFWTTHSG-----------------------------------
MMP-l 
MMP-3 
MMP-8 
MMP-9 
MMP-2 
MMP-3 
MMP-10 
MMP-ll 
MMP-7 
MMP-14 
MMP-12(murine) 
*' * ** *** * * 
DGLPWCSTTANYDTDDRFGFCPSERLYTRDGNADGKPCQFPFIFQGQSYSACTTDGRSDG 
DGFLWCSTTYNFEKDGKYGFCPHEALFTMGGNAEGQPCKFPFRFQGTSYDSCTTEGRTDG 
EDL---------------------------------------------------------
1-,,) 
'Jl 
0' 
MHP-l 
~:1"1 I' - .~ 
MHI'- h 
:".>11' - q 
;~r~1 ~J - :-. 
~"'t~t'- j 
rvrr-1. p- 1 I) 
rvrr-1. P- 11 
MMP-') 
MMP-14 
MHP-12 (murine) 
MMP-l 
MMP-3 
MMP-8 
MMP-9 
MMP-2 
MMP-3 
MMP-10 
'j' H W:A'l T ANY I 1!<,UKL Fe:; F~ rTkJ\L'~) TVMGC;N SAGE LCVF'P F':' FI ,GKE '{ STeT 5ECjl\GUljl\ 
y h W~(;';T I,: [,y URUKKYG H: PETI\M:~ 1"1 - c;r;N SEC;Al'CVFIJ FT FI ,(:;NKYE:;CTSN~P.:) U(;1-\ 
---------------------EYNLHRVAAHELGHSLGLSHSTDIGALMYPSY-TF--SG 
---------------------GYNLFLVAAHEFGHSLGLDHSKDPGALMFPly-TYTGKS 
---------------------NYNLFLVAAHEFGHSLGLAHSSDPGALMyPNy-AFRETS 
LWCATTSNFDSDKKWGFCPDQGYSLFLVAAHEFGHALGLDHSSVPEALMYPMYR-FTEGP 
MWCATTANYDDDRKWGFCPDQGYSLFLVAAHEFGHAMGLEHSQDPGALMAPIY-TYT--K 
---------------------GTNLFLVAAHEIGHSLGLFHSANTEALMYPLYHSLTDLT 
---------------------GTNLFLVAAHELGHSLGLFHSANTEALMYPLYNSFTELA 
tJ 
'J> 
-.J 
MMP-ll -------------------DQGTDLLQVAAHEFGHVLGLQHTTAAKALMSAFY-TFR--Y 
MMP- -7 -- - -- ----- - -- - - ------- --- ---ATHELGHSLGMGHSSDPNAVMYPTY -GNGDPQ 
MMP-l'l --- -----------------~CND 1 FLVAVHELGHALGLF.HSSDPSA lMAPFYQ-WMUTE 
>L1-1P-::':2 (mu r ~ lie I - - - -- - - --- - - - - --- - - --GTNLFLTIWHE IGHS LGLGHSSDPKAVMFPTYK-YVU IN 
MMP-~ 
tll-1P- 3 
MMP-8 
MMP-9 
MMP-2 
MMP-3 
MMP-I0 
MMP-ll 
MMP-7 
MMP-14 
MMP-12 (murine) 
* k * * * * * " * " 
DVJLA0DDI DG IQAI YGRSQNPVQ- ---- ---- -- - ---------- - --- ---- -- --.--
HF1'-1LPUDDVQGIQSLYGPGDE---------DP----------------------------
NYSLPQDDIDGIQAIYGLSSNPIQ------------------------------------
--PLHKDDVNGIRHLYGPRPEPEPRPPTTTTPQPTAPPTVCPTGPPTVHPSERPTAGPTG 
NFRLSQDDIKGIQELYGASPDID----LGTGP----------------------------
RFRLSQDDINGIQSLyGPPPDSPETPLVPTEP----------------------------
QFRLSQDDVNGIQSLyGPPPASTEEPLVPTKS----------------------------
PLSLSPDDCRGVQHLYG-------------QPWPTVTSRTPALGP-------QAGIDTNE 
NFKLSQDDIKGIQKLyG-------------------------------------------
KFVLPHyDPRGIQQLyGGKQGS---------------PPRCP-----LNPGLPPGLLFLI 
TFRLSADDIRGIQSLYGDPKENQRLP----------------------------------
* * * ** 
t-J 
'J> 
00 
MMP-l 
MMP-J 
MHP-h 
t"n~t - q 
t-1t-1I' - ~ 
!~HF- ~ 
t-11-11'-~(J 
t1Jv1I:>- 1 1 
MMP--7 
-PI-GPQTPKACDSKLT----------------FDAITTIRGEVMFFKDRFYMRTN-PFY 
NPK-HPKTPDKCDPSLS----------------~DAITSLRGETMIFKDRFFWRLH-PQQ 
- PT-(;p~;TrKPCDPSLT- --------------- FDA I TTLRGE ILFFKDRYFVmRH- PQL 
t t'SA\; t;c;.'c F l'TAGP.3 T !\'~'I"v'P L.: FVIJI l!\CNVN I FLlA I I\E I GNQL YL FKUGKYWR F:~r:(_;hC; 
T 1''1 U;r'VT PI:: I CK\.2D 1'1- -- - - - -- - - - -- -- - FOG IAOI RGE I F'FFKL'fi, FIWF<TVT Phl 1 
'/ H' -1< ~'r;'T t~I\N(: LPALS- - - - - - - - - - - -- - - - FL1!WS TLRGE I L I FKlJRH FWPK:; - U;:~ 
vp~, -(jSEMPAKCDPALS- -- -- - --- -- -- -- - FDAI STLRGEYLFFKDRY FWfi,R;;- HWN 
I AI-LEPDAPF'--- --------- - --- DACEAS- FDAVST IRGELFFFKAGF\1WRLRGGQL 
MMP-14 NPKNPTyGPNICDGN------------------FDTVAMLRGEMFDFKKRWFWRVRNNUV 
MMP-12(murine) -NP-DNSEPALCDPNLS----------------FDAVTTVGNKIFFFKDRFFWLKV-SER 
MMP-l 
MMP-3 
MMP-8 
MMP-9 
MMP-2 
MMP-3 
MM:P-IO 
MM:P-ll 
PEVE-LNFISVFWPQLPNGLEAAYEFADRDEVRFFKGNKYWAVQGQNVLHGYPKDIYSSF 
VDAE-LFLTKSFWPELPNRIDAAYEHPSHDLIFIFRGRKFWALNGYDILEGYPKKI-SEL 
QRVE-MNFISLFWPSLPTGIQAAYEDFDRDLIFLFKGNQYWALSGYDILQGYPKDI-SNY 
SRPQGPFLIADKWPALPRKLDSVFEEPLSKKLFFFSGRQVWVYTGASVLG--PRRLD-KL 
KPMG-PLLVATFWPELPEKIDAVYEAPQEEKAVFFAGNEYWIYSASTLERGYPKPL-TSL 
LEPE-LHLISSFWPSLPSGVDAAYEVTSKDLVFIFKGNQFWAIRGNEVRAGYPRGIHT-L 
PEPE-FHLISAFWPSLPSYLDAAYEVNSRDTVFIFKGNEFWAIRGNEVQAGYPRGIHT-L 
QPGYPA-LASRHWQGLPSPVDAAFEDAQ-GHIWFFQGAQYWVYDGEKPVLG-PAPL-TEL 
t-.J 
'J'I 
-0 
MMP-7 ------------------------------------------------------------
MMP-14 MIlGYPMP- 1GQFWRGLPAS 1NTAYERKDGKFVF- FKGDKHWVFDEASLEPGYPKH1K-EL 
MMf'-l:2 (mllr ~ lle i PKT:)-VNl.., I SSLWPTLPSG 1El\11. YE I EARNQVFLFKDDKYWLI SNLRPEPNYPKS I HS-;:' 
~-1HP-: (;F£"'rnVKH 1 DAALSE-ENTGKTYFFVANKYWRYDEYKRSl-1DPGYPKMIAHDFPGIGHKVD 
MMP-j CJLPKEVKKISAAVHF-EDTGKTLLFSGNQVWRYDDTNHIMDKDYPRLIEEDFPGIGDKVD 
MMP-8 
MMP-9 
MMP-2 
MMP-3 
GFPSSVQA1DAAVF---YRSKTYFFVNDQFWRYDNQRQFMEPGYPKSISGAFPGIESKVD 
GLGADVAQVTGAL-R-SGRGKMLLFSGRRLWRFDVKAQMVDPRSASEVDRMFPGVPLDTH 
GLPPDVQRVDAAFNW-SKNKKTYIFAGDKFWRYNEVKKKMDPGFPKLIADAWNAIPDNLD 
GFPPTVRKIDAAISD-KEKNKTYFFVEDKYWRFDEKRNSMEPGFPKQIAEDFPGIDSKID 
MMP-10 GFPPTIRKIDAAVSD-KEKKKTYFFAADKYWRFDENSQSMEQGFPRLIADDFPGVEPKVD 
MMP-ll GLVRF--PVHAALVWGPEKNKIYFFRGRDYWRFHPSTRRVDSPVPRR-ATDWRGVPSEID 
MMP-7 -------------KR-SNSRKK--------------------------------------
MMP-14 GRGLPTDKIDAALFW-MPNGKTYFFRGNKYYRFNEELRAVDSEYPKNI-KVWEGIPESPR 
MMP-12(murine) GFPNFVKKIDAAVFN-PRFYRTYFFVDNQYWRYDERRQMMDPGYPKLITKNFQGIGPKID 
MMP-l AVF--MKDGFF----YFFHGTRQYKFDPKTKRILTLQKANS---WFNCRKN---------
MMP-3 AVY--EKNGYI----YFFNGPIQFEYSIWSNRIVRVMPANS---ILWC------------
t-J 
0-
o 
MMP-8 AVF--QQEHFF----HVFSGPRyyAFDLIAQRVTRVARGNK---WLNCRyG---------
MMP-g DVFQyREKAyFCQDRFyWRVSSRSELN----QVDQVGyVTy--DILQCPED---------
MHF-:~ A VVDLQCGGHS- - --YFFKG!\ YYLKLENOS LKSVKFGS IKS- - DWLGC-- ----- -----
t-1HP- -~ A'JF- -u: F'jFF- -- -Y FFTGS::::,\,.JU: FDPNAKKVTHTLKSNS- --WLNC- - - - - - - - ----
1-111P- ~ i.i A'/L- -QI\FGFF- --- YFFSGSSOFE FI,PNARI'1VTH I LKSNS- --WLHC- ---- - --- ---
MHI>- ~ :. JV\F J- UAI,r;'{ - - - -AYFLHGf~LYWKF'UPVKVKALE(; FIJ[-<-LVGPUFFGCAEPANT--- ---
t-1t11' - "I - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
tvft1P-14 (;;) F'MG:~UEVF----TYFYKGNKYWKFNNQKLKVEPGYPK:3ALRDWMGCPSGGF<.PDECTEE 
MMP-12(mur~neJ AVF-ySKNKyy----yFFQGSNQFEyDFLLQRITKTLKSNS---WFGC------------
MMP-l ------------------------------------------------------------
MMP-3 ------------------------------------------------------------
MMP-8 ------------------------------------------------------------
MMP-9 ------------------------------------------------------------
MMP-2 ------------------------------------------------------------
MMP-3 -~----------------------------------------------------------
MMP-IO ------------------------------------------------------------
MMP-ll ----------------------------------------FL------------------
MMP-7 ------------------------------------------------------------
MMP-14 ETEVIIIEVDEEGGGAVSAAAVVLPVLLLLLVLAVGLAVFFFRRHGTPRRLLYCQRSLLD 
MMP-12 (murine) ------- -----------------------------------------------------
ClJ 
C 
·rl 
>-< 
;:j 
8 
~ '::1' N 
,. 
~ :-- r4 r4 
I I 
I I I I 
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Appendix 2. 
CLllSTAL V multiple sequence alignment for all three human TIl\tP sequences. 
t 11: human CL'(:VI'PHPVTAF'(:NSDLVI RAKFVGTPEVNVT~-LYQR----- - Ylo: I KMTKMYKGFQALGUAAIlI k F'VYT 
L'h huma.n CSCS F;VHPQ(2AP:NADWIRAKAVSEKEVDS(;N~'I YGNPI KP IvYE I KQIKMFKGPEK----- Dl EF I YT 
t Jh human CTCSP:3l-lPQUAF'CN~;UIVIRAKWGKKLVKEG- - ----PFGTLVYTIKQMKMyRGFTKM--- PHVQY I HT 
* * * *** **** * ***** * * * ** ** * * 
tlh human PAMESVCGYFHRSHNRSEEFLIAGKLQ-DGLLHITTCSFVAPWNSLSLAQRRGFTKTYTVGCEECTV~PC 
t2h human APSSAVCGVSLDVGGKKE-YLIAGKAEGDGKMHITLCDFIVPWDTLSTTQKKSLNHRYQMGCE-CKITRC 
t3h human EASESLCGLKLEVN-KYQ-YLLTGRVY-DGKMYTGLCNFVERWDQLTLSQRKGLNYRYHLGCN-CKIKSC 
** * * ** * * * * * * ** * 
tlh human LSIPCKLQSGTHCLWTDQLLQGSEKGFQSRHLACLPREPGLCTW ..... --------QSLRSQIA 
t2h human PMIPCYISSPDECLWMDWVTEKNINGHQAKFFACIKRSDGSCAWYRGAAPPKQEFLDIEDP 
t3h human YYLPCFVTSKNECLWTDMLSNFGYPGYQSKHYACIRQKGGYCSWYRGWAPPDKSIINATDP 
** * *** * * * ** * * * 
All sequences were downloaded from the EMBL database. 
* 
t-.) 
0-
w 
AppendixJ. 
CLllST AL V multiple sequence alignment of all known TIMP sequences to date. 
human timp-l 
mouse timp-l 
rabbit timp-l 
rat timp-l 
bovine timp-l 
porcine timp-l 
r~Tr::VF1)HPCJTAFCNSDLVI RIJ<FVGTPEVNQT':'- LYQ- ---- - RYE I KMTKMYKGI·\jALG 
(_::)(~APt'HI)<JTAFCNSDLV I RAKFMGS PE I NF,T'T- LYQ-- ---- RYK I KMTKMLKGF'KAVG 
r:TCVPPHPQTAFCNSDLVI RAKFVGAPEVNHTT- LYQ- - ---- RYE IKTTKMFKGFDALG 
CSCAPTHPQTAFCNSDLVlRAKFMGSPEIIETT-LYQ------RYEIKMTKMLKGFDAVG 
CTCVPPHPQTAFCNSDVVlRAKFVGTAEVNETA-LYQ------RYEIKMTKMFKGFSALR 
CTCVPPHPQTAFCSSDLVlRAKFVGAPEFNQTA-SYQ------RYEIKMTKMFKGFNALG 
CTCVPPHPQTAFCNSEVVlRAKFVGTAEVNETA-LYQ------RYEIKMTKMFKGFSALR 
CTCVPPHPQTAFCNSDLVIRAKFVGTPEVNQTT-LYQ------RYEIKMTKMYKGFQALG 
sheep 
baboon 
human 
bovine 
mouse 
rat 
timp-l 
timp-l 
timp-2 
timp-2 
timp-2 
timp-2 
. . . . . .. 
. . . . . . . . . . 
CSCSPVHPQQAFCNADVVlRAKAVSEKEVDSGNDIYGNPIKRIQYEIKQIKMFKGPEK--
CSCSPVHPQQAFCNADIVlRAKAVNKKEVDSGNDIYGNPIKRIQYEIKQIKMFKGPDQ--
CSCSPVHPQQAFCNADVVIRAKAVSEKEVDSGNDIYGNPIKRIQYEIKQIKMFKGPDK--
CSCSPVHPQQAFCNADVVIRAKAVSEKEVDSGNDIYGNPIKRIQYEIKQIKMFKGPDK--
1-,,) 
0-
~ 
human 
mouse 
chl.ck 
human 
mouse 
rabbit 
rat 
bovine 
timp-3 CTCSPSHPQDAFCNSDIVlRAKVVGKKLVKEG------PFGTLVYTIKQMKMyRGFTKM-
timp-3 CrC-;PSHPQDAFCNSDIVIRAK\lVGKKLVKEG------PFGTLVyT IKQMKMYRGFSKM-
timp-3 ('TC'JP I HPvDAFCN~-;[J I V r RAK'JVGKKLMKDG--- - - - PFGTMRYTVKQMKMYRGFQ IM-
* .. k *. * *. * ... ... .. .. .. * * * * .. 
. . . . . . . 
timp-l 
timp-l 
timp-l 
timp-l 
timp-l 
porcine timp-l 
DAADIRFVYTPAMESVCGYFHRSHNRSEE:-LIAGKLQ-DGLLHITTCSFVAPWNSLSLAQ 
NAADIRYAYTPVMESLCGYAHKSQNRSEEFLITGRLR-NGNLHISACSFLVPWRTLSPAQ 
HATDIRFVYTPAMESVCGYSHKSQNRSEEFLIAGQLR-NGLLHITTCSFVVPWNSLSFSQ 
NATGFRFAYTPAMESLCGYVHKSQNRSEEFLIAGRLR-NGNLHITACSFLVPWHNLSPAQ 
DAPDIRFIYTPAMESVCGYFHRSQNRSEEFLIAGQLS-NGHLHITTCSFVAPWNSMSSAQ 
DAPDIRFIYTPAMESVCGYFHRSQNRSQEFLIAGQLW-NGHLHITTCSFVAPWNSLSSA~ 
DAPDIRFIYTPAMESVCGYFHRSQNRSEEFLIAGQLS-NGHLHITTCSFVAPWNSMSSAQ 
DAADIRFVYTPAMESVCGYFHRSHNRSEEFLIAGKLQ-DGLLHITTCSFVAPWNSLSLAQ 
sheep timp-l 
baboon timp-l 
. . . . . .. . . . .. 
.. . . . . . . . . . 
human timp-2 ---DIEFIYTAPSSAVCGVSLDVGGKKE-YLIAGKAEGDGKMHITLCDFIVPWDTLSTTQ 
bovine timp-2 ---DIEFIYTAPAAAVCGVSLDIGGKKE-YLIAGKAEGNGNMHITLCDFIVPWDTLSATQ 
mouse timp-2 ---DIEFIYTAPSSAVCGVSLDVGGKKE-YLIAGKAEGDGKMHITLCDFIVPWDTLSITQ 
rat timp-2 ---DIEFIYTAPSSAVCGVSLDVGGKKE-YLIAGKAEGDGKMHITLCDFIVPWDTLSITQ 
N 
'" 'J> 
human 
mouse 
chick 
human 
mouse 
rabbit 
rat 
bovine 
timp-3 --PHVQYIHTEASESLCGLKLEVN-KYQ-YLLTGRVY-DGKMYTGLCNFVERWDQLTLSQ 
timp-3 --PHVQYIHTEASESLCGLKLEVN-KYQ-YLLTGRVY-EGKMYTGLCNFVERWDHLTLSO 
timp-3 --PHVQY I YTEASESLCGVKi.,EVN-KYQ-"iLI TGRVY-EGKVYTGLCNWYEKWDRLTLSV 
k 
* * * * * * * * 
timp-l 
timp-l 
timp-l 
timp-l 
timp-l 
porcine timp-l 
RRGFTKTYTVGCEECTVFPCLSI PCKLQSGTHCLWTDQLLQGSEKGFQSRHLACLPREPC 
QRAFSKTYSAGCGVCTVFPCLSI PCKLESDTHCLWTDQVLVGSE-DYQSRHFACLPRNPG 
RSGFTKTYAAGCDMCTVFACASI PCHLESDTHCLWTDSSL-GSDKGFQSRHLACLPQEPG 
QKAFVKTYSAGCGVCTVFPCSAIPCKLESDSHCLWTDQILMGSEKGYQSDHFACLPRNPD 
RRGFTKTYAAGCEECTVFPCSSIPCKLQSDTHCLWTDQLLTGSDKGFQSRHLACLPREPG 
RQGFTEIYAAGCEECTVFPCTSI PCKLQSDTHCLWTDQLLTGSDKGFQSRHLACMPREPG 
RRGFTKTYAAGCEECTVFPCSSIPCKLQSDTHCLWTDQLLTGSDKGFQSRHLACLPREPG 
RRGFTKTYTVGCEECTVFPCLSIPCKLQSGTHCLWTDQLLQGSEKGFQSRHLACLPREPG 
sheep 
baboon 
human 
bovine 
mouse 
rat 
timp-l 
timp-l 
timp-2 
timp-2 
timp-2 
timp-2 
. . . . 
. . . . 
KKSLNHRYQMGCE-CKITRCPMIPCYISSPDECLWMDWVTEKNINGHQAKFFACIKRSDG 
KKSLNHRYQMGCE-CKITRCPMIPCYISSPDECLWMDWVTEKNINGHQAKFFACIKRSDG 
KKSLNHRYQMGCE-CKITRCPMIPCYISSPDECLWMD~~TEKSINGHQAKFFACIKRSDG 
KKSLNHRYQMGCQ-CKITRCPMIPCYISSPDECLWMDWVTEKSINGHQAKFFACIKRSDG 
t...) 
0-
0-
human 
mouse 
chick 
human 
mouse 
rabbit 
rat 
bovine 
timp-3 RKGLNYRYHLGCN-CKI KSCYYLPCFVT~3KNECLWTDMLSNFGYPGYQSKHYAC I RQKCG 
timp-3 RKC.;LNYRYHLC;CN-(~K T KS(~Y'iLf'C !.\J':- :;KNECLWTDMLSN f(;YPG'{QSKHYI\(~ 1 PJJKC;C; 
timp-3 FI KC;LNHP'I'H U-;('C;-CK I P P( "i'I'; ,i( 'l·'[,'=' ,; KNr)' I !,'I]':'IiH:.::N Fe ;H:;U11..)AKH'{ 1\(' I i)hVF:; 
... '- * *: 
'" " * 
• " * * * • • 
· ..... 
timp-l LCTWQSLRSQ1----------A 
timp-l LCTWRSLGAR------------
timp-l LCAWESLRPRK----------[) 
timp-l LCTWQYLGVSMTRSLPLAKAEA 
timp-l LCTWQSLRAQM----------A 
porcine timp-l MCTWQSLRPRV----------A 
sheep timp-l MCTWQSLRPRG----------A 
baboon timp-l LCTWQSLRTRI----------A 
· .............. ...... 
· .............. . ..... 
human timp-2 SCAWYRGAAPPKQEF-LDIEDP 
bovine timp-2 SCAWYRGAAPPKQEF-LDIEDP 
mouse timp-2 SCAWYRGAAPPKQEF-LDIEDP 
rat timp-2 SCAWYRGAAPPKQEF-LDIEDP 
N 
0'-
-....J 
human 
mouse 
chick 
timp-3 
timp-3 
timp-3 
YCSWYRGWAPPDKSI-INATDP 
YCSWYRGWAPPDKSI-SNATDP 
YCSWYRGWAPPDKTI-INATDP 
* * 
All sequences were downloaded from either Genbank. Swissprot or EMBL databases. The overall homology as calculated by ClustalV is marked b~ stars and dots 
under the complete set of 15 sequences. '*' indicates complete conservation and '.' indicates that conservative substitutions have occurred. The homology between 
the individual TIMP families is shown above the group of sequences. A colon indicates total conservation and a dot indicates a conservative substitution. 
Appendix 4 
Structures of Some Common Sugars. 
H 
OH 
H 
H 
Mannose. Fucose 
H 
H H 
Galactose. Glucos(amine), 
H 
H ---",(-_i..-" 
1 oY OY1H 
..,.----.:L-CH-CH-CH20H 
H 
Sialic Acid. 
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Appendix 5 
Random Coil Shifts. 
Residue Struture 
Gly -H 
Ala -('H3 
Val -CH(CH3)2 
De -CH(CH3 )CH2CH3 
Leu -CH2CH«(,H3)2 
tPro -CH2CH2CH2-
Ser -('H20H 
Thr -CH(OH)CH3 
Asp -('H2COOH 
Glu -('H2CH2COOH 
Lys _(,H2CH2(,H2CH2NH3 
Arg _CH2CH2CH2NHCONH2 
Asn -CH2CONH2 
Gin _CH2CH2CONH2 
NH aH PH 
8.39 3.97 
8.25 4.35 1.39 
8.444.182.13 
8.19 4.23 1.90 
8.42 4.38 1.65 
na 4.44 2.28,2.02 
8.38 4.50 3.88 
8.24 4.35 4.22 
8.41 4.76 2.84,2.75 
8.37 4.29 2.09, 1.97 
8.41 4.36 1.85, 1. 76 
8.27 4.38 1.89. 1.79 
8.75 4.75 2.83,2.75 
8.41 4.37 2.13, 2.01 
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Others 
y(,H3 0.97. 0.94 
yCH2 1.48. 1.19 
yCH30.95 
6CH30.89 
yC'H2 1.64 
6(H3 0.94. 0.90 
yCH22.03 
6CH2 3.68. 365 
yCH3 1.23 
yCH2 2.31. 2.28 
yCH2 1.45. 1 45 
6CH2 1. 70, 1. 70 
sCH2 3.02. 3.02 
sNH37.52 
yCH2 1.70, 1 70 
6CH2 3.32. 3 32 
NH 717.662 
yNH2 7.59. 6.91 
yCH2 2.38. 2.38 
cSNH2 6.87. 7 59 
Met 
-CH2CH2SCH3 8.42 4.52 2.15,2.01 yCH2 2M,:2 64 
ECH32.13 
I 
Cys -CH2SH 8.31 4.69 3.28,2.96 
Trp 
-CH2-indole-Ar 8.09 4.70 3.32,3.19 2H 7.24 
4H 7.65 
5H 7.17 
6H 7.24 
7H 7.50 
NH 10.22 
Phe -CH2-Ar 8.23 4.66 3.22,2.99 2,6H 7.30 
3,SH 7.39 
4H 7.34 
Tyr -CH2-Ar-OH 8.18 4.60 3.13,2.92 2,6H 7.15 
3,SH 6.86 
His -CH2-indole 8.41 4.63 3.26,3.20 2H 8.12 
4H 7.14 
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Appendix 6. Tabulated NOE data for C3-C IJ in H20 . 
proton ppm strength proton 1 
V4dHN 0.888 w V4dHy -I 
'14dHN 4.455 w V4dHa 
V4cHa 0.867 w V4cHy' 
V4bHa 0.830 w V4bHy' 
V4cHa 3.813 w P5tH8 
V4bHa 1.957 w V4bH13 
V4bH~ 0.885 w V4bHy 
P5tHa 2.274 w P6cH13 
P5tHa 1.916 w V4a1bH8 
P5tHa 1.084 w TI0albHy 
IAllaH8 
PScHa 3.681 w P6cHo 
P6tHa 3.677 
P6tHCl 2.284 w 
P6tHa 2.184 w P6tH13 
P6tHa 2. ]04 w P6tH13' 
P6tHa 1.017 w V4cHy 
P6tHa 0.944 w V4cHy' 
H7aHN 1.104 w AlleHB 
H7aHN 3.065 s H7aH13 
H7aHN 3.237 m FJ2bH13 
H7aHN 4.228 w TJOcHI3 
H7aHN 4.329 w P8tHa 
H7aHN 4.632 w FI2aJbHa 
H7bHN - 1.096 
H7bHN I. ]97 Allc/dH~ 
H7bHN 2.977 H7bHJ3 
H7bHN 3.187 FJ2aHB 
H7bHN 4.220 , TIOcHI3 
H7cHN 1.104 s AlIaH/3 
H7cHN 1.214 s TJOcHylAIlc 
fW. 
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H7cHN 3.002 m H7cHf3 
H7cHN 3.187 w F12aHf3 
H7cHN 4.094 m Al laHJ3/AI Ic 
Ha 
H7cHN 4.279 s Q9cHa 
H7cHN 4.422 w P6cHalP8cH aI 
TIObHa 
P8tHa 2.289 P8tH~ 
P8tHa 4.070 Alla1eHJ3 
P8tHa 1.947 P8tH~ 
P8cHa 3.164 H7b/cHa 
P8cHa 1.084 m TlOalbHy 
Q9aHN 4.368 m P8tHa 
Q9aHN 4.238 m T10cH~ 
Q9aHN 2.372 m Q9aHy 
Q9aHN 2.136 w Q9aH~ 
-
Q9aHN 1.975 w Q9aH~ 
Q9bHN 4.361 P8tH:t 
Q9bHN 4.220 Q9bHa 
Q9cHN 4.30 Q9cHa 
Q9cHN 2.378 Q9cHy 
Q9cHN 4.455 TI0dHa 
Q9dHN 4.290 Q9dHa 
TlObHa 1.084 
TI0bHy 
TlObHa 2.281 
P8t/cH~1P6Hf3 
TIOcHN 1.146 
TIOcHa 
TIOcHN 2.381 
Q9a/cHy 
TIOcHN 4.000 
T10cHB 
TIOcHN 4.464 
V4dHa 
AllaHN 1.099 
AllaH~ 
AllbHN 4.209 
AllbHa 
AllbHN 4.410 
TIObHu 
AllbHN 4.132 
Q9dHa 
AllcHN 1.198 
AllcHB 
?? 
AllcHN 3.062 
AllcHN 4093 
TIObH(3 
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AllcHN 
AI I dIN 
AllcHN 
AllgHN 
~\llgHN 
AllgHN 
AIIgHN 
AllgHN 
F12aHN 
F12aHN 
FI2aHN 
F12aHN 
FI2aHN 
F12aHN 
FI2bHN 
FI2bHN 
F12cHN 
F12cHN 
FI2cHN 
F12cHN 
CI3bHN 
C13bHN 
C13bHN 
C13aHN 
C13aHN 
CI3aHN 
C13aHN 
C13aHN 
(,13aHN 
4.279 
4.410 
4.475 
2.128 
2.230 
2.376 
4.408 
4.092 
1.121 
1.247 
2.910 
3.221 
4.119 
4.304 
4.103 
1.096 
2.986 
3.137 
3.187 
4.245 
4.293 
3.062 
1.137 
4.279 
3.737 
3.263 
3.070 
1.840 
1.096 
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w 
w 
w 
w 
w 
w 
m 
AllcHa. 
TIObHa. 
V4?? 
V 4cHf3/Q9bHJ3 
? 
H7cH?? 
?? 
AIIgHa. 
TlOHy 
TIOcHy 
F12aHJ3 
F12aHj3' 
TlOaHb 
H7aHa. 
TI0albHP 
TlOalbHy 
C13aHf.!' 
H7b/cH~/C 13c 
HP 
FI2cHJ3 
NT HalH6 ??? 
H7aHa. 
C13bH{3 
TIOdHy 
H7aHa. 
P8tHolP8cHo/ 
AllfHa 
CI3aHP 
C13aHB 
P5tHy 
TlOdiaHy 
Appendix 7. Tabulated NOE data for C3-C 13 in TFE-d2. 
proton ppm strength P!oton 
V4HN 1.071 s V4Hy' 
V4HN 1.196 m V..::Hy 
V4HN 2.067 s V4HO 
V4HN 3.054 s P8HcS' 
V4HN 3.140 w H7HJ3' 
V4HN 3.342 w H7HO 
V4HN 4.244 s P5HcS 
V4HN 4.314 s V4Hy 
H7HN 4.525 s P5Ha 
H7HN 4.458 m H7Ha 
H7HN 4.384 m P6Ha 
H7HN 3.462 m P6HcS 
H7HN 3.348 s H7HO 
H7HN 3.146 m H7HI3' 
H7HN 1.162 w V4aHy 
H7HN 2.070 w V4aHB 
H7HN 2.500 w P6H13 
H7HN 3.032 w P8H8' 
Q9HN 4.439 s P8Ha 
Q9HN 4.353 w Q9Ha 
Q9HN 2.510 m Q9Hy 
Q9HN 2.175 w Q9H13 
Q9HN 2.020 m Q9HJ3' 
Q9HN 1.919 w P8Hf3' 
TIOHN 1.273 s 
TlOHy 
TIOHN 1.942 w P8HJ3' 
TIOHN 2.036 w Q9HP' 
TIOHN 2.16 w 
Q9HB 
TIOHN 4.337 s 
Q9Ha 
TIOHN 4.579 s 
TIOHa 
A11HN 4.136 s 
Al1Ha 
FI2HN 4.773 m 
Fl2Ha 
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F12HN 3.350 m FI2H~ 
F12HN 3.116 s FI2HW 
C13HN 4.773 s FI2Ha 
C13HN 4.431 s CI3Ha 
C13HN 4.127 w AllHa 
CI3HN 3.319 m FI2H~ 
----C13HN 3.085 m FI2HfJ' 
C13HN 1.297 w T10Hy 
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